<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>1300</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="1300"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=1300&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=1200&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=1400&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927748513"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927748513?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927748513&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927748513&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003140"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927748513</prism:url><dc:identifier>SCOPUS_ID:84927748513</dc:identifier><eid>2-s2.0-84927748513</eid><dc:title>Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats</dc:title><dc:creator>Ding R.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>297</prism:volume><prism:pageRange>182-193</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.065</prism:doi><pii>S0306452215003140</pii><dc:description>© 2015 IBRO. Hemoglobin (Hb) is a major constituent of blood and a potent mediator of oxidative or nitrative stress after intracerebral hemorrhage (ICH). Our previous study demonstrated that Hb could induce abundant peroxynitrite (ONOO&lt;sup&gt;-&lt;/sup&gt;) formation in vivo, which may be involved in the blood-brain barrier (BBB) disruption, however, the drug intervention is absent and also the underlying mechanism. Using an experimental stroke model by injecting Hb into the caudate nucleus of male Sprague-Dawley rats, we assessed the role of ONOO&lt;sup&gt;-&lt;/sup&gt; decomposition catalyst, 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinato iron(III) [FeTPPS] in the activation of MMP-9 and Hb-induced neurovascular injuries. 3-Nitrotyrosine (3-NT, as an index of ONOO&lt;sup&gt;-&lt;/sup&gt; formation) and NF-κB expression was measured by western blot (WB) and immunohistochemistry (IHC)/immunofluorescence (IF). Activity of MMP was evaluated by in situ zymography. Neurovascular injury was assessed using zonula occludens-1 (ZO-1) by WB and IF, fibronectin (FN) and neuron-specific nuclear protein (NeuN) IHC. Perihematomal cell death was determined by TUNEL assay. Behavioral outcome was measured by modified neurological severity score (mNSS) test. At the injured striata, profuse 3-NT was produced and mainly expressed in neutrophils and microglia/macrophages. 3-NT formation significantly colocalized with nuclear factor-κB (NF-κB) expression. In situ zymography showed that gelatinase activity was mostly co-localized with neurons and blood vessel walls and partly with neutrophils and microglia/macrophages. Enhanced 3-NT production, NF-κB induction and MMP-9 activation were obviously reduced after FeTPPS treatment. Hb-induced injury to tight junction protein (ZO-1), basal lamina of FN-immunopositive microvasculature and neural cells was evidently ameliorated by FeTPPS. In addition, apoptotic cell numbers as well as behavioral deficits were also improved. The present study shows that the administration of the ONOO&lt;sup&gt;-&lt;/sup&gt; decomposition catalyst FeTPPS protects against Hb-induced neurovascular injuries and improves neurological function, which possibly in part by suppressing MMP-9 activation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60089929</affiliation-url><afid>60089929</afid><affilname>Zhujiang Hospital</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60089929</affiliation-url><afid>60089929</afid><affilname>Zhujiang Hospital</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108938781</affiliation-url><afid>108938781</afid><affilname>Gaoqing People's Hospital</affilname><name-variant>Gaoqing People׳s Hospital</name-variant><affiliation-city>Zibo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103801</affiliation-url><afid>60103801</afid><affilname>University of Jinan</affilname><name-variant>Jinan University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60089929</affiliation-url><afid>60089929</afid><affilname>Zhujiang Hospital</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55618809300</author-url><authid>55618809300</authid><authname>Ding R.</authname><surname>Ding</surname><given-name>R.</given-name><initials>R.</initials><afid>60089929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56226433400</author-url><authid>56226433400</authid><authname>Feng L.</authname><surname>Feng</surname><given-name>L.</given-name><initials>L.</initials><afid>60089929</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56594021500</author-url><authid>56594021500</authid><authname>He L.</authname><surname>He</surname><given-name>L.</given-name><initials>L.</initials><afid>60089929</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14521782000</author-url><authid>14521782000</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Y.</given-name><initials>Y.</initials><afid>60089929</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56414169300</author-url><authid>56414169300</authid><authname>Wen P.</authname><surname>Wen</surname><given-name>P.</given-name><initials>P.</initials><afid>60089929</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55619095900</author-url><authid>55619095900</authid><authname>Fu Z.</authname><surname>Fu</surname><given-name>Z.</given-name><initials>Z.</initials><afid>60089929</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56593844300</author-url><authid>56593844300</authid><authname>Lin C.</authname><surname>Lin</surname><given-name>C.</given-name><initials>C.</initials><afid>60089929</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55619075100</author-url><authid>55619075100</authid><authname>Yang S.</authname><surname>Yang</surname><given-name>S.</given-name><initials>S.</initials><afid>108938781</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55618706600</author-url><authid>55618706600</authid><authname>Deng X.</authname><surname>Deng</surname><given-name>X.</given-name><initials>X.</initials><afid>60103801</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56594149200</author-url><authid>56594149200</authid><authname>Zeng J.</authname><surname>Zeng</surname><given-name>J.</given-name><initials>J.</initials><afid>60089929</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56594072000</author-url><authid>56594072000</authid><authname>Sun G.</authname><surname>Sun</surname><given-name>G.</given-name><initials>G.</initials><afid>60089929</afid></author><authkeywords>Hemoglobin | Intracerebral hemorrhage | Matrix metalloproteinases | Neurovascular injury | Oxidative or nitrative stress | Peroxynitrite</authkeywords><intid>1785665912</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929083381"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929083381?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929083381&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929083381&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115002375"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929083381</prism:url><dc:identifier>SCOPUS_ID:84929083381</dc:identifier><eid>2-s2.0-84929083381</eid><dc:title>The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis</dc:title><dc:creator>Jing X.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>248-252</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.04.038</prism:doi><pii>S0009898115002375</pii><dc:description>© 2015 Elsevier B.V.. Background: High-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) contributed to several beneficial effects in the cardiovascular system. We explored the relationship between the HDL-S1P concentrations and coronary in-stent restenosis (ISR). Methods: Fifty consecutive patients with ISR and 50 normal control subjects were included. The serum S1P, HDL-S1P and clinical data were collected to explore the relationships between these parameters and ISR. Results: The patients with ISR had significantly lower concentrations of serum S1P (96.10 ± 26.33 vs. 113.40 ± 32.72; P. = 0.004) and HDL-S1P (32.81 ± 10.02 vs. 42.72 ± 11.75; P. &lt;. 0.001). All included patients were divided into four quartiles based on their concentrations of HDL-S1P: Quartile 1 (18.63-28.51. ng/ml), Quartile 2 (28.62-37.28. ng/ml), Quartile 3 (37.35-45.27. ng/ml), and Quartile 4 (45.59-79.36. ng/ml). The rates of ISR were 84%, 48%, 40% and 28%, respectively. The patients in Quartile 1 exhibited significantly higher rates of ISR compared with the other groups (P. = 0.001). A multivariate stepwise logistic regression analysis indicated that HDL-S1P (OR. = 0.846, 95% CI. = 0.767-0.932, P. = 0.001) was an independent predictor of ISR. An ROC analysis indicated that HDL-S1P. = 30.37. ng/ml and had a 90% sensitivity and a 52% specificity in predicting ISR. Conclusions: HDL-S1P is an independent predictor of ISR, and patients with higher concentrations of HDL-S1P have a low risk of ISR.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020870</affiliation-url><afid>60020870</afid><affilname>Chongqing University of Medical Sciences</affilname><name-variant>Chongqing Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56000673000</author-url><authid>56000673000</authid><authname>Jing X.</authname><surname>Jing</surname><given-name>Xiao Dong</given-name><initials>X.D.</initials><afid>60020870</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637436800</author-url><authid>56637436800</authid><authname>Wei X.</authname><surname>Wei</surname><given-name>Xiao Ming</given-name><initials>X.M.</initials><afid>60020870</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56437185200</author-url><authid>56437185200</authid><authname>Deng S.</authname><surname>Deng</surname><given-name>Song Bai</given-name><initials>S.B.</initials><afid>60020870</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56437096400</author-url><authid>56437096400</authid><authname>Du J.</authname><surname>Du</surname><given-name>Jian Lin</given-name><initials>J.L.</initials><afid>60020870</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56436968100</author-url><authid>56436968100</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Ya Jie</given-name><initials>Y.J.</initials><afid>60020870</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14322220100</author-url><authid>14322220100</authid><authname>She Q.</authname><surname>She</surname><given-name>Qiang</given-name><initials>Q.</initials><afid>60020870</afid></author><authkeywords>High-density lipoprotein | In-stent restenosis | Inflammation | Sphingosine-1-phosphate</authkeywords><intid>1785902924</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925710883"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925710883?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925710883&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925710883&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0166093415000828"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925710883</prism:url><dc:identifier>SCOPUS_ID:84925710883</dc:identifier><eid>2-s2.0-84925710883</eid><dc:title>A new quantitative PCR for human parvovirus B19 genotypes</dc:title><dc:creator>Toppinen M.</dc:creator><prism:publicationName>Journal of Virological Methods</prism:publicationName><prism:issn>01660934</prism:issn><prism:eIssn>18790984</prism:eIssn><prism:volume>218</prism:volume><prism:pageRange>40-45</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jviromet.2015.03.006</prism:doi><pii>S0166093415000828</pii><dc:description>© 2015 Elsevier B.V. Parvovirus B19 (B19V) is a minute ssDNA virus associated with a wide range of diseases from childhood erythema to fetal death. After primary infection, the viral genomes persist lifelong in solid tissues of most types. Quantification of the viral DNA is important in the timing of primary infection, assessment of tissue persistence and screening of blood donor plasma. In this study, we present a new PCR assay for detection and quantification as well as for differentiation of all three B19V genotypes.A new B19V qPCR was designed to target a 154-bp region of the NS1 area. Serum, plasma and solid tissue samples were suitable for testing in the assay. The WHO International Reference Panel for Parvovirus B19 Genotypes was utilized to validate the assay for detection of different genotypes of B19V in clinical material. Each panel member yielded, by the new qPCR, a quantity similar to the one reported by National Institute for Biological Standards and Control (NIBSC). The qPCR was specific for B19V and amplified and quantified all three genotypes with detection sensitivities of ≤10 copies/reaction. The differentiation of B19V genotypes was performed by Sanger sequencing of the amplified products.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002952</affiliation-url><afid>60002952</afid><affilname>Helsingin Yliopisto</affilname><name-variant>University of Helsinki</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016987</affiliation-url><afid>60016987</afid><affilname>Helsinki University Central Hospital</affilname><name-variant>Helsinki University Central Hospital</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028758</affiliation-url><afid>60028758</afid><affilname>Finnish Red Cross Blood Service</affilname><name-variant>Finnish Red Cross Blood Transfusion Service</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016987</affiliation-url><afid>60016987</afid><affilname>Helsinki University Central Hospital</affilname><name-variant>Helsinki University Central Hospital</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55701847500</author-url><authid>55701847500</authid><authname>Toppinen M.</authname><surname>Toppinen</surname><given-name>M.</given-name><initials>M.</initials><afid>60002952</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6503984028</author-url><authid>6503984028</authid><authname>Norja P.</authname><surname>Norja</surname><given-name>P.</given-name><initials>P.</initials><afid>60002952</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005845448</author-url><authid>7005845448</authid><authname>Aaltonen L.</authname><surname>Aaltonen</surname><given-name>L. M.</given-name><initials>L.M.</initials><afid>60016987</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8922387100</author-url><authid>8922387100</authid><authname>Wessberg S.</authname><surname>Wessberg</surname><given-name>S.</given-name><initials>S.</initials><afid>60028758</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7007166089</author-url><authid>7007166089</authid><authname>Hedman L.</authname><surname>Hedman</surname><given-name>L.</given-name><initials>L.</initials><afid>60002952</afid><afid>60016987</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7007166089</author-url><authid>7007166089</authid><authname>Hedman L.</authname><surname>Hedman</surname><given-name>L.</given-name><initials>L.</initials><afid>60002952</afid><afid>60016987</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603440454</author-url><authid>6603440454</authid><authname>Söderlund-Venermo M.</authname><surname>Söderlund-Venermo</surname><given-name>M.</given-name><initials>M.</initials><afid>60002952</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006799529</author-url><authid>7006799529</authid><authname>Hedman K.</authname><surname>Hedman</surname><given-name>K.</given-name><initials>K.</initials><afid>60002952</afid><afid>60016987</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006799529</author-url><authid>7006799529</authid><authname>Hedman K.</authname><surname>Hedman</surname><given-name>K.</given-name><initials>K.</initials><afid>60002952</afid><afid>60016987</afid></author><authkeywords>B19V | Genotyping | Parvovirus | QPCR</authkeywords><intid>2035343322</intid><source-id>20241</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928730018"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928730018?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928730018&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928730018&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115001965"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928730018</prism:url><dc:identifier>SCOPUS_ID:84928730018</dc:identifier><eid>2-s2.0-84928730018</eid><dc:title>A cohort study of incident microalbuminuria in relation to HOMA-IR in Korean men</dc:title><dc:creator>Park S.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>111-116</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.03.043</prism:doi><pii>S0009898115001965</pii><dc:description>© 2015 Elsevier B.V. Background: Despite the previous studies showing the relationship between microalbuminuria and insulin resistance, longitudinal effect of insulin resistance on development of microalbuminuria is not clearly identified in non-diabetic population. Methods: One thousand six hundred three non-diabetic Korean men without microalbuminuria in 2005 had been followed up for the development of microalbuminuria until 2010. Microalbuminuria was evaluated by urine-albumin creatinine ration, and insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR). Cox proportional hazards model was used to estimate the risk for microalbuminuria according to the tertile of HOMA-IR. Results: During 5465.8 person-y of average follow-up, microalbuminuria developed in 76 (4.7%) participants. Incidence of microalbuminuria increased in proportion to the level of HOMA-IR (tertile 1: 3.0%, tertile 2: 4.1%, tertile 3: 7.1%, P&lt;. 0.001). When the 1st tertile of HOMA-IR was set as reference, hazard ratios and 95% confidence interval were 1.15 (0.56-2.35) and 2.07 (1.05-4.09) for those in the 2nd and 3rd tertiles of HOMA-IR, even after adjusting multiple covariates, respectively (. P for linear trend. =. 0.054). Conclusions: Increased insulin resistance was a predictor of microalbuminuria in Korean men.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016329</affiliation-url><afid>60016329</afid><affilname>SungKyunKwan University, School of Medicine</affilname><name-variant>Sungkyunkwan University School of Medicine</name-variant><affiliation-city>Suwon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030358</affiliation-url><afid>60030358</afid><affilname>Ewha Womans University School of Medicine</affilname><name-variant>Ewha Womans University School of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001873</affiliation-url><afid>60001873</afid><affilname>Kyung Hee University</affilname><name-variant>Kyung Hee University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030358</affiliation-url><afid>60030358</afid><affilname>Ewha Womans University School of Medicine</affilname><name-variant>Ewha Womans University School of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023859</affiliation-url><afid>60023859</afid><affilname>Soonchunhyang University, College of Medicine</affilname><name-variant>Soonchunhyang University Hospital</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030358</affiliation-url><afid>60030358</afid><affilname>Ewha Womans University School of Medicine</affilname><name-variant>Ewha Womans University School of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007511</affiliation-url><afid>60007511</afid><affilname>Sungkyunkwan University</affilname><name-variant>Sungkyunkwan University</name-variant><affiliation-city>Jongno-gu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007511</affiliation-url><afid>60007511</afid><affilname>Sungkyunkwan University</affilname><name-variant>Sungkyunkwan University</name-variant><affiliation-city>Jongno-gu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016329</affiliation-url><afid>60016329</afid><affilname>SungKyunKwan University, School of Medicine</affilname><name-variant>Sungkyunkwan University School of Medicine</name-variant><affiliation-city>Suwon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:53264671000</author-url><authid>53264671000</authid><authname>Park S.</authname><surname>Park</surname><given-name>Sung Keun</given-name><initials>S.K.</initials><afid>60016329</afid><afid>60001873</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:53264671000</author-url><authid>53264671000</authid><authname>Park S.</authname><surname>Park</surname><given-name>Sung Keun</given-name><initials>S.K.</initials><afid>60016329</afid><afid>60001873</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56519143900</author-url><authid>56519143900</authid><authname>Chun H.</authname><surname>Chun</surname><given-name>Hyejin</given-name><initials>H.</initials><afid>60030358</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37115985100</author-url><authid>37115985100</authid><authname>Ryoo J.</authname><surname>Ryoo</surname><given-name>Jae Hong</given-name><initials>J.H.</initials><afid>60001873</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55662653200</author-url><authid>55662653200</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Sang Wha</given-name><initials>S.W.</initials><afid>60030358</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56518562600</author-url><authid>56518562600</authid><authname>Lee H.</authname><surname>Lee</surname><given-name>Hong Soo</given-name><initials>H.S.</initials><afid>60030358</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8724567500</author-url><authid>8724567500</authid><authname>Shim K.</authname><surname>Shim</surname><given-name>Kyung Won</given-name><initials>K.W.</initials><afid>60030358</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24471460000</author-url><authid>24471460000</authid><authname>Cho C.</authname><surname>Cho</surname><given-name>Choo Yon</given-name><initials>C.Y.</initials><afid>60023859</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56545161300</author-url><authid>56545161300</authid><authname>Ryu D.</authname><surname>Ryu</surname><given-name>Dong Ryeol</given-name><initials>D.R.</initials><afid>60030358</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56519172400</author-url><authid>56519172400</authid><authname>Ko T.</authname><surname>Ko</surname><given-name>Taeg Su</given-name><initials>T.S.</initials><afid>60007511</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56585080000</author-url><authid>56585080000</authid><authname>Kim E.</authname><surname>Kim</surname><given-name>Eugene</given-name><initials>E.</initials><afid>60007511</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55717248500</author-url><authid>55717248500</authid><authname>Park S.</authname><surname>Park</surname><given-name>Se Jin</given-name><initials>S.J.</initials><afid>60007511</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56610927300</author-url><authid>56610927300</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jai Hyung</given-name><initials>J.H.</initials><afid>60007511</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56610969500</author-url><authid>56610969500</authid><authname>Hong S.</authname><surname>Hong</surname><given-name>Seok Jin</given-name><initials>S.J.</initials><afid>60007511</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56431948900</author-url><authid>56431948900</authid><authname>Hong H.</authname><surname>Hong</surname><given-name>Hyun Pyo</given-name><initials>H.P.</initials><afid>60016329</afid></author><authkeywords>HOMA-IR | Insulin resistance | Microalbuminuria</authkeywords><intid>1035834425</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928155896"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928155896?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928155896&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928155896&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115001783"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928155896</prism:url><dc:identifier>SCOPUS_ID:84928155896</dc:identifier><eid>2-s2.0-84928155896</eid><dc:title>Sources of variation analysis and derivation of reference intervals for ALP, LDH, and amylase isozymes using sera from the Asian multicenter study on reference values</dc:title><dc:creator>Shimizu Y.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>64-72</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.03.034</prism:doi><pii>S0009898115001783</pii><dc:description>© 2015. Background: Sources of variation (SV) of ALP, LDH, and amylase isozymes were explored. Methods: We analyzed 3511 sera from well-defined healthy individuals recruited during the 2009 Asian project for derivation of common reference intervals (RIs). Up-to-date electrophoresis auto-analyzer and reagents were employed for high resolution and reproducibility. SVs including sex, age, body mass index (BMI), ABO blood groups, and levels of drinking, smoking, and exercise were analyzed by multiple regression analysis. RIs were determined by parametric methods after refining healthy individuals by use of latent reference values exclusion method. Results: Age-related changes in ALP2-3 were different in females: ALP2, linear increase from 20-64. y; ALP3, lowering until 45 y and rising steeply thereafter. ALP2 increased with BMI especially in females. ALP5 was barely detectable except in blood-types O and B. Age-related increases in LDH1-LDH3 were noted in females, whereas BMI-related increases were found only for LDH2-LDH5 in both sexes. Pancreatic amylase showed age-related increase in females and was slightly higher in blood-type O. RIs for absolute and relative activities of each isozyme were derived in consideration of sex and age. Conclusions: Investigation of these isozymes revealed various age-, BMI-, and blood-type-related changes that are all relevant in clinical interpretation of enzyme test results.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090377</affiliation-url><afid>60090377</afid><affilname>Yamaguchi University Graduate School of Medicine</affilname><name-variant>Yamaguchi University Graduate School of Medicine</name-variant><affiliation-city>Ube</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55835608800</author-url><authid>55835608800</authid><authname>Shimizu Y.</authname><surname>Shimizu</surname><given-name>Yoshihisa</given-name><initials>Y.</initials><afid>60090377</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55320325700</author-url><authid>55320325700</authid><authname>Ichihara K.</authname><surname>Ichihara</surname><given-name>Kiyoshi</given-name><initials>K.</initials><afid>60090377</afid></author><authkeywords>ABO blood group | Age-related change | ANOVA | Multiple regression analysis | Regionality</authkeywords><intid>535734347</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925642029"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925642029?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925642029&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925642029&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0045782515000882"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925642029</prism:url><dc:identifier>SCOPUS_ID:84925642029</dc:identifier><eid>2-s2.0-84925642029</eid><dc:title>Simulating flexible fiber suspensions using a scalable immersed boundary algorithm</dc:title><dc:creator>Wiens J.</dc:creator><prism:publicationName>Computer Methods in Applied Mechanics and Engineering</prism:publicationName><prism:issn>00457825</prism:issn><prism:volume>290</prism:volume><prism:pageRange>1-18</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cma.2015.02.026</prism:doi><pii>S0045782515000882</pii><dc:description>© 2015 Elsevier B.V. We present an approach for numerically simulating the dynamics of flexible fibers in a three-dimensional shear flow using a scalable immersed boundary (IB) algorithm based on Guermond and Minev's pseudo-compressible fluid solver. The fibers are treated as one-dimensional neutrally-buoyant Kirchhoff rods that resist stretching, bending, and twisting, within the generalized IB framework. We perform a careful numerical comparison against experiments on single fibers performed by S.G. Mason and co-workers, who categorized the fiber dynamics into several distinct orbit classes. We show that the orbit class may be determined using a single dimensionless parameter for low Reynolds flows. Lastly, we simulate dilute suspensions containing up to hundreds of fibers using a distributed-memory computer cluster. These simulations serve as a stepping stone for studying more complex suspension dynamics involving aggregation of fibers (or flocculation) and particle sedimentation due to added mass.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018491</affiliation-url><afid>60018491</afid><affilname>Simon Fraser University</affilname><name-variant>Simon Fraser University</name-variant><affiliation-city>Burnaby</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55625222400</author-url><authid>55625222400</authid><authname>Wiens J.</authname><surname>Wiens</surname><given-name>Jeffrey K.</given-name><initials>J.K.</initials><afid>60018491</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602957303</author-url><authid>6602957303</authid><authname>Stockie J.</authname><surname>Stockie</surname><given-name>John M.</given-name><initials>J.M.</initials><afid>60018491</afid></author><authkeywords>Flexible fibers | Fluid-structure interaction | Immersed boundary method | Kirchhoff rod theory | Parallel algorithm | Pseudo-compressibility method</authkeywords><intid>1535329028</intid><source-id>18158</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926191781"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926191781?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926191781&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926191781&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001922"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926191781</prism:url><dc:identifier>SCOPUS_ID:84926191781</dc:identifier><eid>2-s2.0-84926191781</eid><dc:title>Functional proteomics of synaptic plasma membrane ATP-ases of rat hippocampus: Effect of l-acetylcarnitine and relationships with Dementia and Depression pathophysiology</dc:title><dc:creator>Ferrari F.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>756</prism:volume><prism:pageRange>67-74</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.011</prism:doi><pii>S0014299915001922</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Synaptic energy state and mitochondrial dysfunction are crucial factors in many brain pathologies. l-acetylcarnitine, a natural derivative of carnitine, improves brain energy metabolism, and has been proposed for the Therapy of many neurological and psychiatric diseases. The effects of the drug on the maximum rate (V&lt;inf&gt;max&lt;/inf&gt;) of enzymatic activities related to hippocampal synaptic energy utilization were evaluated, in the perspective of its employment for Dementias and Depression Therapy. Two types of synaptic plasma membranes (SPM1 and SPM2) were isolated from the hippocampus of rats treated with l-acetylcarnitine (30 and 60 mg/kg i.p., 28 days, 5 days/week). Acetylcholinesterase (AChE); Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;, Mg&lt;sup&gt;2+&lt;/sup&gt;-ATP-ase; ouabain-insensitive Mg&lt;sup&gt;2+&lt;/sup&gt;-ATP-ase; Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;-ATP-ase; Ca&lt;sup&gt;2+&lt;/sup&gt;, Mg&lt;sup&gt;2+&lt;/sup&gt;-ATP-ase activities were evaluated. In control animals, enzymatic activities were differently expressed in SPM1, being the evaluated enzymatic activities higher in SPM2. Subchronic treatment with l-acetylcarnitine (i) did not modify AChE on both SPMs; (ii) increased Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;, Mg&lt;sup&gt;2+&lt;/sup&gt;-ATP-ase, ouabain-insensitive Mg&lt;sup&gt;2+&lt;/sup&gt;-ATP-ase and Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;-ATP-ase at the dose of 30 and 60 mg/kg on SPM1 and SPM2; (iii) increased Ca&lt;sup&gt;2+&lt;/sup&gt;, Mg&lt;sup&gt;2+&lt;/sup&gt;-ATP-ase activity on both SPMs at the dose of 60 mg/kg. These results have been discussed considering the pathophysiology and treatment of Dementias and Depression because, although referred to normal healthy animals, they support the notion that l-acetylcarnitine may have positive effects in these pathologies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>Università di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55658056027</author-url><authid>55658056027</authid><authname>Ferrari F.</authname><surname>Ferrari</surname><given-name>Federica</given-name><initials>F.</initials><afid>60015197</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004559218</author-url><authid>7004559218</authid><authname>Gorini A.</authname><surname>Gorini</surname><given-name>Antonella</given-name><initials>A.</initials><afid>60015197</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7103186898</author-url><authid>7103186898</authid><authname>Villa R.</authname><surname>Villa</surname><given-name>Roberto Federico</given-name><initials>R.F.</initials><afid>60015197</afid></author><authkeywords>ATP-ases | Dementias | Depression | Functional proteomics | Hippocampus | L-acetylcarnitine</authkeywords><intid>535569930</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927665964"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927665964?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927665964&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927665964&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115001837"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927665964</prism:url><dc:identifier>SCOPUS_ID:84927665964</dc:identifier><eid>2-s2.0-84927665964</eid><dc:title>Chromogranin A in gastrinomas: Promises and pitfalls</dc:title><dc:creator>Rehfeld J.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>15-20</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.03.039</prism:doi><pii>S0009898115001837</pii><dc:description>© 2015 Elsevier B.V. Patients with neuroendocrine tumors are found with increasing frequency. Accordingly, knowledge about relevant tumor markers and assays for diagnosis and control has become essential. Neuroendocrine tumors release one or more granin proteins. Of these, chromogranin A (CgA) has so far become the most widely used general marker. The CgA protein is, however, extensively cleaved and otherwise modified during the biosynthetic processing. In addition, the CgA-processing in individual tumors varies considerably. But only few CgA-assays have taken the processing into account and characterized the assays with respect to precise epitope-specificity. Consequently, we do not know which fragments most CgA-assays measure. It is therefore at present difficult to compare CgA-measurements from tumor patients. Some tumors, however, release - in addition to granins - also a specific hormone that causes a clinical syndrome. This review uses gastrinomas (gastrin-producing tumors) as a starting point for discussion of CgA versus peptide hormone as tumor marker. Data available so far indicate that well-defined assays for gastrin have significantly higher diagnostic sensitivity than CgA measurements in gastrinomas. But the review suggests that CgA-quantitation using processing-independent analysis (PIA) may provide an equally high diagnostic sensitivity and in addition offer a simple possibility for estimation of the tumor-burden.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35399970100</author-url><authid>35399970100</authid><authname>Rehfeld J.</authname><surname>Rehfeld</surname><given-name>Jens F.</given-name><initials>J.F.</initials><afid>60030840</afid></author><authkeywords>Chromogranin A | Gastrin | Gastrinomas | Granins | Neuroendocrine tumors</authkeywords><intid>535646647</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924347782"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924347782?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924347782&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924347782&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0048969715002624"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924347782</prism:url><dc:identifier>SCOPUS_ID:84924347782</dc:identifier><eid>2-s2.0-84924347782</eid><dc:title>A review and comparative analysis of European priority indices for noise action plans</dc:title><dc:creator>D'Alessandro F.</dc:creator><prism:publicationName>Science of the Total Environment</prism:publicationName><prism:issn>00489697</prism:issn><prism:eIssn>18791026</prism:eIssn><prism:volume>518-519</prism:volume><prism:pageRange>290-301</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.scitotenv.2015.02.102</prism:doi><pii>S0048969715002624</pii><dc:description>© 2015 Elsevier B.V. The European Union has provided in recent years (and is going to update) several tools to harmonise noise mapping methodologies through directives and guidelines. Unfortunately the same efforts have not been put in the harmonisation of approaches for Noise Action Plans, the effective instruments to manage noise impacts. As a consequence, each European Member State at national or even at local level defined its own methodology, usually considerably different one from the others. Nevertheless, the most common approach to deal with noise impact at a policy, economic and strategy level is the use of priority indices focused to highlight areas or buildings where mitigation actions are more advisable or urgent. The aim of the present research is to provide a review of the most used European priority indices and also to test some of them in a study area. The comparative analysis demonstrates that the method chosen for the prioritisation deeply affects the ranking of the areas where noise measures need to be realized. Some methods tend to give high priority to noise sensitive locations, others to high populated buildings, and others to the areas where noise levels are high. The study proves how much common approaches are needed also for Noise Action Plans to reach a coherent noise policy within European boundaries.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003003</affiliation-url><afid>60003003</afid><affilname>Universita degli Studi di Perugia</affilname><name-variant>Università di Perugia</name-variant><affiliation-city>Perugia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003003</affiliation-url><afid>60003003</afid><affilname>Universita degli Studi di Perugia</affilname><name-variant>Università di Perugia</name-variant><affiliation-city>Perugia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55089055700</author-url><authid>55089055700</authid><authname>D'Alessandro F.</authname><surname>D'Alessandro</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60003003</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55354894400</author-url><authid>55354894400</authid><authname>Schiavoni S.</authname><surname>Schiavoni</surname><given-name>Samuele</given-name><initials>S.</initials><afid>60003003</afid></author><authkeywords>Action plan | Annoyance | Environmental noise | Health effects | Noise planning | Priority indices</authkeywords><intid>1785137416</intid><source-id>25349</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925670432"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925670432?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925670432&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925670432&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001958"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925670432</prism:url><dc:identifier>SCOPUS_ID:84925670432</dc:identifier><eid>2-s2.0-84925670432</eid><dc:title>Effect of propane-2-sulfonic acid octadec-9-enyl-amide on the expression of adhesion molecules in human umbilical vein endothelial cells</dc:title><dc:creator>Chen C.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>756</prism:volume><prism:pageRange>15-21</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.014</prism:doi><pii>S0014299915001958</pii><dc:description>© 2015 Elsevier B.V.All rights reserved. Oleoylethanolamide (OEA), an endogenous agonist of PPARα, has been reported to have anti-atherosclerotic properties. However, OEA can be enzymatically hydrolyzed to oleic acid and ethanolamine and, thus, is not expected to be orally active. In the present study, we designed and synthesized an OEA analog, propane-2-sulfonic acid octadec-9-enyl-amide (N15), which is resistant to enzymatic hydrolysis. The purpose of this study was to investigate the effects of N15 on the expression of adhesion molecules in human umbilical vein endothelial cells (HUVECs). The results showed that N15 inhibited TNFα-induced production of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and the adhesion of monocytes to TNFα-induced HUVECs. Furthermore, the protective effect of N15 on inflammation is dependent upon a PPAR-α/γ-mediated mechanism. In conclusion, N15 protects against TNFα-induced vascular endothelial inflammation. This anti-inflammatory effect of N15 is dependent on PPAR-α/γ dual targets.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018205</affiliation-url><afid>60018205</afid><affilname>Xiamen University</affilname><name-variant>Xiamen University</name-variant><affiliation-city>Xiamen</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100332957</affiliation-url><afid>100332957</afid><affilname>Zhongshan Hospital</affilname><name-variant>Xiamen Zhongshan Hospital</name-variant><affiliation-city>Xiamen</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56160530000</author-url><authid>56160530000</authid><authname>Chen C.</authname><surname>Chen</surname><given-name>Cai Xia</given-name><initials>C.X.</initials><afid>60018205</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35224160200</author-url><authid>35224160200</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Li Chao</given-name><initials>L.C.</initials><afid>60018205</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56571625000</author-url><authid>56571625000</authid><authname>Xu X.</authname><surname>Xu</surname><given-name>Xu Dong</given-name><initials>X.D.</initials><afid>100332957</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55487194100</author-url><authid>55487194100</authid><authname>Wei X.</authname><surname>Wei</surname><given-name>Xiao</given-name><initials>X.</initials><afid>60018205</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56160491600</author-url><authid>56160491600</authid><authname>Gai Y.</authname><surname>Gai</surname><given-name>Ya Ting</given-name><initials>Y.T.</initials><afid>60018205</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56160285100</author-url><authid>56160285100</authid><authname>Peng L.</authname><surname>Peng</surname><given-name>Lu</given-name><initials>L.</initials><afid>60018205</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56542172500</author-url><authid>56542172500</authid><authname>Guo H.</authname><surname>Guo</surname><given-name>Han</given-name><initials>H.</initials><afid>60018205</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:43761726800</author-url><authid>43761726800</authid><authname>Hao-Zhou </authname><surname>Hao-Zhou</surname><given-name/><initials/><afid>60018205</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56481731500</author-url><authid>56481731500</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yi Qing</given-name><initials>Y.Q.</initials><afid>100332957</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35503528100</author-url><authid>35503528100</authid><authname>Jin X.</authname><surname>Jin</surname><given-name>Xin</given-name><initials>X.</initials><afid>60018205</afid></author><authkeywords>Adhesion molecules | Atherosclerosis | Human umbilical vein endothelial cells | Peroxisome proliferator-activated receptor-α | Peroxisome proliferator-activated receptor-γ | Propane-2-sulfonic acid octadec-9-enylamide</authkeywords><intid>1785330901</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922774666"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922774666?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922774666&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922774666&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0144861715000703"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922774666</prism:url><dc:identifier>SCOPUS_ID:84922774666</dc:identifier><eid>2-s2.0-84922774666</eid><dc:title>Inhibition of α-amylase activity by cellulose: Kinetic analysis and nutritional implications</dc:title><dc:creator>Dhital S.</dc:creator><prism:publicationName>Carbohydrate Polymers</prism:publicationName><prism:issn>01448617</prism:issn><prism:volume>123</prism:volume><prism:pageRange>305-312</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.carbpol.2015.01.039</prism:doi><pii>S0144861715000703</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. We report on inhibition of α-amylase activity by cellulose based on in vitro experiments. The presence of cellulose in the hydrolysing medium reduced the initial velocity of starch hydrolysis in a concentration dependent manner. α-Amylase adsorption to cellulose was reversible, attaining equilibrium within 30 min of incubation, and showed a higher affinity at 37 °C compared to 20 and 0 °C. The adsorption was almost unchanged in the presence of maltose (2.5-20 mM) but was hindered in the presence of excess protein, suggesting non-specific adsorption of α-amylase to cellulose. Kinetic analyses of α-amylase hydrolysis of maize starch in the presence of cellulose showed that the inhibition is of a mixed type. The dissociation constant (Kic) of the EI complex was found to be ca. 3 mg/mL. The observed inhibition of α-amylase activity suggests that cellulose in the diet can potentially attenuate starch hydrolysis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35203263700</author-url><authid>35203263700</authid><authname>Dhital S.</authname><surname>Dhital</surname><given-name>Sushil</given-name><initials>S.</initials><afid>60031004</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004273819</author-url><authid>7004273819</authid><authname>Gidley M.</authname><surname>Gidley</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60031004</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:40762420900</author-url><authid>40762420900</authid><authname>Warren F.</authname><surname>Warren</surname><given-name>Frederick J.</given-name><initials>F.J.</initials><afid>60031004</afid></author><authkeywords>Adsorption isotherm | Alpha-amylase | Cellulose | Inhibition | Michaelis-Menten kinetics | Starch</authkeywords><intid>2034864419</intid><source-id>25801</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927639668"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927639668?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927639668&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927639668&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115001849"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927639668</prism:url><dc:identifier>SCOPUS_ID:84927639668</dc:identifier><eid>2-s2.0-84927639668</eid><dc:title>Joint effects of serum uric acid and body mass index on risk of prehypertension in Chinese population</dc:title><dc:creator>Jiang L.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>1-5</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.03.040</prism:doi><pii>S0009898115001849</pii><dc:description>© 2015 Elsevier B.V. Background: There are few data available on the association between serum uric acid (UA) and prehypertension when hypertension prevention efforts may be applicable. Methods: We performed a cross-sectional study to evaluate risk of prehypertension and its association with serum UA and other confounding factors. Levels of serum UA, blood pressure, body mass index (BMI) and some related factors were detected. Results: Participants with prehypertension had higher levels of serum UA and BMI. Compared to those with normotension, the multivariate-adjusted odds ratios [ORs, 95% confidence interval (CI)] for men with prehypertension were 1.33 (95% CI, 1.08-3.91) of serum UA and 1.21 (95% CI, 1.17-1.29) of BMI. In women, the ORs were 1.96 (95% CI, 1.21-3.46) and 1.28 (95% CI, 1.14-2.46), respectively. Increasing serum UA and BMI were associated with increased risk of prehypertension. Compared with the lowest quartiles, the highest serum UA and BMI quartiles entailed &gt;. 4.4 times greater risk of prehypertension. In sex-specific analysis, OR was 2.41 (95% CI, 1.55-3.75) for men and 7.37 (95% CI, 4.16-13.0) for women. Conclusions: Both high serum UA and high BMI are associated with risk of prehypertension. Individuals with higher serum UA and BMI simultaneously have a higher risk for prehypertension, especially for women.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069723</affiliation-url><afid>60069723</afid><affilname>Hospital of Nanjing Medical University</affilname><name-variant>Hospital of Nanjing Medical University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112580499</affiliation-url><afid>112580499</afid><affilname>National Key Clinical Department of Laboratory Medicine</affilname><name-variant>National Key Clinical Department of Laboratory Medicine</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108610226</affiliation-url><afid>108610226</afid><affilname>Jiangsu Shengze Hospital</affilname><name-variant>Jiangsu Shengze Hospital</name-variant><affiliation-city>Suzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56591038900</author-url><authid>56591038900</authid><authname>Jiang L.</authname><surname>Jiang</surname><given-name>Li</given-name><initials>L.</initials><afid>60069723</afid><afid>112580499</afid><afid>108610226</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56591038900</author-url><authid>56591038900</authid><authname>Jiang L.</authname><surname>Jiang</surname><given-name>Li</given-name><initials>L.</initials><afid>60069723</afid><afid>112580499</afid><afid>108610226</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56591038900</author-url><authid>56591038900</authid><authname>Jiang L.</authname><surname>Jiang</surname><given-name>Li</given-name><initials>L.</initials><afid>60069723</afid><afid>112580499</afid><afid>108610226</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56149978500</author-url><authid>56149978500</authid><authname>Mo D.</authname><surname>Mo</surname><given-name>Dongping</given-name><initials>D.</initials><afid>60069723</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56591058800</author-url><authid>56591058800</authid><authname>Yang R.</authname><surname>Yang</surname><given-name>Ruixia</given-name><initials>R.</initials><afid>60069723</afid><afid>112580499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56591058800</author-url><authid>56591058800</authid><authname>Yang R.</authname><surname>Yang</surname><given-name>Ruixia</given-name><initials>R.</initials><afid>60069723</afid><afid>112580499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36897986100</author-url><authid>36897986100</authid><authname>Ye Q.</authname><surname>Ye</surname><given-name>Qin</given-name><initials>Q.</initials><afid>60069723</afid><afid>112580499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36897986100</author-url><authid>36897986100</authid><authname>Ye Q.</authname><surname>Ye</surname><given-name>Qin</given-name><initials>Q.</initials><afid>60069723</afid><afid>112580499</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56151245000</author-url><authid>56151245000</authid><authname>Wu J.</authname><surname>Wu</surname><given-name>Jing</given-name><initials>J.</initials><afid>108610226</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56591102900</author-url><authid>56591102900</authid><authname>Yu G.</authname><surname>Yu</surname><given-name>Gang</given-name><initials>G.</initials><afid>108610226</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56150742100</author-url><authid>56150742100</authid><authname>Xu J.</authname><surname>Xu</surname><given-name>Jian</given-name><initials>J.</initials><afid>60069723</afid><afid>112580499</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56150742100</author-url><authid>56150742100</authid><authname>Xu J.</authname><surname>Xu</surname><given-name>Jian</given-name><initials>J.</initials><afid>60069723</afid><afid>112580499</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:15766240800</author-url><authid>15766240800</authid><authname>Pan S.</authname><surname>Pan</surname><given-name>Shiyang</given-name><initials>S.</initials><afid>60069723</afid><afid>112580499</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:15766240800</author-url><authid>15766240800</authid><authname>Pan S.</authname><surname>Pan</surname><given-name>Shiyang</given-name><initials>S.</initials><afid>60069723</afid><afid>112580499</afid></author><authkeywords>Body mass index | Prehypertension | Serum uric acid</authkeywords><intid>1785647491</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84897889113"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84897889113?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84897889113&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84897889113&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0300483X14000389"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84897889113</prism:url><dc:identifier>SCOPUS_ID:84897889113</dc:identifier><eid>2-s2.0-84897889113</eid><dc:title>Myeloperoxidase deficiency attenuates nitrogen mustard-induced skin injuries</dc:title><dc:creator>Jain A.</dc:creator><prism:publicationName>Toxicology</prism:publicationName><prism:issn>0300483X</prism:issn><prism:eIssn>18793185</prism:eIssn><prism:volume>320</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>25-33</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.tox.2014.02.013</prism:doi><pii>S0300483X14000389</pii><dc:description>The pathologic mechanisms of skin injuries, following the acute inflammatory response induced by vesicating agents sulfur mustard (SM) and nitrogen mustard (NM) exposure, are poorly understood. Neutrophils which accumulate at the site of injury, abundantly express myeloperoxidase (MPO), a heme protein that is implicated in oxidant-related antimicrobial and cytotoxic responses. Our previous studies have shown that exposure to SM analog 2-chloroethyl ethyl sulfide (CEES) or NM results in an inflammatory response including increased neutrophilic infiltration and MPO activity. To further define the role of neutrophil-derived MPO in NM-induced skin injury, here we used a genetic approach and examined the effect of NM exposure (12. h and 24. h) on previously established injury endpoints in C57BL/6J wild type (WT) and B6.129X1-MPOtm1Lus/J mice (MPO KO), homozygous null for MPO gene. NM exposure caused a significant increase in skin bi-fold thickness, epidermal thickness, microvesication, DNA damage and apoptosis in WT mice compared to MPO KO mice. MPO KO mice showed relatively insignificant effect. Similarly, NM induced increases in the expression of inflammatory and proteolytic mediators, including COX-2, iNOS and MMP-9 in WT mice, while having a significantly lower effect in MPO KO mice. Collectively, these results show that MPO, which generates microbicidal oxidants, plays an important role in NM-induced skin injuries. This suggests the development of mechanism-based treatments against NM- and SM-induced skin injuries that inhibit MPO activity and attenuate MPO-derived oxidants. © 2014 Elsevier Ireland Ltd.</dc:description><citedby-count>3</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009866</affiliation-url><afid>60009866</afid><affilname>University of Colorado Health Sciences Center</affilname><name-variant>University of Colorado</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009866</affiliation-url><afid>60009866</afid><affilname>University of Colorado Health Sciences Center</affilname><name-variant>University of Colorado</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009866</affiliation-url><afid>60009866</afid><affilname>University of Colorado Health Sciences Center</affilname><name-variant>University of Colorado</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><pubmed-id>24631667</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55470986800</author-url><authid>55470986800</authid><authname>Jain A.</authname><surname>Jain</surname><given-name>Anil K.</given-name><initials>A.K.</initials><afid>60009866</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15766090000</author-url><authid>15766090000</authid><authname>Tewari-Singh N.</authname><surname>Tewari-Singh</surname><given-name>Neera</given-name><initials>N.</initials><afid>60009866</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:42261805000</author-url><authid>42261805000</authid><authname>Inturi S.</authname><surname>Inturi</surname><given-name>Swetha</given-name><initials>S.</initials><afid>60009866</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004487996</author-url><authid>7004487996</authid><authname>Orlicky D.</authname><surname>Orlicky</surname><given-name>David J.</given-name><initials>D.J.</initials><afid>60009866</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55543700500</author-url><authid>55543700500</authid><authname>White C.</authname><surname>White</surname><given-name>Carl W.</given-name><initials>C.W.</initials><afid>60009866</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55567592000</author-url><authid>55567592000</authid><authname>Agarwal R.</authname><surname>Agarwal</surname><given-name>Rajesh</given-name><initials>R.</initials><afid>60009866</afid></author><authkeywords>Apoptosis | DNA damage | Inflammation | Myeloperoxidase | Nitrogen mustard | Sulfur mustard</authkeywords><intid>1030704313</intid><source-id>25219</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929660282"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929660282?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929660282&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929660282&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0304394015003377"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929660282</prism:url><dc:identifier>SCOPUS_ID:84929660282</dc:identifier><eid>2-s2.0-84929660282</eid><dc:title>Human mesenchymal stem cells improve the neurodegeneration of femoral nerve in a diabetic foot ulceration rats</dc:title><dc:creator>Xia N.</dc:creator><prism:publicationName>Neuroscience Letters</prism:publicationName><prism:issn>03043940</prism:issn><prism:eIssn>18727972</prism:eIssn><prism:volume>597</prism:volume><prism:pageRange>84-89</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neulet.2015.04.038</prism:doi><pii>S0304394015003377</pii><dc:description>© 2015 Elsevier Ireland Ltd. Neuropathy is observed in 50% of diabetic patients with diabetic foot. This study attempted to explore the potential role of human mesenchymal stem cells-umbilical cord blood (hMSCs-UC) in femoral nerve (FN) neuropathy. The model rats were established by one time administration of streptozotocin and empyrosis on the dorsal hind foot. At 3d, 7d, 14d after treatment with hMSCs-UC or saline through left femoral artery, the serum NGF was examined by ELISA; NF-200 expression in FN was evaluated by immunohistochemistry; the diameter and roundness of FN, the ratio of capillary and muscular fiber of gastrocnemius were calculated under light microscope; and neuronal degenerations, such as demyelization, axonal atrophy, and loose arrangement of nerve fibers, were observed by electronic microscope. The results showed that, in hMSCs-UC-treated model rats, serum NGF was increased with higher positive rate of NF-200. Although the difference in FN diameters was not established among groups, improvement of roundness of FN was confirmed with increase in the numbers of capillary in FN-innervated gastrocnemius; additionally, degenerative neuropathy was significantly improved. Importantly, the functional study of electroneurogram (ENG) showed that, slowed conduction of FN in model rats was significantly restored by hMSCs-CU treatment. These data suggested that hMSCs-UC-treatment partially reverse the neuronal degeneration and nerve function of FN, which might be contributed by the upregulation of NGF with dramatic angiogenesis in FN-innervated gastrocnemius, consequently reversing neuronal structure and function, preventing or curing foot ulceration.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021615</affiliation-url><afid>60021615</afid><affilname>Harbin Medical University</affilname><name-variant>Harbin Medical University</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55976234800</author-url><authid>55976234800</authid><authname>Xia N.</authname><surname>Xia</surname><given-name>Nan</given-name><initials>N.</initials><afid>60021615</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56419001100</author-url><authid>56419001100</authid><authname>Xu J.</authname><surname>Xu</surname><given-name>Jin Mei</given-name><initials>J.M.</initials><afid>60021615</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55976731600</author-url><authid>55976731600</authid><authname>Zhao N.</authname><surname>Zhao</surname><given-name>Nan</given-name><initials>N.</initials><afid>60021615</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55976554400</author-url><authid>55976554400</authid><authname>Zhao Q.</authname><surname>Zhao</surname><given-name>Qing Song</given-name><initials>Q.S.</initials><afid>60021615</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56508602600</author-url><authid>56508602600</authid><authname>Li M.</authname><surname>Li</surname><given-name>Ming</given-name><initials>M.</initials><afid>60021615</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24491654400</author-url><authid>24491654400</authid><authname>Cheng Z.</authname><surname>Cheng</surname><given-name>Zhi Feng</given-name><initials>Z.F.</initials><afid>60021615</afid></author><authkeywords>Diabetic foot | Electroneurogram | Human mesenchymal stem cells from umbilical cord matrix | Neurofilament | NGF | Peripheral neuropathy</authkeywords><intid>35990762</intid><source-id>18046</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929305206"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929305206?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929305206&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929305206&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1386142515002590"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929305206</prism:url><dc:identifier>SCOPUS_ID:84929305206</dc:identifier><eid>2-s2.0-84929305206</eid><dc:title>Surface-enhanced Raman spectroscopy of genomic DNA from in vitro grown tomato (Lycopersicon esculentum Mill.) cultivars before and after plant cryopreservation</dc:title><dc:creator>Muntean C.</dc:creator><prism:publicationName>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</prism:publicationName><prism:issn>13861425</prism:issn><prism:volume>144</prism:volume><prism:pageRange>107-114</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.saa.2015.02.085</prism:doi><pii>S1386142515002590</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. In this work the surface-enhanced Raman scattering (SERS) spectra of five genomic DNAs from non-cryopreserved control tomato plants (Lycopersicon esculentum Mill. cultivars Siriana, Darsirius, Kristin, Pontica and Capriciu) respectively, have been analyzed in the wavenumber range 400-1800 cm&lt;sup&gt;-1&lt;/sup&gt;. Structural changes induced in genomic DNAs upon cryopreservation were discussed in detail for four of the above mentioned tomato cultivars. The surface-enhanced Raman vibrational modes for each of these cases, spectroscopic band assignments and structural interpretations of genomic DNAs are reported. We have found, that DNA isolated from Siriana cultivar leaf tissues suffers the weakest structural changes upon cryogenic storage of tomato shoot apices. On the contrary, genomic DNA extracted from Pontica cultivar is the most responsive system to cryopreservation process. Particularly, both C2′-endo-anti and C3'-endo-anti conformations have been detected. As a general observation, the wavenumber range 1511-1652 cm&lt;sup&gt;-1&lt;/sup&gt;, being due to dA, dG and dT residues seems to be influenced by cryopreservation process. These changes could reflect unstacking of DNA bases. However, not significant structural changes of genomic DNAs from Siriana, Darsirius and Kristin have been found upon cryopreservation process of tomato cultivars. Based on this work, specific plant DNA-ligand interactions or accurate local structure of DNA in the proximity of a metallic surface, might be further investigated using surface-enhanced Raman spectroscopy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018494</affiliation-url><afid>60018494</afid><affilname>National Institute for Research and Development of Isotopic and Molecular Technologies</affilname><name-variant>National Institute for Research and Development of Isotopic and Molecular Technologies</name-variant><affiliation-city>Cluj Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024417</affiliation-url><afid>60024417</afid><affilname>Universitatea Babes-Bolyai din Cluj-Napoca</affilname><name-variant>Babes-Bolyai University</name-variant><affiliation-city>Cluj Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001705</affiliation-url><afid>60001705</afid><affilname>National Institute for Research and Development in Microtechnologies Romania</affilname><name-variant>National Institute for Research and Development in Microtechnologies</name-variant><affiliation-city>Bucharest</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9244723900</author-url><authid>9244723900</authid><authname>Muntean C.</authname><surname>Muntean</surname><given-name>Cristina M.</given-name><initials>C.M.</initials><afid>60018494</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003947980</author-url><authid>7003947980</authid><authname>Leopold N.</authname><surname>Leopold</surname><given-name>Nicolae</given-name><initials>N.</initials><afid>60024417</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14038527500</author-url><authid>14038527500</authid><authname>Tripon C.</authname><surname>Tripon</surname><given-name>Carmen</given-name><initials>C.</initials><afid>60018494</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:9636235300</author-url><authid>9636235300</authid><authname>Coste A.</authname><surname>Coste</surname><given-name>Ana</given-name><initials>A.</initials><afid>60001705</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:16645529400</author-url><authid>16645529400</authid><authname>Halmagyi A.</authname><surname>Halmagyi</surname><given-name>Adela</given-name><initials>A.</initials><afid>60001705</afid></author><authkeywords>DNA | Leaf tissue | Silver colloidal nanoparticles | Surface-enhanced Raman scattering (SERS) | Tomato cultivars</authkeywords><intid>2035940958</intid><source-id>24530</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928919837"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928919837?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928919837&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928919837&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1570023215002111"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928919837</prism:url><dc:identifier>SCOPUS_ID:84928919837</dc:identifier><eid>2-s2.0-84928919837</eid><dc:title>Determination of 3-mercaptopropionic acid by HPLC: A sensitive method for environmental applications</dc:title><dc:creator>Salgado P.</dc:creator><prism:publicationName>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</prism:publicationName><prism:issn>15700232</prism:issn><prism:eIssn>1873376X</prism:eIssn><prism:volume>992</prism:volume><prism:pageRange>103-108</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jchromb.2015.04.008</prism:doi><pii>S1570023215002111</pii><dc:description>© 2015 Elsevier B.V. The organic sulfur compound 3-mercaptopropionic acid (3-MPA) is an important thiol intermediate in organic sulfur metabolism in natural environments. It is generated during degradation of sulfur-containing amino acids (e.g. methionine) and from demethylation of dimethylsulfoniopropionate (DMSP). This pathway is an alternative enzymatic process in the DMSP catabolism that routes sulfur away from the climatically-active dimethyl sulfide (DMS). 3-MPA detection and subsequent quantification in different matrices is difficult due to its extreme reactivity. We therefore developed a sensitive method for determination of 3-MPA based on pre-column derivatization with monobromobimane and analysis by high-performance liquid chromatography (HPLC) with fluorescence detection. This methodology was first tested with 3-MPA standards under low (0.005-0.2μmolL&lt;sup&gt;-1&lt;/sup&gt;) and high (1-25μmolL&lt;sup&gt;-1&lt;/sup&gt;) concentrations. For the optimization of the reaction, CHES and, alternatively, Tris-HCl buffers were evaluated in the derivatization step, with Tris-HCl showing more effective separation of thiol derivatives and a better 3-MPA peak shape. The detection limit was 4.3nmolL&lt;sup&gt;-1&lt;/sup&gt; with a 10μL sample injection, and mean recoveries of 3-MPA ranged from 97 to 105% in estuarine waters with different salinities (0.17 and 35.9ppt). The linearity (r&gt;0.99) and repeatability of detector response, with intra- and inter-day precision (% CV) of 2.68-7.01% and 4.86-12.5%, respectively, confirmed the reliability of the method. Previous 3-MPA analytical methods required immediate analysis due to unstable derivatives, but in this method we achieved high stability of the derivatized samples when stored at 4°C, with only a 3-5% loss after more than one year of storage. This method was successfully applied to measure 3-MPA concentrations and rates of 3-MPA production in a variety of intertidal estuarine sediment slurries. Dissolved 3-MPA concentrations in these sediment slurries varied between 2 and 237μmolL&lt;sup&gt;-1&lt;/sup&gt; and, 3-MPA net fluxes ranged in wet sediments between -3.6±1.7 and 30±5μmolL&lt;sup&gt;-1&lt;/sup&gt;g&lt;sup&gt;-1&lt;/sup&gt;h&lt;sup&gt;-1&lt;/sup&gt;. Thus, the application of this optimized methodology showed an efficient performance for measuring 3-MPA in environmental samples, with a straightforward sample derivatization and a simple analysis of stable 3-MPA derivatives.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007249</affiliation-url><afid>60007249</afid><affilname>Universidade do Porto</affilname><name-variant>Universidade do Porto</name-variant><affiliation-city>Porto</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000705</affiliation-url><afid>60000705</afid><affilname>University of South Alabama</affilname><name-variant>University of South Alabama</name-variant><affiliation-city>Mobile</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008318</affiliation-url><afid>60008318</afid><affilname>Dauphin Island Sea Laboratory</affilname><name-variant>Dauphin Island Sea Laboratory</name-variant><affiliation-city>Dauphin Island</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54783266600</author-url><authid>54783266600</authid><authname>Salgado P.</authname><surname>Salgado</surname><given-name>P.</given-name><initials>P.</initials><afid>60007249</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26425353300</author-url><authid>26425353300</authid><authname>Visnevschi-Necrasov T.</authname><surname>Visnevschi-Necrasov</surname><given-name>T.</given-name><initials>T.</initials><afid>60007249</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004339376</author-url><authid>7004339376</authid><authname>Kiene R.</authname><surname>Kiene</surname><given-name>R. P.</given-name><initials>R.P.</initials><afid>60000705</afid><afid>60008318</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004339376</author-url><authid>7004339376</authid><authname>Kiene R.</authname><surname>Kiene</surname><given-name>R. P.</given-name><initials>R.P.</initials><afid>60000705</afid><afid>60008318</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56622504100</author-url><authid>56622504100</authid><authname>Azevedo I.</authname><surname>Azevedo</surname><given-name>I.</given-name><initials>I.</initials><afid>60007249</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56647022900</author-url><authid>56647022900</authid><authname>Rocha A.</authname><surname>Rocha</surname><given-name>A. C S</given-name><initials>A.C.S.</initials><afid>60007249</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56622324200</author-url><authid>56622324200</authid><authname>Almeida C.</authname><surname>Almeida</surname><given-name>C. M R</given-name><initials>C.M.R.</initials><afid>60007249</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:22980541800</author-url><authid>22980541800</authid><authname>Magalhães C.</authname><surname>Magalhães</surname><given-name>C.</given-name><initials>C.</initials><afid>60007249</afid></author><authkeywords>3-Mercaptopropionic acid (3-MPA) | High-Performance Liquid Chromatography (HPLC) | Monobromobimane | Thiols</authkeywords><intid>1535862356</intid><source-id>24172</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925937189"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925937189?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925937189&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925937189&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0272771415000669"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925937189</prism:url><dc:identifier>SCOPUS_ID:84925937189</dc:identifier><eid>2-s2.0-84925937189</eid><dc:title>Definition of sanitary boundaries to prevent ISAv spread between salmon farms in southern Chile based on numerical simulations of currents</dc:title><dc:creator>Olivares G.</dc:creator><prism:publicationName>Estuarine, Coastal and Shelf Science</prism:publicationName><prism:issn>02727714</prism:issn><prism:volume>158</prism:volume><prism:pageRange>31-39</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ecss.2015.02.013</prism:doi><pii>S0272771415000669</pii><dc:description>© 2015 Elsevier Ltd. The infectious Salmon Anemia virus (ISAv) is a pathogen that mainly affects the Atlantic Salmon (Salmo salar). It was detected in Norway in 1984 and in June 2007 appeared in Chile, producing a drop of more than 30% in the country's production level. It is expected that with certain regularity, outbreaks will continue to appear in Chile without the need of reintroducing the virus from foreign countries. We present a numerical study of the influence of winds and tides in the dispersion of lagrangian particles to simulate the transport of ISAv in the Aysen region, in southern Chile. This study combines the use of numerical models of the ocean and atmosphere, lagrangian tracking and biological aspects of ISAv infections. As in previous results, a wider dispersion of ISAv was observed during spring tides. Temporal changes in wind significantly modified the transport of viral particles from an infected center. Under similar forcing conditions, the areas of risk associated to culture sites separated by a few kilometers could be very different. Our main results remark the importance of the use of a detailed knowledge of hydrographic and atmospheric circulation in the definition of boundaries for sanitary management areas. We suggest that a methodology similar to the one presented in this study should be considered to define sanitary strategies to minimize the occurrence of native outbreaks of ISAv.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112682472</affiliation-url><afid>112682472</afid><affilname>University of Los Lagos</affilname><name-variant>University of Los Lagos</name-variant><affiliation-city>Puerto Montt</affiliation-city><affiliation-country>Chile</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001282</affiliation-url><afid>60001282</afid><affilname>University of Concepcion</affilname><name-variant>University of Concepción</name-variant><affiliation-city>Biobio</affiliation-city><affiliation-country>Chile</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112595467</affiliation-url><afid>112595467</afid><affilname>Centro de Estudios Avanzados en Zonas Aridas</affilname><name-variant>Centro de Estudios Avanzados en Zonas Aridas</name-variant><affiliation-city>La Serena</affiliation-city><affiliation-country>Chile</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029195</affiliation-url><afid>60029195</afid><affilname>Universidad Catolica del Norte</affilname><name-variant>Universidad Católica del Norte</name-variant><affiliation-city>Antofagasta</affiliation-city><affiliation-country>Chile</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071612</affiliation-url><afid>60071612</afid><affilname>Universidad de la Republica</affilname><name-variant>Universidad de la República</name-variant><affiliation-city>Montevideo</affiliation-city><affiliation-country>Uruguay</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56350370600</author-url><authid>56350370600</authid><authname>Olivares G.</authname><surname>Olivares</surname><given-name>Gonzalo</given-name><initials>G.</initials><afid>112682472</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25822830600</author-url><authid>25822830600</authid><authname>Sepúlveda H.</authname><surname>Sepúlveda</surname><given-name>H. H.</given-name><initials>H.H.</initials><afid>60001282</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56113627000</author-url><authid>56113627000</authid><authname>Yannicelli B.</authname><surname>Yannicelli</surname><given-name>B.</given-name><initials>B.</initials><afid>112595467</afid><afid>60029195</afid><afid>60071612</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56113627000</author-url><authid>56113627000</authid><authname>Yannicelli B.</authname><surname>Yannicelli</surname><given-name>B.</given-name><initials>B.</initials><afid>112595467</afid><afid>60029195</afid><afid>60071612</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56113627000</author-url><authid>56113627000</authid><authname>Yannicelli B.</authname><surname>Yannicelli</surname><given-name>B.</given-name><initials>B.</initials><afid>112595467</afid><afid>60029195</afid><afid>60071612</afid></author><authkeywords>Atlantic salmon | Chile | ISAv | Numerical model | Sanitary boundaries | Spread</authkeywords><intid>35387772</intid><source-id>26844</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929167621"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929167621?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929167621&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929167621&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115002351"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929167621</prism:url><dc:identifier>SCOPUS_ID:84929167621</dc:identifier><eid>2-s2.0-84929167621</eid><dc:title>Clinical correlation between a point-of-care testing system and laboratory automation for lipid profile</dc:title><dc:creator>Ferreira C.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>263-266</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.04.036</prism:doi><pii>S0009898115002351</pii><dc:description>© 2015 Published by Elsevier B.V. Background: We evaluated the clinical correlation between the CardioChek PA analyzer and a clinical laboratory reference method to use for screening program purposes. Methods: Fasting blood samples were collected on 516 patients (age 20-85 y). One venous sample was collected using a serum tube for the evaluation on a COBAS reference analyzer. A second venous sample was collected in a lithium heparin tube and was evaluated on the CardioChek PA analyzer (CCPA venous). A fingerstick sample (CCPA fingerstick) was evaluated only on the CardioChek PA analyzer. Linear regression analyses were performed for each measured analyte, total cholesterol, HDL-cholesterol and triglycerides. Results: The correlation between the CCPA fingerstick and CCPA venous was extremely high for HDL-C and triglycerides, and good for total cholesterol. Our results demonstrated a good clinical agreement for total cholesterol, HDL-C and triglycerides between 97.7% and 94.6% in the comparison of the CCPA to the reference analyzer. Conclusions: We identified the pre-analytic phase as an important step to guarantee the quality of results and indicate that the CardioChek PA is a reliable lipid point-of-care testing system that can be used for the application of clinical screening anywhere.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016295</affiliation-url><afid>60016295</afid><affilname>Hospital Israelita Albert Einstein</affilname><name-variant>Albert Einstein Hospital</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014992</affiliation-url><afid>60014992</afid><affilname>Universidade Federal de Sao Paulo</affilname><name-variant>Federal University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013701</affiliation-url><afid>60013701</afid><affilname>Universidade de Santo Amaro</affilname><name-variant>Universidade de Santo Amaro</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015043</affiliation-url><afid>60015043</afid><affilname>Universidade Federal do Parana</affilname><name-variant>Universidade Federal do Paraná</name-variant><affiliation-city>Curitiba</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113802849</affiliation-url><afid>113802849</afid><affilname>ZIVD, LLC</affilname><name-variant>ZIVD, LLC</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202112347</author-url><authid>7202112347</authid><authname>Ferreira C.</authname><surname>Ferreira</surname><given-name>Carlos Eduardo dos Santos</given-name><initials>C.E.d.S.</initials><afid>60016295</afid><afid>60014992</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202112347</author-url><authid>7202112347</authid><authname>Ferreira C.</authname><surname>Ferreira</surname><given-name>Carlos Eduardo dos Santos</given-name><initials>C.E.d.S.</initials><afid>60016295</afid><afid>60014992</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36805287100</author-url><authid>36805287100</authid><authname>França C.</authname><surname>França</surname><given-name>Carolina Nunes</given-name><initials>C.N.</initials><afid>60014992</afid><afid>60013701</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36805287100</author-url><authid>36805287100</authid><authname>França C.</authname><surname>França</surname><given-name>Carolina Nunes</given-name><initials>C.N.</initials><afid>60014992</afid><afid>60013701</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:9245743000</author-url><authid>9245743000</authid><authname>Correr C.</authname><surname>Correr</surname><given-name>Cassyano Januário</given-name><initials>C.J.</initials><afid>60015043</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640867200</author-url><authid>56640867200</authid><authname>Zucker M.</authname><surname>Zucker</surname><given-name>Márcia L.</given-name><initials>M.L.</initials><afid>113802849</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6601955934</author-url><authid>6601955934</authid><authname>Andriolo A.</authname><surname>Andriolo</surname><given-name>Adagmar</given-name><initials>A.</initials><afid>60014992</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6507957387</author-url><authid>6507957387</authid><authname>Scartezini M.</authname><surname>Scartezini</surname><given-name>Marileia</given-name><initials>M.</initials><afid>60015043</afid></author><authkeywords>CardioChek PA | Cardiovascular diseases | Point-of-care testing</authkeywords><intid>535919256</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927739541"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927739541?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927739541&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927739541&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003164"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927739541</prism:url><dc:identifier>SCOPUS_ID:84927739541</dc:identifier><eid>2-s2.0-84927739541</eid><dc:title>The role of TRPM2 in hydrogen peroxide-induced expression of inflammatory cytokine and chemokine in rat trigeminal ganglia</dc:title><dc:creator>Chung M.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>297</prism:volume><prism:pageRange>160-169</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.067</prism:doi><pii>S0306452215003164</pii><dc:description>© 2015 IBRO. Trigeminal ganglia (TG) contain neuronal cell bodies surrounded by satellite glial cells. Although peripheral injury is well known to induce changes in gene expression within sensory ganglia, detailed mechanisms whereby peripheral injury leads to gene expression within sensory ganglia are not completely understood. Reactive oxygen species (ROS) are an important modulator of hyperalgesia, but the role of ROS generated within sensory ganglia is unclear. Since ROS are known to affect transcription processes, ROS generated within sensory ganglia could directly influence gene expression and induce cellular changes at the soma level. In this study, we hypothesized that peripheral inflammation leads to cytokine and chemokine production and ROS generation within TG and that transient receptor potential melastatin (TRPM2), a well known oxidative sensor, contributes to ROS-induced gene regulation within TG. The masseter injection of complete Freund's adjuvant (CFA) resulted in a significantly elevated level of ROS within TG of the inflamed side with a concurrent increase in cytokine expression in TG. Treatment of TG cultures with H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; significantly up-regulated mRNA and protein levels of cytokine/chemokine such as interleukin 6 (IL-6) and chemokine (C-X-C motif) ligand 2 (CXCL2). TRPM2 was expressed in both neurons and non-neuronal cells in TG, and pretreatment of TG cultures with 2-aminoethoxydiphenyl borate (2-APB), an inhibitor of TRPM2, or siRNA against TRPM2 attenuated H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;-induced up-regulation of IL-6 and CXCL2. These results suggested that activation of TRPM2 could play an important role in the modulation of cytokine/chemokine expression within TG under oxidative stress and that such changes may contribute to amplification of nociceptive signals leading to pathological pain conditions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020304</affiliation-url><afid>60020304</afid><affilname>University of Maryland</affilname><name-variant>University of Maryland</name-variant><affiliation-city>College Park</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56594175300</author-url><authid>56594175300</authid><authname>Chung M.</authname><surname>Chung</surname><given-name>M. K.</given-name><initials>M.K.</initials><afid>60020304</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55877009700</author-url><authid>55877009700</authid><authname>Asgar J.</authname><surname>Asgar</surname><given-name>J.</given-name><initials>J.</initials><afid>60020304</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56594140800</author-url><authid>56594140800</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>J.</given-name><initials>J.</initials><afid>60020304</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56594521300</author-url><authid>56594521300</authid><authname>Shim M.</authname><surname>Shim</surname><given-name>M. S.</given-name><initials>M.S.</initials><afid>60020304</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56595286300</author-url><authid>56595286300</authid><authname>Dumler C.</authname><surname>Dumler</surname><given-name>C.</given-name><initials>C.</initials><afid>60020304</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16073043500</author-url><authid>16073043500</authid><authname>Ro J.</authname><surname>Ro</surname><given-name>J. Y.</given-name><initials>J.Y.</initials><afid>60020304</afid></author><authkeywords>CXCL2 | IL-6 | Myositis | Oxidative stress | Satellite glial cells</authkeywords><intid>35665929</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926218025"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926218025?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926218025&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926218025&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915002824"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926218025</prism:url><dc:identifier>SCOPUS_ID:84926218025</dc:identifier><eid>2-s2.0-84926218025</eid><dc:title>Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type i diabetic kidney</dc:title><dc:creator>Morita T.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>756</prism:volume><prism:pageRange>85-91</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.053</prism:doi><pii>S0014299915002824</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. We previously reported that the functional deletion of p21, a cyclin-dependent kinase inhibitor, in mice attenuated renal cell senescence in streptozotocin (STZ)-induced type 1 diabetic mice. In the present study, we investigated the effect of iron chelation on renal cell senescence and inflammation in the type 1 diabetic kidney. STZ-treated mice showed increase in iron accumulation, tubular cell senescence and macrophage infiltration at week 28 in the kidney. Administering deferasirox, which removes only dietary iron, significantly attenuated iron accumulation in proximal tubules and the number of infiltrating F4/80-positive cells without effecting blood glucose, hematocrit or hemoglobin levels. In contrast however, deferasirox did not influence renal cell senescence. The lack of p21 decreased the renal tubular iron accumulation and did not change tubular cell senescence. Interestingly, the STZ-treated animals showed an increase in p16, another cyclin-dependent kinase inhibitor. The results suggest that type 1 diabetes increases renal tubular iron accumulation and macrophage infiltration through a p21-dependent mechanism, and that the chelation of dietary iron attenuates these responses.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032492</affiliation-url><afid>60032492</afid><affilname>Kagawa University</affilname><name-variant>Kagawa University</name-variant><affiliation-city>Takamatsu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026645</affiliation-url><afid>60026645</afid><affilname>Kansai Medical University</affilname><name-variant>Kansai Medical University</name-variant><affiliation-city>Moriguchi</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025639</affiliation-url><afid>60025639</afid><affilname>Tokyo Women's Medical University</affilname><name-variant>Tokyo Women's Medical University</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56579616800</author-url><authid>56579616800</authid><authname>Morita T.</authname><surname>Morita</surname><given-name>Tatsuyori</given-name><initials>T.</initials><afid>60032492</afid><afid>60026645</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56579616800</author-url><authid>56579616800</authid><authname>Morita T.</authname><surname>Morita</surname><given-name>Tatsuyori</given-name><initials>T.</initials><afid>60032492</afid><afid>60026645</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004424413</author-url><authid>7004424413</authid><authname>Nakano D.</authname><surname>Nakano</surname><given-name>Daisuke</given-name><initials>D.</initials><afid>60032492</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56542970000</author-url><authid>56542970000</authid><authname>Kitada K.</authname><surname>Kitada</surname><given-name>Kento</given-name><initials>K.</initials><afid>60032492</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56579687500</author-url><authid>56579687500</authid><authname>Morimoto S.</authname><surname>Morimoto</surname><given-name>Satoshi</given-name><initials>S.</initials><afid>60025639</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56536098400</author-url><authid>56536098400</authid><authname>Ichihara A.</authname><surname>Ichihara</surname><given-name>Atsuhiro</given-name><initials>A.</initials><afid>60025639</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56579995900</author-url><authid>56579995900</authid><authname>Hitomi H.</authname><surname>Hitomi</surname><given-name>Hirofumi</given-name><initials>H.</initials><afid>60032492</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:26643284900</author-url><authid>26643284900</authid><authname>Kobori H.</authname><surname>Kobori</surname><given-name>Hiroyuki</given-name><initials>H.</initials><afid>60032492</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003965506</author-url><authid>7003965506</authid><authname>Shiojima I.</authname><surname>Shiojima</surname><given-name>Ichiro</given-name><initials>I.</initials><afid>60025639</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7102743908</author-url><authid>7102743908</authid><authname>Nishiyama A.</authname><surname>Nishiyama</surname><given-name>Akira</given-name><initials>A.</initials><afid>60032492</afid></author><authkeywords>Cellular senescence | Diabetic nephropathy | Iron | P21 | Proximal tubular cells</authkeywords><intid>2035399811</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928817893"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928817893?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928817893&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928817893&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874114008794"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928817893</prism:url><dc:identifier>SCOPUS_ID:84928817893</dc:identifier><eid>2-s2.0-84928817893</eid><dc:title>Scent and synaesthesia: The medical use of spice bags in early China</dc:title><dc:creator>Lu D.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>167</prism:volume><prism:pageRange>38-46</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2014.12.008</prism:doi><pii>S0378874114008794</pii><dc:description>© 2015 Published by Elsevier Ireland Ltd. Ethnopharmacological relevance The history of Chinese spices has received increasing attention in recent years, but little research been carried out on where they fit on the food-medicine continuum for early China, during the formation of the classical medical system. This paper describes how the synaesthetic qualities of spices attracted a particular analysis in that emerging system which serves to mark them as different to other medical materials and foodstuffs. We aim to clarify the special role created for spices to accommodate their boundary-crossing synaesthetic action on the body. Material and methods This paper analyses the contents of several spice bags excavated in 1972 from a tomb that was closed in the second century BCE. It uses archaeological reports of material culture together with the early Chinese textual record, extant in both manuscripts and received texts, to bring out the role of spices in ritual, food and medicine. Results Noting that the flavours and aromas of early China were assigned physiological potency in the first centuries BCE, we argue that by medieval times the unique synaesthetic role that spices played in mediating the senses was systematically medicalised. While being deployed for the purpose of curing disease in medicine, they also remained within the realm of everyday healthcare, and religious practice, deployed both as aromatics to perfume the environment, attracting benign spirits, but also to ward off the agents of disease, as well as for enhancing health through their use in cookery. Conclusion While foodstuffs entered the digestive system spices were all considered 'pungent' in the emerging clasical medical system. They acted on the body through the nose and lungs, making them neither food nor drug. This implicit categorisation medicalised spices which, like music, could affect the passions and lighten the spirit, codifying observations about the impact on the body of the ritual environment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56612712200</author-url><authid>56612712200</authid><authname>Lu D.</authname><surname>Lu</surname><given-name>Di</given-name><initials>D.</initials><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005645870</author-url><authid>7005645870</authid><authname>Lo V.</authname><surname>Lo</surname><given-name>Vivienne</given-name><initials>V.</initials><afid>60022148</afid></author><authkeywords>Han dynasty | Spice Sichuan pepper | Yangsheng | Zanthoxylum armatum DC</authkeywords><intid>35851077</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927653732"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927653732?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927653732&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927653732&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115001825"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927653732</prism:url><dc:identifier>SCOPUS_ID:84927653732</dc:identifier><eid>2-s2.0-84927653732</eid><dc:title>Apolipoprotein M</dc:title><dc:creator>Ren K.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>21-29</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.03.038</prism:doi><pii>S0009898115001825</pii><dc:description>© 2015 Elsevier B.V. Apolipoprotein M (ApoM) is a novel apolipoprotein that was discovered in 1999 and is bound primarily to high-density lipoproteins (HDLs) in the plasma. Multiple factors may influence its expression at both the post-transcriptional and the transcriptional levels both in vivo and ex vivo as follows: hepatocyte nuclear factor-1α, 4α (HNF-1α, 4α), liver receptor homolog-1 (LRH-1), forkhead box A2 (Foxa2) and platelet activating factor (PAF) upregulate its expression; liver X receptor (LXR), retinoid X receptor (RXR), farnesoid X receptor (FXR), small heterodimer partner (SHP) and the majority of cytokines downregulate its expression. However, mechanisms underlying these processes remain unknown. Structurally, there exists a characterized hydrophobic binding pocket within the apoM protein, which enables it to bind functional lipids such as Sphingosine-1-Phosphate (S1P). Functionally, it facilitates the formation of preβ-HDL and enhances an avalanche of atheroprotective effects exerted by HDL. Moreover, in patients with diabetes, the levels of plasma apoM may decrease, whereas the augmentation of apoM decreases plasma glucose levels and magnifies the secretion of insulin. This article offers a panorama of the progress made in the research regarding the characteristics of apoM, particularly the regulation of its expression and its functions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088268</affiliation-url><afid>60088268</afid><affilname>University of South China</affilname><name-variant>University of South China</name-variant><affiliation-city>Hengyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56468812100</author-url><authid>56468812100</authid><authname>Ren K.</authname><surname>Ren</surname><given-name>Kun</given-name><initials>K.</initials><afid>60088268</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56591104700</author-url><authid>56591104700</authid><authname>Tang Z.</authname><surname>Tang</surname><given-name>Zhen Li</given-name><initials>Z.L.</initials><afid>60088268</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56590867300</author-url><authid>56590867300</authid><authname>Jiang Y.</authname><surname>Jiang</surname><given-name>Yue</given-name><initials>Y.</initials><afid>60088268</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56591095000</author-url><authid>56591095000</authid><authname>Tan Y.</authname><surname>Tan</surname><given-name>Yan Mei</given-name><initials>Y.M.</initials><afid>60088268</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7101660753</author-url><authid>7101660753</authid><authname>Yi G.</authname><surname>Yi</surname><given-name>Guang Hui</given-name><initials>G.H.</initials><afid>60088268</afid></author><authkeywords>Apolipoprotein M | Function | Regulation</authkeywords><intid>2035641092</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928406406"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928406406?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928406406&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928406406&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279714003421"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928406406</prism:url><dc:identifier>SCOPUS_ID:84928406406</dc:identifier><eid>2-s2.0-84928406406</eid><dc:title>Comparative and evolutionary studies of vertebrate ALDH1A-like genes and proteins</dc:title><dc:creator>Holmes R.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>234</prism:volume><prism:pageRange>4-11</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2014.11.002</prism:doi><pii>S0009279714003421</pii><dc:description>© 2014 Elsevier Ireland Ltd. All rights reserved. Vertebrate ALDH1A-like genes encode cytosolic enzymes capable of metabolizing all-trans-retinaldehyde to retinoic acid which is a molecular 'signal' guiding vertebrate development and adipogenesis. Bioinformatic analyses of vertebrate and invertebrate genomes were undertaken using known ALDH1A1, ALDH1A2 and ALDH1A3 amino acid sequences. Comparative analyses of the corresponding human genes provided evidence for distinct modes of gene regulation and expression with putative transcription factor binding sites (TFBS), CpG islands and micro-RNA binding sites identified for the human genes. ALDH1A-like sequences were identified for all mammalian, bird, lizard and frog genomes examined, whereas fish genomes displayed a more restricted distribution pattern for ALDH1A1 and ALDH1A3 genes. The ALDH1A1 gene was absent in many bony fish genomes examined, with the ALDH1A3 gene also absent in the medaka and tilapia genomes. Multiple ALDH1A1-like genes were identified in mouse, rat and marsupial genomes. Vertebrate ALDH1A1, ALDH1A2 and ALDH1A3 subunit sequences were highly conserved throughout vertebrate evolution. Comparative amino acid substitution rates showed that mammalian ALDH1A2 sequences were more highly conserved than for the ALDH1A1 and ALDH1A3 sequences. Phylogenetic studies supported an hypothesis for ALDH1A2 as a likely primordial gene originating in invertebrate genomes and undergoing sequential gene duplication to generate two additional genes, ALDH1A1 and ALDH1A3, in most vertebrate genomes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032987</affiliation-url><afid>60032987</afid><affilname>Griffith University</affilname><name-variant>Griffith University</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34969174300</author-url><authid>34969174300</authid><authname>Holmes R.</authname><surname>Holmes</surname><given-name>Roger S.</given-name><initials>R.S.</initials><afid>60032987</afid></author><authkeywords>Aldehyde dehydrogenases | ALDH1A1 | ALDH1A2 | ALDH1A3 | Evolution | Vertebrates</authkeywords><intid>1035774331</intid><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920926338"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920926338?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920926338&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920926338&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566314009981"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920926338</prism:url><dc:identifier>SCOPUS_ID:84920926338</dc:identifier><eid>2-s2.0-84920926338</eid><dc:title>Portable oxidative stress sensor: Dynamic and non-invasive measurements of extracellular H2O2 released by algae</dc:title><dc:creator>Koman V.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>68</prism:volume><prism:pageRange>245-252</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2014.12.044</prism:doi><pii>S0956566314009981</pii><dc:description>© 2015. Reactive oxygen species (ROS) generated by aerobic organisms are essential for physiological processes such as cell signaling, apoptosis, immune defense and oxidative stress mechanisms. Unbalanced oxidant/antioxidant budgets are involved in many diseases and, therefore, the sensitive measurement of ROS is of great interest. Here, we present a new device for the real-time monitoring of oxidative stress by measuring one of the most stable ROS, namely hydrogen peroxide (H2O2). This portable oxidative stress sensor contains the heme protein cytochrome c (cyt c) as sensing element whose spectral response enables the detection of H2O2 down to a detection limit of 40nM. This low detection limit is achieved by introducing cyt c in a random medium, enabling multiscattering that enhances the optical trajectory through the cyt c spot. A contact microspotting technique is used to produce reproducible and reusable cyt c spots which are stable for several days. Experiments in static and microfluidic regimes, as well as numerical simulations demonstrate the suitability of the cyt c/H2O2 reaction system for the real-time sensing of the kinetics of biological processes without H2O2 depletion in the measurement chamber. As an example, we detect the release of H2O2 from the green alga Chlamydomonas reinhardtii exposed to either 180nM functionalized CdSe/ZnS core shell quantum dots, or to 10mg/l TiO2 nanoparticles. The continuous measurement of extracellular H2O2 by this optical sensor with high sensitivity is a promising new means for real-time cytotoxicity tests, the investigation of oxidative stress and other physiological cell processes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028186</affiliation-url><afid>60028186</afid><affilname>Ecole Polytechnique Federale de Lausanne</affilname><name-variant>EPFL</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004718</affiliation-url><afid>60004718</afid><affilname>Universite de Geneve</affilname><name-variant>Université de Genève</name-variant><affiliation-city>Geneve</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55704980000</author-url><authid>55704980000</authid><authname>Koman V.</authname><surname>Koman</surname><given-name>Volodymyr B.</given-name><initials>V.B.</initials><afid>60028186</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8520858000</author-url><authid>8520858000</authid><authname>Santschi C.</authname><surname>Santschi</surname><given-name>Christian</given-name><initials>C.</initials><afid>60028186</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55502670600</author-url><authid>55502670600</authid><authname>von Moos N.</authname><surname>von Moos</surname><given-name>Nadia R.</given-name><initials>N.R.</initials><afid>60004718</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56343144400</author-url><authid>56343144400</authid><authname>Slaveykova V.</authname><surname>Slaveykova</surname><given-name>Vera I.</given-name><initials>V.I.</initials><afid>60004718</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56480063100</author-url><authid>56480063100</authid><authname>Martin O.</authname><surname>Martin</surname><given-name>Olivier J F</given-name><initials>O.J.F.</initials><afid>60028186</afid></author><authkeywords>Cytochrome c | Hydrogen peroxide | Multiscattering | Optical detection | Toxicity</authkeywords><intid>1534553821</intid><source-id>15437</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928116597"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928116597?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928116597&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928116597&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0304394015002979"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928116597</prism:url><dc:identifier>SCOPUS_ID:84928116597</dc:identifier><eid>2-s2.0-84928116597</eid><dc:title>CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery</dc:title><dc:creator>Hong J.</dc:creator><prism:publicationName>Neuroscience Letters</prism:publicationName><prism:issn>03043940</prism:issn><prism:eIssn>18727972</prism:eIssn><prism:volume>597</prism:volume><prism:pageRange>19-24</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neulet.2015.04.016</prism:doi><pii>S0304394015002979</pii><dc:description>© 2015 Elsevier Ireland Ltd. Increased matrix metalloproteinase (MMP) activity contributes to glial scar formation that inhibits the repair path after spinal cord injury (SCI). We examined whether treatment with N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA), a selective synthetic cannabinoid receptor (CB1R) agonist, inhibits MMP and improves functional and histological recovery in a mouse spinal cord compression injury model. Injured mice randomly received either intraperitoneal ACEA (3. mg/kg/day) or vehicle for up to 3 weeks. Behavioral, histological and biochemical assays were performed. Rotarod assessment and the Basso Mouse Scale score showed an improved performance following ACEA treatment concomitant with a decrease in compression lesion volume. MMP-9 and MMP-2 activity was measured at 1, 7 and 14 days post-SCI. SCI markedly increased MMP-9, but had negligible effect on MMP-2 activity. ACEA-treatment decreased MMP-9 activity by 80%, 49%, and 56%, respectively (P&lt;. 0.05) and had a smaller effect on MMP-2 activity. The CB1R antagonist SR141716, but not the CB2R antagonist SR144528, blocked ACEA-mediated decrease in MMP-9 activity confirming the role of the CB1R in the process. Collectively these data demonstrate that post-injury CB1R agonism can improve SCI outcome and also indicate marked attenuation of MMP-9 proteolytic enzyme activity as a biochemical mechanism.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005200</affiliation-url><afid>60005200</afid><affilname>Duke University School of Medicine</affilname><name-variant>Duke University Medical Center</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100546610</affiliation-url><afid>100546610</afid><affilname>Tangshan Gongren Hospital</affilname><name-variant>Tangshan Gongren Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018554</affiliation-url><afid>60018554</afid><affilname>Zhengzhou University</affilname><name-variant>Zhengzhou University of Light Industry</name-variant><affiliation-city>Zhengzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032941</affiliation-url><afid>60032941</afid><affilname>North Carolina Central University</affilname><name-variant>North Carolina Central University</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032941</affiliation-url><afid>60032941</afid><affilname>North Carolina Central University</affilname><name-variant>North Carolina Central University</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26652283900</author-url><authid>26652283900</authid><authname>Hong J.</authname><surname>Hong</surname><given-name>Jun</given-name><initials>J.</initials><afid>60005200</afid><afid>100546610</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26652283900</author-url><authid>26652283900</authid><authname>Hong J.</authname><surname>Hong</surname><given-name>Jun</given-name><initials>J.</initials><afid>60005200</afid><afid>100546610</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56600738100</author-url><authid>56600738100</authid><authname>Nandiwada V.</authname><surname>Nandiwada</surname><given-name>Vijaya</given-name><initials>V.</initials><afid>60032941</afid><afid>60032941</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56600738100</author-url><authid>56600738100</authid><authname>Nandiwada V.</authname><surname>Nandiwada</surname><given-name>Vijaya</given-name><initials>V.</initials><afid>60032941</afid><afid>60032941</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55899239400</author-url><authid>55899239400</authid><authname>Jones V.</authname><surname>Jones</surname><given-name>Victoria</given-name><initials>V.</initials><afid>60032941</afid><afid>60032941</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55899239400</author-url><authid>55899239400</authid><authname>Jones V.</authname><surname>Jones</surname><given-name>Victoria</given-name><initials>V.</initials><afid>60032941</afid><afid>60032941</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55460879300</author-url><authid>55460879300</authid><authname>Lu M.</authname><surname>Lu</surname><given-name>Miaomiao</given-name><initials>M.</initials><afid>60005200</afid><afid>60018554</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55460879300</author-url><authid>55460879300</authid><authname>Lu M.</authname><surname>Lu</surname><given-name>Miaomiao</given-name><initials>M.</initials><afid>60005200</afid><afid>60018554</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7201613918</author-url><authid>7201613918</authid><authname>Warner D.</authname><surname>Warner</surname><given-name>David S.</given-name><initials>D.S.</initials><afid>60005200</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35547617900</author-url><authid>35547617900</authid><authname>Mukhopadhyay S.</authname><surname>Mukhopadhyay</surname><given-name>Somnath</given-name><initials>S.</initials><afid>60032941</afid><afid>60032941</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35547617900</author-url><authid>35547617900</authid><authname>Mukhopadhyay S.</authname><surname>Mukhopadhyay</surname><given-name>Somnath</given-name><initials>S.</initials><afid>60032941</afid><afid>60032941</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7201933502</author-url><authid>7201933502</authid><authname>Sheng H.</authname><surname>Sheng</surname><given-name>Huaxin</given-name><initials>H.</initials><afid>60005200</afid></author><authkeywords>ACEA | Agonist | Cannabinoid receptor 1 | Matrix metalloproteinase 9 | Spinal cord injury</authkeywords><intid>35733316</intid><source-id>18046</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927596658"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927596658?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927596658&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927596658&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003061"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927596658</prism:url><dc:identifier>SCOPUS_ID:84927596658</dc:identifier><eid>2-s2.0-84927596658</eid><dc:title>Electrophysiological characterization of activation state-dependent Ca&lt;inf&gt;v&lt;/inf&gt;2 channel antagonist TROX-1 in spinal nerve injured rats</dc:title><dc:creator>Patel R.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>297</prism:volume><prism:pageRange>47-57</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.057</prism:doi><pii>S0306452215003061</pii><dc:description>© 2015 The Authors. Prialt, a synthetic version of Ca&lt;inf&gt;v&lt;/inf&gt;2.2 antagonist ω-conotoxin MVIIA derived from Conus magus, is the first clinically approved voltage-gated calcium channel blocker for refractory chronic pain. However, due to the narrow therapeutic window and considerable side effects associated with systemic dosing, Prialt is only administered intrathecally. N-triazole oxindole (TROX-1) is a novel use-dependent and activation state-selective small-molecule inhibitor of Ca&lt;inf&gt;v&lt;/inf&gt;2.1, 2.2 and 2.3 calcium channels designed to overcome the limitations of Prialt. We have examined the neurophysiological and behavioral effects of blocking calcium channels with TROX-1. In vitro, TROX-1, in contrast to state-independent antagonist Prialt, preferentially inhibits Ca&lt;inf&gt;v&lt;/inf&gt;2.2 currents in rat dorsal root ganglia (DRG) neurons under depolarized conditions. In vivo electrophysiology was performed to record from deep dorsal horn lamina V/VI wide dynamic range neurons in non-sentient spinal nerve-ligated (SNL) and sham-operated rats. In SNL rats, spinal neurons exhibited reduced responses to innocuous and noxious punctate mechanical stimulation of the receptive field following subcutaneous administration of TROX-1, an effect that was absent in sham-operated animals. No effect was observed on neuronal responses evoked by dynamic brushing, heat or cold stimulation in SNL or sham rats. The wind-up response of spinal neurons following repeated electrical stimulation of the receptive field was also unaffected. Spinally applied TROX-1 dose dependently inhibited mechanically evoked neuronal responses in SNL but not sham-operated rats, consistent with behavioral observations. This study confirms the pathological state-dependent actions of TROX-1 through a likely spinal mechanism and reveals a modality selective change in calcium channel function following nerve injury.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072306</affiliation-url><afid>60072306</afid><affilname>Grunenthal GmbH</affilname><name-variant>Grünenthal GmbH</name-variant><affiliation-city>Aachen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55646177000</author-url><authid>55646177000</authid><authname>Patel R.</authname><surname>Patel</surname><given-name>R.</given-name><initials>R.</initials><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8675534500</author-url><authid>8675534500</authid><authname>Rutten K.</authname><surname>Rutten</surname><given-name>K.</given-name><initials>K.</initials><afid>60072306</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56593083400</author-url><authid>56593083400</authid><authname>Valdor M.</authname><surname>Valdor</surname><given-name>M.</given-name><initials>M.</initials><afid>60072306</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602098972</author-url><authid>6602098972</authid><authname>Schiene K.</authname><surname>Schiene</surname><given-name>K.</given-name><initials>K.</initials><afid>60072306</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56593260900</author-url><authid>56593260900</authid><authname>Wigge S.</authname><surname>Wigge</surname><given-name>S.</given-name><initials>S.</initials><afid>60072306</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55405344600</author-url><authid>55405344600</authid><authname>Schunk S.</authname><surname>Schunk</surname><given-name>S.</given-name><initials>S.</initials><afid>60072306</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24830417200</author-url><authid>24830417200</authid><authname>Damann N.</authname><surname>Damann</surname><given-name>N.</given-name><initials>N.</initials><afid>60072306</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6602745900</author-url><authid>6602745900</authid><authname>Christoph T.</authname><surname>Christoph</surname><given-name>T.</given-name><initials>T.</initials><afid>60072306</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7101706308</author-url><authid>7101706308</authid><authname>Dickenson A.</authname><surname>Dickenson</surname><given-name>A. H.</given-name><initials>A.H.</initials><afid>60022148</afid></author><authkeywords>Ca&lt;inf&gt;v&lt;/inf&gt;2.2 | Dorsal horn | Dorsal root ganglia | Electrophysiology | N-type calcium channel | Spinal nerve ligation</authkeywords><intid>2035642084</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928407585"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928407585?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928407585&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928407585&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279714003597"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928407585</prism:url><dc:identifier>SCOPUS_ID:84928407585</dc:identifier><eid>2-s2.0-84928407585</eid><dc:title>Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3</dc:title><dc:creator>Schaupp C.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>234</prism:volume><prism:pageRange>154-161</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2014.11.010</prism:doi><pii>S0009279714003597</pii><dc:description>© 2014 Elsevier Ireland Ltd. All rights reserved. Doxorubicin is highly effective at inducing DNA double-strand breaks in rapidly dividing cells, which has led to it being a widely used cancer chemotherapeutic. However, clinical administration of doxorubicin is limited by off-target cardiotoxicity, which is thought to be mediated by doxorubicinol, the primary alcohol metabolite of doxorubicin. Carbonyl reductase 1 (CBR1), a well-characterized monomeric enzyme present at high basal levels in the liver, is known to exhibit activity toward doxorubicin. Little is known about a closely related enzyme, carbonyl reductase 3 (CBR3), which is present in the liver at low basal levels but is highly inducible by the transcription factor Nrf2. Genetic polymorphisms in CBR3, but not CBR1, are associated with differential cardiac outcomes in doxorubicin treated pediatric patients. Cbr3 mRNA and CBR3 protein are highly expressed in the livers of Gclm-/- mice (a mouse model of glutathione deficiency) relative to wild type mice. In the present study, we first investigated the ability of CBR3 to metabolize doxorubicin. Incubations of doxorubicin and purified recombinant murine CBR3 (mCBR3) were analyzed for doxorubicinol formation using HPLC, revealing for the first time that doxorubicin is a substrate of mCBR3. Moreover, hepatocytes from Gclm-/- mice produced more doxorubicinol than Gclm+/+ hepatocytes. In addition, differentiated rat myoblasts (C2C12 cells) co-cultured with primary Gclm-/- murine hepatocytes were more sensitive to doxorubicin-induced cytostasis/cytotoxicity than incubations with Gclm+/+ hepatocytes. Our results indicate a potentially important role for CBR3 in doxorubicin-induced cardiotoxicity. Because there is likely to be variability in hepatic CBR3 activity in humans (due to either genetic or epigenetic influences on its expression), these data also suggest that inhibition of CBR3 may provide protection from doxorubicinol cardiotoxicity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013402</affiliation-url><afid>60013402</afid><affilname>Oregon State University</affilname><name-variant>Oregon State University</name-variant><affiliation-city>Corvallis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56271795800</author-url><authid>56271795800</authid><authname>Schaupp C.</authname><surname>Schaupp</surname><given-name>Christopher M.</given-name><initials>C.M.</initials><afid>60015481</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7404153245</author-url><authid>7404153245</authid><authname>White C.</authname><surname>White</surname><given-name>Collin C.</given-name><initials>C.C.</initials><afid>60015481</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:19636162300</author-url><authid>19636162300</authid><authname>Merrill G.</authname><surname>Merrill</surname><given-name>Gary F.</given-name><initials>G.F.</initials><afid>60013402</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35392997800</author-url><authid>35392997800</authid><authname>Kavanagh T.</authname><surname>Kavanagh</surname><given-name>Terrance J.</given-name><initials>T.J.</initials><afid>60015481</afid></author><authkeywords>Carbonyl reductase | Cardiotoxicity | Doxorubicin | Glutathione deficiency | Pharmacogenetics</authkeywords><intid>2035774450</intid><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928408120"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928408120?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928408120&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928408120&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279714003263"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928408120</prism:url><dc:identifier>SCOPUS_ID:84928408120</dc:identifier><eid>2-s2.0-84928408120</eid><dc:title>Development of a high-throughput in vitro assay to identify selective inhibitors for human ALDH1A1</dc:title><dc:creator>Morgan C.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>234</prism:volume><prism:pageRange>29-37</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2014.10.028</prism:doi><pii>S0009279714003263</pii><dc:description>© 2014 Elsevier Ireland Ltd. All rights reserved. The human aldehyde dehydrogenase (ALDH) superfamily consists of at least 19 enzymes that metabolize endogenous and exogenous aldehydes. Currently, there are no commercially available inhibitors that target ALDH1A1 but have little to no effect on the structurally and functionally similar ALDH2. Here we present the first human ALDH1A1 structure, as the apo-enzyme and in complex with its cofactor NADH to a resolution of 1.75 and 2.1 Å, respectfully. Structural comparisons of the cofactor binding sites in ALDH1A1 with other closely related ALDH enzymes illustrate a high degree of similarity. In order to minimize discovery of compounds that inhibit both isoenzymes by interfering with their conserved cofactor binding sites, this study reports the use of an in vitro, NAD&lt;sup&gt;+&lt;/sup&gt;-independent, esterase-based high-throughput screen (HTS) of 64,000 compounds to discover novel, selective inhibitors of ALDH1A1. We describe 256 hits that alter the esterase activity of ALDH1A1. The effects on aldehyde oxidation of 67 compounds were further analyzed, with 30 selectively inhibiting ALDH1A1 compared to ALDH2 and ALDH3A1. One compound inhibited ALDH1A1 and ALDH2, while another inhibited ALDH1A1, ALDH2, and the more distantly related ALDH3A1. The results presented here indicate that this in vitro enzyme activity screening protocol successfully identified ALDH1A1 inhibitors with a high degree of isoenzyme selectivity. The compounds identified via this screen plus the screening methodology itself represent a starting point for the development of highly potent and selective inhibitors of ALDH1A1 that may be utilized to better understand the role of this enzyme in both normal and disease states.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021947</affiliation-url><afid>60021947</afid><affilname>Indiana University School of Medicine Indianapolis</affilname><name-variant>Indiana University School of Medicine</name-variant><affiliation-city>Indianapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402338560</author-url><authid>7402338560</authid><authname>Morgan C.</authname><surname>Morgan</surname><given-name>Cynthia A.</given-name><initials>C.A.</initials><afid>60021947</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102918923</author-url><authid>7102918923</authid><authname>Hurley T.</authname><surname>Hurley</surname><given-name>Thomas D.</given-name><initials>T.D.</initials><afid>60021947</afid></author><authkeywords>Aldehyde dehydrogenase | Enzyme inhibition | High-throughput screen | Retinaldehyde dehydrogenase | Small molecule inhibitors</authkeywords><intid>535780385</intid><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925639280"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925639280?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925639280&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925639280&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001843"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925639280</prism:url><dc:identifier>SCOPUS_ID:84925639280</dc:identifier><eid>2-s2.0-84925639280</eid><dc:title>Rutaecarpine prevented dysfunction of endothelial gap junction induced by Ox-LDL via activation of TRPV1</dc:title><dc:creator>Peng W.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>756</prism:volume><prism:pageRange>8-14</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.02.051</prism:doi><pii>S0014299915001843</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Abstract Gap junctions, which is formed by connexins, has been proved to play an important role in the atherogenesis development. Rutaecarpine was reported to inhibited monocyte migration, which indicates its potential for anti-atherosclerosis activity. This study evaluated the effect of rutaecarpine on endothelial dysfunction, and focused on the regulation of connexin expression in endothelial cells by rutaecarpine. Endothelia damage was induced by exposing HUVEC-12 to Ox-LDL (100 mg/l) for 24 h, which decreased the expression of protective proteins Cx37 and Cx40, but induced atherogenic Cx43 expression, in both mRNA and protein levels, concomitant with the impaired propidium iodide diffusion through the gap junctions. Pretreatment with rutaecarpine effectively recovered the expression of Cx37 and Cx40, but inhibited Cx43 expression, thereby improving gap junction communication and significantly prevented the endothelial dysfunction. Consequently, the cell viability and nitric oxide production were increased, lactate dehydrogenase production was decreased and monocyte adhesion was inhibited. These protective effects of rutaecarpine were remarkably attenuated by pretreatment with capsazepine, a competitive antagonist of transient receptor potential vanilloid subtype 1 (TRPV1). In summary, this study is the first to report that rutaecarpine prevents endothelial injury and gap junction dysfunction induced by Ox-LDL in vitro, which is related to regulation of connexin expression patterns via TRPV1 activation. These results suggest that rutaecarpine has the potential for use as an anti-atherosclerosis agent with a novel mechanism.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008332</affiliation-url><afid>60008332</afid><affilname>Nanchang University</affilname><name-variant>Nanchang University</name-variant><affiliation-city>Nanchang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112863600</affiliation-url><afid>112863600</afid><affilname>Ganzhou Cancer Hospital</affilname><name-variant>Ganzhou Institute of Cancer Research</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56571945300</author-url><authid>56571945300</authid><authname>Peng W.</authname><surname>Peng</surname><given-name>Wei Jie</given-name><initials>W.J.</initials><afid>60008332</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55124321600</author-url><authid>55124321600</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Yong</given-name><initials>Y.</initials><afid>112863600</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56420714900</author-url><authid>56420714900</authid><authname>Yu Y.</authname><surname>Yu</surname><given-name>Yan Rong</given-name><initials>Y.R.</initials><afid>60008332</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56571762700</author-url><authid>56571762700</authid><authname>Fu Y.</authname><surname>Fu</surname><given-name>Yan Qi</given-name><initials>Y.Q.</initials><afid>60008332</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7406634223</author-url><authid>7406634223</authid><authname>Zhao Y.</authname><surname>Zhao</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60008332</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56572222800</author-url><authid>56572222800</authid><authname>Kuang H.</authname><surname>Kuang</surname><given-name>Hai Bing</given-name><initials>H.B.</initials><afid>60008332</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55467437500</author-url><authid>55467437500</authid><authname>Huang Q.</authname><surname>Huang</surname><given-name>Qi Ren</given-name><initials>Q.R.</initials><afid>60008332</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36470278800</author-url><authid>36470278800</authid><authname>He M.</authname><surname>He</surname><given-name>Ming</given-name><initials>M.</initials><afid>60008332</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7202658357</author-url><authid>7202658357</authid><authname>Luo D.</authname><surname>Luo</surname><given-name>Dan</given-name><initials>D.</initials><afid>60008332</afid></author><authkeywords>Connexin | Endothelial cells | Gap junction | Oxidized low-density lipoprotein (Ox-LDL) | Rutaecarpine | Transient receptor potential vanilloid subtype 1 (TRPV1)</authkeywords><intid>1535327159</intid><article-number>69804</article-number><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927720580"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927720580?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927720580&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927720580&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215002857"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927720580</prism:url><dc:identifier>SCOPUS_ID:84927720580</dc:identifier><eid>2-s2.0-84927720580</eid><dc:title>Respiratory deficits in a rat model of Parkinson's disease</dc:title><dc:creator>Tuppy M.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>297</prism:volume><prism:pageRange>194-204</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.048</prism:doi><pii>S0306452215002857</pii><dc:description>© 2015 IBRO. Parkinson's disease (PD) is a neurodegenerative disease characterized by loss of the dopaminergic nigrostriatal pathway. In addition to deficits in voluntary movement, PD involves a disturbance of breathing regulation. However, the cause and nature of this disturbance are not well understood. Here, we investigated breathing at rest and in response to hypercapnia (7% CO&lt;inf&gt;2&lt;/inf&gt;) or hypoxia (8% O&lt;inf&gt;2&lt;/inf&gt;), as well as neuroanatomical changes in brainstem regions essential for breathing, in a 6-hydroxydopamine (6-OHDA) rat model of PD. Bilateral injections of 6-OHDA (24μg/μl) into the striatum decreased tyrosine hydroxylase (TH&lt;sup&gt;+&lt;/sup&gt;)-neurons in the substantia nigra pars compacta (SNpc), transcription factor phox2b-expressing neurons in the retrotrapezoid nucleus and neurokinin-1 receptors in the ventral respiratory column. In 6-OHDA-lesioned rats, respiratory rate was reduced at rest, leading to a reduction in minute ventilation. These animals also showed a reduction in the tachypneic response to hypercapnia, but not to hypoxia challenge. These results suggest that the degeneration of TH&lt;sup&gt;+&lt;/sup&gt; neurons in the SNpc leads to impairment of breathing at rest and in hypercapnic conditions. Our data indicate that respiratory deficits in a 6-OHDA rat model of PD are related to downregulation of neural systems involved in respiratory rhythm generation. The present study suggests a new avenue to better understand the respiratory deficits observed in chronic stages of PD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56595133600</author-url><authid>56595133600</authid><authname>Tuppy M.</authname><surname>Tuppy</surname><given-name>M.</given-name><initials>M.</initials><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55210330100</author-url><authid>55210330100</authid><authname>Barna B.</authname><surname>Barna</surname><given-name>B. F.</given-name><initials>B.F.</initials><afid>60008088</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56595061900</author-url><authid>56595061900</authid><authname>Alves-dos-Santos L.</authname><surname>Alves-dos-Santos</surname><given-name>L.</given-name><initials>L.</initials><afid>60008088</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005912602</author-url><authid>7005912602</authid><authname>Britto L.</authname><surname>Britto</surname><given-name>L. R G</given-name><initials>L.R.G.</initials><afid>60008088</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602342926</author-url><authid>6602342926</authid><authname>Chiavegatto S.</authname><surname>Chiavegatto</surname><given-name>S.</given-name><initials>S.</initials><afid>60008088</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004203019</author-url><authid>7004203019</authid><authname>Moreira T.</authname><surname>Moreira</surname><given-name>T. S.</given-name><initials>T.S.</initials><afid>60008088</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003321511</author-url><authid>7003321511</authid><authname>Takakura A.</authname><surname>Takakura</surname><given-name>A. C.</given-name><initials>A.C.</initials><afid>60008088</afid></author><authkeywords>Brainstem | Breathing | Hypercapnia | Hypoxia | Parkinson's disease</authkeywords><intid>1785667509</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925854821"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925854821?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925854821&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925854821&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021999115001709"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925854821</prism:url><dc:identifier>SCOPUS_ID:84925854821</dc:identifier><eid>2-s2.0-84925854821</eid><dc:title>Direct numerical simulation of rigid bodies in multiphase flow within an Eulerian framework</dc:title><dc:creator>Rauschenberger P.</dc:creator><prism:publicationName>Journal of Computational Physics</prism:publicationName><prism:issn>00219991</prism:issn><prism:eIssn>10902716</prism:eIssn><prism:volume>291</prism:volume><prism:pageRange>238-253</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jcp.2015.03.023</prism:doi><pii>S0021999115001709</pii><dc:description>© 2015 Elsevier Inc. A new method is presented to simulate rigid body motion in the Volume-of-Fluid based multiphase code Free Surface 3D. The specific feature of the new method is that it works within an Eulerian framework without the need for a Lagrangian representation of rigid bodies. Several test cases are shown to prove the validity of the numerical scheme. The technique is able to conserve the shape of arbitrarily shaped rigid bodies and predict terminal velocities of rigid spheres. The instability of a falling ellipsoid is captured. Multiple rigid bodies including collisions may be considered using only one Volume-of-Fluid variable which allows to simulate the drafting, kissing and tumbling phenomena of two rigid spheres. The method can easily be extended to rigid bodies undergoing phase change processes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015815</affiliation-url><afid>60015815</afid><affilname>Universitat Stuttgart</affilname><name-variant>University of Stuttgart</name-variant><affiliation-city>Stuttgart</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55661621400</author-url><authid>55661621400</authid><authname>Rauschenberger P.</authname><surname>Rauschenberger</surname><given-name>P.</given-name><initials>P.</initials><afid>60015815</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003275717</author-url><authid>7003275717</authid><authname>Weigand B.</authname><surname>Weigand</surname><given-name>B.</given-name><initials>B.</initials><afid>60015815</afid></author><authkeywords>Direct numerical simulation | Eulerian framework | Rigid body | Volume of fluid</authkeywords><intid>1785373462</intid><source-id>13191</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927537313"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927537313?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927537313&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927537313&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0045782515001103"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927537313</prism:url><dc:identifier>SCOPUS_ID:84927537313</dc:identifier><eid>2-s2.0-84927537313</eid><dc:title>Parallel embedded boundary methods for fluid and rigid-body interaction</dc:title><dc:creator>Samaniego C.</dc:creator><prism:publicationName>Computer Methods in Applied Mechanics and Engineering</prism:publicationName><prism:issn>00457825</prism:issn><prism:volume>290</prism:volume><prism:pageRange>387-419</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cma.2015.03.008</prism:doi><pii>S0045782515001103</pii><dc:description>© 2015 Elsevier B.V. The implementations of an updated body-fitted and a non body-fitted method to deal with the interaction of a fluid and a rigid body are described. The physics of the fluid is modeled by the incompressible Navier-Stokes equations. A parallel fluid solver based on the VMS (Variational Multiscale) Finite Element method serves as the basis for the implementation. For the rigid body movement, the Newton-Euler equations are solved numerically. To account for the interaction, the force that the fluid exerts on the rigid body is determined, on the one hand. On the other hand, the velocity of the rigid body is imposed as a Dirichlet boundary condition on the fluid. A fixed Eulerian mesh discretizes the fluid domain, except for nodes in the vicinity of the rigid body boundary for the case of the updated body-fitted approach. The wet boundary of the rigid body is embedded in the fluid mesh and tracked by a moving surface mesh. It is a distinctive characteristic of the updated body-fitted strategy that, in order to impose velocities on the interface, some of the nodes near the body surface are moved by using a local r-adaptivity algorithm to conform with this surface. By contrast, the non body-fitted approach uses kriging interpolation for velocity prescription over the fluid on the interface. Given that fluid nodes can become solid nodes and vice versa due to the rigid body movement, we have adopted the FMALE approach, a variation of the ALE method to keep the fluid mesh fixed. Algorithms to ensure high performance, like skd-trees to determine if a given spatial point is currently inside the solid, are also used. All these ingredients constitute two approaches that are both computationally efficient and accurate. Numerical experiments are presented to assess their performance comparatively.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Edificio NEXUS I</affilname><name-variant>Barcelona Supercomputing Center (BSC-CNS)</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Universidad de Cuenca</affilname><name-variant>School of Engineering</name-variant><name-variant>Departamento de Recursos Hídricos y Ciencias Ambientales</name-variant><affiliation-city>Cuenca</affiliation-city><affiliation-country>Ecuador</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>IIIA-CSIC</affilname><affiliation-city>Bellaterra</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:53985090600</author-url><authid>53985090600</authid><authname>Samaniego C.</authname><surname>Samaniego</surname><given-name>C.</given-name><initials>C.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55901894500</author-url><authid>55901894500</authid><authname>Houzeaux G.</authname><surname>Houzeaux</surname><given-name>G.</given-name><initials>G.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55887979900</author-url><authid>55887979900</authid><authname>Samaniego E.</authname><surname>Samaniego</surname><given-name>E.</given-name><initials>E.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7401539932</author-url><authid>7401539932</authid><authname>Vázquez M.</authname><surname>Vázquez</surname><given-name>M.</given-name><initials>M.</initials><afid/><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7401539932</author-url><authid>7401539932</authid><authname>Vázquez M.</authname><surname>Vázquez</surname><given-name>M.</given-name><initials>M.</initials><afid/><afid/></author><authkeywords>Embedded boundary method | Finite element method | Fluid and rigid-body interaction | FMALE | Navier-Stokes | Parallelization</authkeywords><intid>2035629686</intid><source-id>18158</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930088080"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930088080?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930088080&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930088080&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0300483X15000852"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930088080</prism:url><dc:identifier>SCOPUS_ID:84930088080</dc:identifier><eid>2-s2.0-84930088080</eid><dc:title>Reprint of PopGen: A virtual human population generator</dc:title><dc:creator>McNally K.</dc:creator><prism:publicationName>Toxicology</prism:publicationName><prism:issn>0300483X</prism:issn><prism:eIssn>18793185</prism:eIssn><prism:volume>332</prism:volume><prism:pageRange>77-93</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.tox.2015.04.014</prism:doi><pii>S0300483X15000852</pii><dc:description>© 2015 Published by Elsevier Ireland Ltd. The risk assessment of environmental chemicals and drugs is moving towards a paradigm shift in approach which seeks the full replacement animal testing with high throughput, mechanistic, in vitro systems. This new vision will be reliant on the measurement in vitro, of concentration-dependent responses where prolonged excessive perturbations of specific biochemical pathways are likely to lead to adverse health effects in an intact organism. Such an approach requires a framework, into which disparate data generated using in vitro, in silico and in chemico systems, can be integrated and utilised for quantitative in vitro-to-. in vivo extrapolation (QIVIVE), ultimately to the human population level. Physiologically based pharmacokinetic (PBPK) models are ideally suited for this and are obligatory in order to translate in vitro concentration-response relationships to an exposure or dose, route and duration regime in people. In this report we describe PopGen a virtual human population generator which is a user friendly, open access web-based application for the prediction of realistic anatomical, physiological and phase 1 metabolic variation in a wide range of healthy human populations. We demonstrate how PopGen can be used for QIVIVE by providing input to a PBPK model, at an appropriate level of detail, to reconstruct exposure from human biomonitoring data. We discuss how the process of exposure reconstruction from blood biomarkers, in general, is analogous to exposure or dose reconstruction from concentration-response measurements made in proposed in vitro cell based systems which are assumed to be surrogates for target organs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023173</affiliation-url><afid>60023173</afid><affilname>Health &amp; Safety Laboratory</affilname><name-variant>Health and Safety Laboratory</name-variant><affiliation-city>Derbyshire</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114090042</affiliation-url><afid>114090042</afid><affilname>TDL Ltd.</affilname><name-variant>TDL Ltd</name-variant><affiliation-city>Buxton</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35216296200</author-url><authid>35216296200</authid><authname>McNally K.</authname><surname>McNally</surname><given-name>Kevin</given-name><initials>K.</initials><afid>60023173</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36440928200</author-url><authid>36440928200</authid><authname>Cotton R.</authname><surname>Cotton</surname><given-name>Richard</given-name><initials>R.</initials><afid>114090042</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55353680300</author-url><authid>55353680300</authid><authname>Hogg A.</authname><surname>Hogg</surname><given-name>Alex</given-name><initials>A.</initials><afid>60023173</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15319414100</author-url><authid>15319414100</authid><authname>Loizou G.</authname><surname>Loizou</surname><given-name>George</given-name><initials>G.</initials><afid>60023173</afid></author><authkeywords>PBPK | Population variability | QIVIVE | Reverse dosimetry | Virtual human population generator</authkeywords><intid>536064195</intid><source-id>25219</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924037609"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924037609?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924037609&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924037609&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0022286015001179"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924037609</prism:url><dc:identifier>SCOPUS_ID:84924037609</dc:identifier><eid>2-s2.0-84924037609</eid><dc:title>Studies on the π-π Stacking features of imidazole units present in a series of 5-amino-1-alkylimidazole-4-carboxamides</dc:title><dc:creator>Ray S.</dc:creator><prism:publicationName>Journal of Molecular Structure</prism:publicationName><prism:issn>00222860</prism:issn><prism:volume>1089</prism:volume><prism:pageRange>146-152</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>5 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.molstruc.2015.02.032</prism:doi><pii>S0022286015001179</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Reaction of 2-ethoxymethyleneamino-2-cyanoacetamide with primary alkyl amines in acetonitrile solvent affords 1-substituted-5-aminoimidazole-4-carboxamides. Single crystal X-ray diffraction studies of these imidazole compounds show that there are both anti-parallel and syn-parallel π-π stackings between two imidazole units in parallel-displaced (PD) conformations and the distance between two π-π stacked imidazole units depends mainly on the anti/ syn-parallel nature and to some extent on the alkyl group attached to N-1 of imidazole; molecules with anti-parallel PD-stacking arrangements of the imidazole units have got vertical π-π stacking distance short enough to impart stabilization whereas the imidazole unit having syn-parallel stacking arrangement have got much larger π-π stacking distances. DFT studies on a pair of anti-parallel imidazole units of such an AICA lead to curves for 'π-π stacking stabilization energy vs. π-π stacking distance' which have got similarity with the 'Morse potential energy diagram for a diatomic molecule' and this affords to find out a minimum π-π stacking distance corresponding to the maximum stacking stabilization energy between the pair of imidazole units. On the other hand, a DFT calculation based curve for 'π-π stacking stabilization energy vs. π-π stacking distance' of a pair of syn-parallel imidazole units is shown to have an exponential nature.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Calcutta</affilname><name-variant>University College of Science</name-variant><affiliation-city>Kolkata</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402324483</author-url><authid>7402324483</authid><authname>Ray S.</authname><surname>Ray</surname><given-name>Sibdas</given-name><initials>S.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56535732400</author-url><authid>56535732400</authid><authname>Das A.</authname><surname>Das</surname><given-name>Aniruddha</given-name><initials>A.</initials><afid/></author><authkeywords>AICA | Anti-parallel stacking of imidazoles | DFT studies on π-π stacking energies | Syn-parallel stacking of imidazoles | X-ray crystallographic studies | π-π stacking stabilization energies</authkeywords><intid>1035076774</intid><source-id>24642</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927601656"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927601656?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927601656&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927601656&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215002924"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927601656</prism:url><dc:identifier>SCOPUS_ID:84927601656</dc:identifier><eid>2-s2.0-84927601656</eid><dc:title>Differential gene expression profiles of two excitable rat cell lines after over-expression of WT- and C121W-β1 sodium channel subunits</dc:title><dc:creator>Baroni D.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>297</prism:volume><prism:pageRange>105-117</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.052</prism:doi><pii>S0306452215002924</pii><dc:description>© 2015 IBRO. Voltage-dependent sodium channels are membrane proteins essential for cell excitability. They are composed by a pore-forming α-subunit, encoded in mammals by up to nine different genes, and four different ancillary β-subunits. The expression pattern of the α subunit isoforms confers the distinctive functional and pharmacological properties to different excitable tissues. β-Subunits are important modulators of channel function and expression. Mutation C121W of the β1-subunit causes an autosomal dominant epileptic syndrome without cardiac symptoms. In neuroectoderm GH3 and cardiac H9C2 cells, the over-expression of β1 subunit augments α subunit mRNA and protein levels as well as sodium current density. Interestingly, the introduction of the epileptogenic C121W-β1 subunit produces additional changes in the α-subunit expression pattern of H9C2 cells, leaving unaltered the sodium channel isoform composition of GH3 cells. The challenge of the present work was to identify those genes that were differentially expressed in response to WT- or C121W-β1 subunit over-expression in the two rat cell lines under analysis. Hence, we analyzed the total mRNA extracted from control-untransfected and from WT- and C121W-β1-transfected GH3 and H9C2 cells by DNA-microarray. We found that, in agreement with their different embryonal origin, the over-expression of WT- and C121W-β1 subunits modifies the expression of different gene sets in GH3 and H9C2 cells. Focusing on the effects of the C121W mutation, we found that it causes the modification of 214 genes, most of them were down-regulated (202) in GH3 cells; on the contrary, it determined the up-regulation of only five genes in H9C2 cells. Interestingly, most genes modified by the C121W β1 subunit are involved in pivotal processes of the cell such as cellular communication and protein expression. Our results confirm the important role of the sodium channel β1 subunit in the control of NaCh gene expression, and highlight once more the tissue-specific effect of the C121W mutation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021199</affiliation-url><afid>60021199</afid><affilname>Consiglio Nazionale delle Ricerche</affilname><name-variant>CNR</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506412986</author-url><authid>6506412986</authid><authname>Baroni D.</authname><surname>Baroni</surname><given-name>D.</given-name><initials>D.</initials><afid>60021199</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006556796</author-url><authid>7006556796</authid><authname>Moran O.</authname><surname>Moran</surname><given-name>O.</given-name><initials>O.</initials><afid>60021199</afid></author><authkeywords>DNA-microarray | Epilepsy | Gene expression | MRNA | Voltage-gated sodium channel</authkeywords><intid>1035643792</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928743458"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928743458?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928743458&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928743458&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009898115002284"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928743458</prism:url><dc:identifier>SCOPUS_ID:84928743458</dc:identifier><eid>2-s2.0-84928743458</eid><dc:title>Melatonin and male reproduction</dc:title><dc:creator>Li C.</dc:creator><prism:publicationName>Clinica Chimica Acta</prism:publicationName><prism:issn>00098981</prism:issn><prism:eIssn>18733492</prism:eIssn><prism:volume>446</prism:volume><prism:pageRange>175-180</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cca.2015.04.029</prism:doi><pii>S0009898115002284</pii><dc:description>© 2015 . Melatonin is a neurohormone secreted by the pineal gland whose concentrations in the body are regulated by both the dark-light and seasonal cycles. The reproductive function of seasonal breeding animals is clearly influenced by the circadian variation in melatonin levels. Moreover, a growing body of evidence indicates that melatonin has important effects in the reproduction of some non-seasonal breeding animals. In males, melatonin affects reproductive regulation in three main ways. First, it regulates the secretion of two key neurohormones, GnRH and LH. Second, it regulates testosterone synthesis and testicular maturation. Third, as a potent free radical scavenger that is both lipophilic and hydrophilic, it prevents testicular damage caused by environmental toxins or inflammation. This review summarizes the existing data on the possible biological roles of melatonin in male reproduction. Overall, the literature data indicate that melatonin affects the secretion of both gonadotropins and testosterone while also improving sperm quality. This implies that it has important effects on the regulation of testicular development and male reproduction.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007711</affiliation-url><afid>60007711</afid><affilname>Jilin University</affilname><name-variant>Jilin University</name-variant><affiliation-city>Changchun</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56262139300</author-url><authid>56262139300</authid><authname>Li C.</authname><surname>Li</surname><given-name>Chunjin</given-name><initials>C.</initials><afid>60007711</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36460276800</author-url><authid>36460276800</authid><authname>Zhou X.</authname><surname>Zhou</surname><given-name>Xu</given-name><initials>X.</initials><afid>60007711</afid></author><authkeywords>Antioxidant | Male reproduction | Melatonin | Sperm | Testis</authkeywords><intid>1535839319</intid><source-id>29286</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928122032"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928122032?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928122032&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928122032&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003346"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928122032</prism:url><dc:identifier>SCOPUS_ID:84928122032</dc:identifier><eid>2-s2.0-84928122032</eid><dc:title>Cortical neuronal activity does not regulate sleep homeostasis</dc:title><dc:creator>Qiu M.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>297</prism:volume><prism:pageRange>211-218</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.070</prism:doi><pii>S0306452215003346</pii><dc:description>© 2015 IBRO. The neural substrate of sleep homeostasis is unclear, but both cortical and subcortical structures are thought to be involved in sleep regulation. To test whether prior neuronal activity in the cortex or in subcortical regions drives sleep rebound, we systemically administered atropine (100. mg/kg) to rats, producing a dissociated state with slow-wave cortical electroencephalogram (EEG) but waking behavior (e.g. locomotion). Atropine injections during the light period produced 6. h of slow-wave cortical EEG but also subcortical arousal. Afterward, rats showed a significant increase in non-rapid eye movement (NREM) sleep, compared to the same period on a baseline day. Consistent with the behavioral and cortical EEG state produced by systemic atropine, c-Fos expression was low in the cortex but high in multiple subcortical arousal systems. These data suggest that subcortical arousal and behavior are sufficient to drive sleep homeostasis, while a sleep-like pattern of cortical activity is not sufficient to satisfy sleep homeostasis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009860</affiliation-url><afid>60009860</afid><affilname>Fudan University</affilname><name-variant>Fudan University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030058</affiliation-url><afid>60030058</afid><affilname>Beth Israel Deaconess Medical Center</affilname><name-variant>Beth Israel Deaconess Medical Center</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7103349322</author-url><authid>7103349322</authid><authname>Qiu M.</authname><surname>Qiu</surname><given-name>M. H.</given-name><initials>M.H.</initials><afid>60009860</afid><afid>60030058</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7103349322</author-url><authid>7103349322</authid><authname>Qiu M.</authname><surname>Qiu</surname><given-name>M. H.</given-name><initials>M.H.</initials><afid>60009860</afid><afid>60030058</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56599265000</author-url><authid>56599265000</authid><authname>Chen M.</authname><surname>Chen</surname><given-name>M. C.</given-name><initials>M.C.</initials><afid>60030058</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36065866500</author-url><authid>36065866500</authid><authname>Lu J.</authname><surname>Lu</surname><given-name>J.</given-name><initials>J.</initials><afid>60030058</afid></author><authkeywords>Arousal | Atropine | C-Fos | Cortex | Homeostasis</authkeywords><intid>1785733992</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927588412"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927588412?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927588412&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927588412&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215002602"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927588412</prism:url><dc:identifier>SCOPUS_ID:84927588412</dc:identifier><eid>2-s2.0-84927588412</eid><dc:title>Ecto-5'-nucleotidase (CD73) is involved in chronic cerebral hypoperfusion-induced white matter lesions and cognitive impairment by regulating glial cell activation and pro-inflammatory cytokines</dc:title><dc:creator>Hou X.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>297</prism:volume><prism:pageRange>118-126</prism:pageRange><prism:coverDate>2015-06-05</prism:coverDate><prism:coverDisplayDate>June 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.033</prism:doi><pii>S0306452215002602</pii><dc:description>© 2015 IBRO. Recent studies have demonstrated that inflammatory and immune mechanisms play important roles in the progression of chronic cerebral hypoperfusion (CCH)-induced white matter lesions (WMLs). As an endogenous neuromodulator in the brain, the extracellular levels of adenosine represent a critical endogenous mechanism for the regulation of immune and inflammatory responses. Ecto-5'-nucleotidase (CD73), which dephosphorylates AMP to adenosine, is considered to catalyze the rate-limiting step in the generation of extracellular adenosine. However, the role of CD73 in the development of CCH-induced WMLs remains unclear. In the present study, we investigated the expression and activity of CD73 using immunohistochemistry, Western blot analysis and measurements of the rate of AMP hydrolysis in a mouse model of CCH via bilateral common carotid artery stenosis (BCAS) surgery. Moreover, C57BL/6-CD73 knockout (KO) and their wild-type littermates were subjected to BCAS surgery to further investigate the functional roles of CD73 in the WMLs. White matter (WM) changes, astrocyte and microglia proliferation, proinflammatory cytokine levels in the corpus callosum and cognitive function were assessed on the 30th day after BCAS. The results indicated that CD73 expression and activities significantly increased in the corpus callosum on the 30th day after BCAS. Moreover, CD73 deficiency exacerbated CCH-induced WMLs and cognitive impairment. More reactive astrocytes and microglia were observed in the corpus callosum in CD73-KO mice. CD73 deficiency significantly increased the levels of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in the BCAS model of CCH. These findings suggest that CD73 plays a protective role in the development of CCH-induced WMLs and cognitive impairment via the regulation of glial cell activation and proinflammatory cytokine expression.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073574</affiliation-url><afid>60073574</afid><affilname>Kunming General Hospital of Chengdu Military Command</affilname><name-variant>Kunming General Hospital of Chengdu Military Command</name-variant><affiliation-city>Kunming</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006385</affiliation-url><afid>60006385</afid><affilname>Boston University School of Medicine</affilname><name-variant>Boston University School of Medicine</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56574616500</author-url><authid>56574616500</authid><authname>Hou X.</authname><surname>Hou</surname><given-name>X.</given-name><initials>X.</initials><afid>60023797</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56591100000</author-url><authid>56591100000</authid><authname>Liang X.</authname><surname>Liang</surname><given-name>X.</given-name><initials>X.</initials><afid>60073574</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7501880629</author-url><authid>7501880629</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>J. F.</given-name><initials>J.F.</initials><afid>60006385</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56590969200</author-url><authid>56590969200</authid><authname>Zheng J.</authname><surname>Zheng</surname><given-name>J.</given-name><initials>J.</initials><afid>60023797</afid></author><authkeywords>Chronic cerebral hypoperfusion | Cognitive impairment | Ecto-5'-nucleotidase (CD73) | Proinflammatory cytokine | White matter lesions</authkeywords><intid>2035641099</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926500169"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926500169?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926500169&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926500169&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215002559"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926500169</prism:url><dc:identifier>SCOPUS_ID:84926500169</dc:identifier><eid>2-s2.0-84926500169</eid><dc:title>Comparison of noradrenaline, dopamine and serotonin in mediating the tachycardic and thermogenic effects of methamphetamine in the ventral medial prefrontal cortex</dc:title><dc:creator>Hassan S.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>295</prism:volume><prism:pageRange>209-220</prism:pageRange><prism:coverDate>2015-06-04</prism:coverDate><prism:coverDisplayDate>June 04, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.028</prism:doi><pii>S0306452215002559</pii><dc:description>© 2015 IBRO. Methamphetamine (METH) is a psychostimulant that disrupts monoaminergic neurotransmission to evoke profound behavioral and physiological effects. Rapidly distributing to forebrain regions to increase synaptic concentrations of three monoamines (dopamine (DA), serotonin (5-HT) and noradrenaline (NA)), the medial prefrontal cortex (mPFC) is important in METH-altered behavioral and psychological profiles. Activation of the ventral mPFC can modify physiological variables, however, METH-evoked autonomic changes from this region are unknown. Therefore, the aim of this study was to characterize the respiratory, metabolic and cardiovascular effects of microinjection of METH, DA, 5-HT and NA into the ventral mPFC in urethane-anesthetized Sprague-Dawley rats. METH and NA microinjection evoked dose-related increases in heart rate, interscapular brown adipose tissue temperature and expired CO&lt;inf&gt;2&lt;/inf&gt;, a pattern of response characteristic of non-shivering thermogenesis. NA and 5-HT microinjection elicited pressor and depressor responses, respectively, with matching baroreflex adjustments in sympathetic nerve activity while METH and DA evoked no change in vasomotor outflow. Low doses of METH and DA may evoke respiratory depression. These data suggest that METH's actions in the ventral mPFC, likely via adrenergic receptors, evoke non-shivering thermogenesis which may contribute to the increased body temperature and tachycardia seen in those that abuse METH.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088314</affiliation-url><afid>60088314</afid><affilname>Macquarie University, Australian School of Advanced Medicine</affilname><name-variant>Macquarie University</name-variant><affiliation-city/><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019544</affiliation-url><afid>60019544</afid><affilname>Macquarie University</affilname><name-variant>Macquarie University</name-variant><affiliation-city>North Ryde</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55501844100</author-url><authid>55501844100</authid><authname>Hassan S.</authname><surname>Hassan</surname><given-name>S. F.</given-name><initials>S.F.</initials><afid>60088314</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56584739900</author-url><authid>56584739900</authid><authname>Zumut S.</authname><surname>Zumut</surname><given-name>S.</given-name><initials>S.</initials><afid>60088314</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23768052700</author-url><authid>23768052700</authid><authname>Burke P.</authname><surname>Burke</surname><given-name>P. G.</given-name><initials>P.G.</initials><afid>60088314</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8412339900</author-url><authid>8412339900</authid><authname>McMullan S.</authname><surname>McMullan</surname><given-name>S.</given-name><initials>S.</initials><afid>60088314</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102230491</author-url><authid>7102230491</authid><authname>Cornish J.</authname><surname>Cornish</surname><given-name>J. L.</given-name><initials>J.L.</initials><afid>60019544</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004153900</author-url><authid>7004153900</authid><authname>Goodchild A.</authname><surname>Goodchild</surname><given-name>A. K.</given-name><initials>A.K.</initials><afid>60088314</afid></author><authkeywords>Cardiovascular | Respiration | Thermoregulation</authkeywords><intid>1535452806</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927557032"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927557032?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927557032&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927557032&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215002869"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927557032</prism:url><dc:identifier>SCOPUS_ID:84927557032</dc:identifier><eid>2-s2.0-84927557032</eid><dc:title>No role of beta receptors in cognitive flexibility: Evidence from a task-switching paradigm in a randomized controlled trial</dc:title><dc:creator>Steenbergen L.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>295</prism:volume><prism:pageRange>237-242</prism:pageRange><prism:coverDate>2015-06-04</prism:coverDate><prism:coverDisplayDate>June 04, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.049</prism:doi><pii>S0306452215002869</pii><dc:description>© 2015 IBRO. There is evidence that noradrenergic coeruleo-cortical projections are involved in different forms of cognitive flexibility. So far, no studies in humans have investigated the involvement of beta receptors on task-switching performance, a well-established measure of cognitive flexibility. The present study investigated whether the administration of propranolol (a central and peripheral beta-adrenergic antagonist) affected switching costs (i.e., the increase of reaction time in task-switching trials relative to task-repetition trials). Sixteen healthy adult human subjects performed a global-local task-switching paradigm in a double-blind, within-subjects design study investigating the effects of 80. mg of propranolol hydrochloride (a β1 and β2 adrenergic receptor antagonist) vs. an oral dose of microcrystalline cellulose (placebo pill).The acute administration of propranolol did not affect the size of switching costs compared to the intake of the neutral placebo. Our results, corroborated by Bayesian inference, suggest that beta receptors do not modulate cognitive flexibility as measured by task-switching performance.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019816</affiliation-url><afid>60019816</afid><affilname>Leiden University</affilname><name-variant>University of Leiden</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019816</affiliation-url><afid>60019816</afid><affilname>Leiden University</affilname><name-variant>University of Leiden</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55966140800</author-url><authid>55966140800</authid><authname>Steenbergen L.</authname><surname>Steenbergen</surname><given-name>L.</given-name><initials>L.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55966140800</author-url><authid>55966140800</authid><authname>Steenbergen L.</authname><surname>Steenbergen</surname><given-name>L.</given-name><initials>L.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55032724300</author-url><authid>55032724300</authid><authname>Sellaro R.</authname><surname>Sellaro</surname><given-name>R.</given-name><initials>R.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55032724300</author-url><authid>55032724300</authid><authname>Sellaro R.</authname><surname>Sellaro</surname><given-name>R.</given-name><initials>R.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14830223700</author-url><authid>14830223700</authid><authname>de Rover M.</authname><surname>de Rover</surname><given-name>M.</given-name><initials>M.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14830223700</author-url><authid>14830223700</authid><authname>de Rover M.</authname><surname>de Rover</surname><given-name>M.</given-name><initials>M.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005738313</author-url><authid>7005738313</authid><authname>Hommel B.</authname><surname>Hommel</surname><given-name>B.</given-name><initials>B.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005738313</author-url><authid>7005738313</authid><authname>Hommel B.</authname><surname>Hommel</surname><given-name>B.</given-name><initials>B.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6507926993</author-url><authid>6507926993</authid><authname>Colzato L.</authname><surname>Colzato</surname><given-name>L. S.</given-name><initials>L.S.</initials><afid>60019816</afid><afid>60019816</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6507926993</author-url><authid>6507926993</authid><authname>Colzato L.</authname><surname>Colzato</surname><given-name>L. S.</given-name><initials>L.S.</initials><afid>60019816</afid><afid>60019816</afid></author><authkeywords>Beta receptors | Cognitive flexibility | Norepinephrine | Task-switching</authkeywords><intid>2035629744</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930268707"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930268707?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930268707&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930268707&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930268707</prism:url><dc:identifier>SCOPUS_ID:84930268707</dc:identifier><eid>2-s2.0-84930268707</eid><dc:title>Research protocol for a randomized controlled trial of the health effects of volunteering for seniors</dc:title><dc:creator>Pettigrew S.</dc:creator><prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName><prism:eIssn>14777525</prism:eIssn><prism:coverDate>2015-06-04</prism:coverDate><prism:coverDisplayDate>June 04, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12955-015-0263-z</prism:doi><dc:description>© 2015 Pettigrew et al.; licensee BioMed Central. Background: A growing evidence base demonstrates that interventions that focus on participation in physical and social activities can assist in preventing and treating both physical and mental health problems. In addition, there is some evidence that engaging in volunteering activities can provide beneficial social, physical, psychological, and cognitive outcomes for older people. This study will use a randomized controlled trial approach to investigate the potential for interventions involving volunteer activities to produce positive physical and psychological outcomes for older people, thereby contributing to the limited evidence relating to the potential for volunteering to provide multiple health effects. Methods/Design: This randomized controlled trial will involve 400 retired/non-employed individuals in good health aged 60+ years living in the metropolitan area in Perth, Western Australia. Participants will be recruited from the Perth metropolitan area using a variety of recruitment methods to achieve a diverse sample in terms of age, gender, and socioeconomic status. Consenting and eligible participants will be randomly assigned to an intervention (n = 200) or control group (n = 200). Those in the intervention group will be asked to engage in a minimum 60 min of volunteer activities per week for a period of 6 months, while those in the control group will be asked to maintain their existing lifestyle or take on new activities as they see fit. Physical and psychological outcomes will be assessed. Primary physical outcomes will include physical activity and sedentary time (measured using pedometers and Actigraph monitors) and physical health (measured using a battery of physical functioning tests, resting heart rate, blood pressure, BMI, and girth). Primary psychological outcomes will include psychological well-being, depression, self-esteem, and quality of life (measured using the Warwick-Edinburgh Mental Well-Being Scale, Center for Epidemiologic Studies Depression Scale, the Rosenberg Self-Esteem Survey, and the Global Quality of Life Scale, respectively). Secondary outcomes of interest will include attitudes to volunteering (measured via open-ended interviews) and personal growth, purpose in life, social support, and self-efficacy (measured using the Personal Growth and Purpose in Life subscales of Ryff's Psychological Well-Being Scale, the Social Provisions Scale, and the Generalized Self-Efficacy Scale, respectively). Participants will be re-assessed on these measures after 6 months. Discussion: The results of this randomized controlled trial will generate new knowledge relating to the physical and psychological health benefits of different levels and types of volunteering for older people. In addition, insight will be provided into the major factors influencing the recruitment and retention of older volunteers. Understanding the full potential for volunteering to affect physical and mental well-being will provide policy makers with the evidence they require to determine appropriate investment in the volunteering sector, especially in relation to encouraging volunteering among older people who constitute an important resource for the community. Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12615000091505. Date registered: 3 February, 2015.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city/><affiliation-country/></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city/><affiliation-country/></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city/><affiliation-country/></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city/><affiliation-country/></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12545715600</author-url><authid>12545715600</authid><authname>Pettigrew S.</authname><surname>Pettigrew</surname><given-name>Simone</given-name><initials>S.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56079257800</author-url><authid>56079257800</authid><authname>Jongenelis M.</authname><surname>Jongenelis</surname><given-name>Michelle</given-name><initials>M.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663829400</author-url><authid>56663829400</authid><authname>Newton R.</authname><surname>Newton</surname><given-name>Robert U.</given-name><initials>R.U.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005969297</author-url><authid>7005969297</authid><authname>Warburton J.</authname><surname>Warburton</surname><given-name>Jeni</given-name><initials>J.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:16230148900</author-url><authid>16230148900</authid><authname>Jackson B.</authname><surname>Jackson</surname><given-name>Ben</given-name><initials>B.</initials><afid/></author><authkeywords>Physical health | Psychological well-being | Seniors | Volunteering</authkeywords><intid>36091548</intid><source-id>20846</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926198148"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926198148?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926198148&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926198148&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215002377"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926198148</prism:url><dc:identifier>SCOPUS_ID:84926198148</dc:identifier><eid>2-s2.0-84926198148</eid><dc:title>HIF1α is necessary for exercise-induced neuroprotection while HIF2α is needed for dopaminergic neuron survival in the substantia nigra pars compacta</dc:title><dc:creator>Smeyne M.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>295</prism:volume><prism:pageRange>23-38</prism:pageRange><prism:coverDate>2015-06-04</prism:coverDate><prism:coverDisplayDate>June 04, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.03.015</prism:doi><pii>S0306452215002377</pii><dc:description>© 2015 The Authors. Exercise reduces the risk of developing a number of neurological disorders and increases the efficiency of cellular energy production. However, overly strenuous exercise produces oxidative stress. Proper oxygenation is crucial for the health of all tissues, and tight regulation of cellular oxygen is critical to balance O&lt;inf&gt;2&lt;/inf&gt; levels and redox homeostasis in the brain. Hypoxia Inducible Factor (HIF)1α and HIF2α are transcription factors regulated by cellular oxygen concentration that initiate gene regulation of vascular development, redox homeostasis, and cell cycle control. HIF1α and HIF2α contribute to important adaptive mechanisms that occur when oxygen and ROS homeostasis become unbalanced. It has been shown that preconditioning by exposure to a stressor prior to a hypoxic event reduces damage that would otherwise occur. Previously we reported that 3months of exercise protects SNpc dopaminergic (DA) neurons from toxicity caused by Complex I inhibition. Here, we identify the cells in the SNpc that express HIF1α and HIF2α and show that running exercise produces hypoxia in SNpc DA neurons, and alters the expression of HIF1α and HIF2α. In mice carrying a conditional knockout of Hif1α in postnatal neurons we observe that exercise alone produces SNpc TH+ DA neuron loss. Loss of HIF1α also abolishes exercise-induced neuroprotection. In mice lacking Hif2α in postnatal neurons, the number of TH+ DA neurons in the adult SNpc is diminished, but 3months of exercise rescues this loss. We conclude that HIF1α is necessary for exercise-induced neuroprotection and both HIF1α and HIF2α are necessary for the survival and function of adult SNpc DA neurons.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105249531</affiliation-url><afid>105249531</afid><affilname>St. Jude Children's Research Hospital</affilname><name-variant>St. Jude Children's Research Hospital</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002194</affiliation-url><afid>60002194</afid><affilname>University of Tennessee Health Science Center</affilname><name-variant>University of Tennessee</name-variant><affiliation-city>Memphis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6505979002</author-url><authid>6505979002</authid><authname>Smeyne M.</authname><surname>Smeyne</surname><given-name>M.</given-name><initials>M.</initials><afid>105249531</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56580375200</author-url><authid>56580375200</authid><authname>Sladen P.</authname><surname>Sladen</surname><given-name>P.</given-name><initials>P.</initials><afid>105249531</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56579665700</author-url><authid>56579665700</authid><authname>Jiao Y.</authname><surname>Jiao</surname><given-name>Y.</given-name><initials>Y.</initials><afid>105249531</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602121541</author-url><authid>6602121541</authid><authname>Dragatsis I.</authname><surname>Dragatsis</surname><given-name>I.</given-name><initials>I.</initials><afid>60002194</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004484921</author-url><authid>7004484921</authid><authname>Smeyne R.</authname><surname>Smeyne</surname><given-name>R. J.</given-name><initials>R.J.</initials><afid>105249531</afid></author><authkeywords>Exercise | Hypoxia | Neuroprotection | Oxidative stress | Preconditioning | Substantia nigra</authkeywords><intid>535408383</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930077345"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930077345?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930077345&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930077345&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930077345</prism:url><dc:identifier>SCOPUS_ID:84930077345</dc:identifier><eid>2-s2.0-84930077345</eid><dc:title>Survival predictor for penetrating cardiac injury; a 10-year consecutive cohort from a scandinavian trauma center</dc:title><dc:creator>Kaljusto M.</dc:creator><prism:publicationName>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</prism:publicationName><prism:eIssn>17577241</prism:eIssn><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>June 03, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13049-015-0125-z</prism:doi><dc:description>© 2015 Kaljusto et al. Background: Penetrating cardiac injuries in Europe have been poorly studied. We present a 10-year outcome for patients with penetrating heart injuries at Oslo University Hospital. Methods: Data from 01.01.2001 until 31.12.2010 was collected from the Oslo University Hospital Trauma Registry and from the patients' records. Results: Thirty-one patients were admitted with a penetrating cardiac injury. Fourteen patients survived (45 %). Four out of 8 patients (50 %) with gunshot wounds survived compared to 10 out of 23 (44 %) with stab wounds. Median (quartiles) for the following values were: Injury Severity Score 25 (21-35), Revised Trauma Score 0 (0-6,9), Probability of Survival 0,015 (0,004-0,956), Glasgow Coma Scale 3 (3-13). Thirteen patients had signs of life on admission and survived. Eighteen patients were admitted without signs of life and received emergency department thoracotomy. Eight of these had no signs of life at the scene of injury and did not survive. Out of the remaining 10 patients, one survived. Conclusions: The outcome of patients with penetrating cardiac injury reaching the emergency department with signs of life was excellent. Hemodynamic instability indicates immediate surgery. Stable patients with penetrating thoracic trauma and possible cardiac injury detected by imaging should be considered for conservative treatment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010348</affiliation-url><afid>60010348</afid><affilname>Universitetet i Oslo</affilname><name-variant>University of Oslo</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010348</affiliation-url><afid>60010348</afid><affilname>Universitetet i Oslo</affilname><name-variant>University of Oslo</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:13205133200</author-url><authid>13205133200</authid><authname>Kaljusto M.</authname><surname>Kaljusto</surname><given-name>Mari Liis</given-name><initials>M.L.</initials><afid>60105037</afid><afid>60010348</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:13205133200</author-url><authid>13205133200</authid><authname>Kaljusto M.</authname><surname>Kaljusto</surname><given-name>Mari Liis</given-name><initials>M.L.</initials><afid>60105037</afid><afid>60010348</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8840247200</author-url><authid>8840247200</authid><authname>Skaga N.</authname><surname>Skaga</surname><given-name>Nils Oddvar</given-name><initials>N.O.</initials><afid>60010348</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004653910</author-url><authid>7004653910</authid><authname>Pillgram-Larsen J.</authname><surname>Pillgram-Larsen</surname><given-name>Johan</given-name><initials>J.</initials><afid>60105037</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7007176147</author-url><authid>7007176147</authid><authname>Tønnessen T.</authname><surname>Tønnessen</surname><given-name>Theis</given-name><initials>T.</initials><afid>60105037</afid><afid>60010348</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7007176147</author-url><authid>7007176147</authid><authname>Tønnessen T.</authname><surname>Tønnessen</surname><given-name>Theis</given-name><initials>T.</initials><afid>60105037</afid><afid>60010348</afid></author><intid>1036056592</intid><source-id>19700166521</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930149016"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930149016?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930149016&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930149016&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930149016</prism:url><dc:identifier>SCOPUS_ID:84930149016</dc:identifier><eid>2-s2.0-84930149016</eid><dc:title>Consequences of high-sensitivity troponin T testing applied in a primary care population with chest pain compared with a commercially available point-of-care troponin T analysis: An observational prospective study</dc:title><dc:creator>Andersson P.</dc:creator><prism:publicationName>BMC Research Notes</prism:publicationName><prism:eIssn>17560500</prism:eIssn><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>June 03, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13104-015-1174-0</prism:doi><dc:description>© 2015 Andersson et al. Background: There is a demand for a highly sensitive and specific point-of care test to detect acute myocardial infarction (AMI). It is unclear if a high-sensitivity troponin assay will have enough discriminative power to become a decision support in primary care. The aim of this study was to evaluate a high-sensitivity troponin T assay performed in three primary health care centres in southeast Sweden and to compare the outcome with a point-of-care troponin T test. Methods: This study included 115 patients who consulted their general practitioner for chest pain, dyspnoea on exertion, unexplained weakness and/or fatigue in the last 7 days. Troponin T was analysed by a point-of-care test and a high-sensitivity method together with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and creatinine. All patients were checked for AMI or unstable angina (UA) within 30 days of study enrolment. Univariate and multivariate logistic regression was carried out to examine possible connections between troponin T ≥ 15 ng/L, clinical variables and laboratory findings at baseline. In addition, 21 patients with troponin T ≥ 15 ng/L and no signs of AMI or UA were followed up for 2-3 years. Results: Three patients were diagnosed with AMI and three with UA. At the ≥ 15 ng/L cut-off, the troponin T method had 100% sensitivity, 75% specificity for AMI and a positive predictive value of 10%. The troponin T point-of-care test missed one case of AMI and the detection limit was 50 ng/L. Troponin T ≥ 15 ng/L was correlated to age ≥65 years (odds ratio (OR), 10.9 95% CI 2.28-51.8) and NT-proBNP in accordance with heart failure (OR 8.62 95% CI 1.61-46.1). Fourteen of the 21 patients, without signs of AMI or UA at baseline, still had increased troponin T at follow-up after 2-3 years. Conclusions: A high-sensitivity troponin T assay could become useful in primary care as a point-of-care test for patients &lt;65 years. For patients older than 65-70 years, a higher decision limit than ≥15 ng/L should be considered and used in conjunction with clinical parameters and possibly with NT-proBNP.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009358</affiliation-url><afid>60009358</afid><affilname>Linkopings universitet</affilname><name-variant>Linköping University</name-variant><affiliation-city>Linkoping</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106277745</affiliation-url><afid>106277745</afid><affilname>County Council of Jönköping</affilname><name-variant>Regional Development Council of Jönköping County</name-variant><affiliation-city>Jonkoping</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009358</affiliation-url><afid>60009358</afid><affilname>Linkopings universitet</affilname><name-variant>Linköping University</name-variant><affiliation-city>Linkoping</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009358</affiliation-url><afid>60009358</afid><affilname>Linkopings universitet</affilname><name-variant>Linköping University</name-variant><affiliation-city>Linkoping</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009358</affiliation-url><afid>60009358</afid><affilname>Linkopings universitet</affilname><name-variant>Linköping University</name-variant><affiliation-city>Linkoping</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661781600</author-url><authid>56661781600</authid><authname>Andersson P.</authname><surname>Andersson</surname><given-name>Per O.</given-name><initials>P.O.</initials><afid>60009358</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202167901</author-url><authid>7202167901</authid><authname>Karlsson J.</authname><surname>Karlsson</surname><given-name>Jan Erik</given-name><initials>J.E.</initials><afid>106277745</afid><afid>60009358</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202167901</author-url><authid>7202167901</authid><authname>Karlsson J.</authname><surname>Karlsson</surname><given-name>Jan Erik</given-name><initials>J.E.</initials><afid>106277745</afid><afid>60009358</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16166378700</author-url><authid>16166378700</authid><authname>Landberg E.</authname><surname>Landberg</surname><given-name>Eva</given-name><initials>E.</initials><afid>60009358</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:22134098700</author-url><authid>22134098700</authid><authname>Festin K.</authname><surname>Festin</surname><given-name>Karin</given-name><initials>K.</initials><afid>60009358</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56446274700</author-url><authid>56446274700</authid><authname>Nilsson S.</authname><surname>Nilsson</surname><given-name>Staffan</given-name><initials>S.</initials><afid>60009358</afid></author><authkeywords>Acute coronary syndrome | Chest pain | Point-of-care testing | Primary health care | Troponin T</authkeywords><intid>36076410</intid><source-id>19600166028</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927655128"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927655128?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927655128&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927655128&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1874391915001396"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927655128</prism:url><dc:identifier>SCOPUS_ID:84927655128</dc:identifier><eid>2-s2.0-84927655128</eid><dc:title>Basal and exercise induced label-free quantitative protein profiling of m. vastus lateralis in trained and untrained individuals</dc:title><dc:creator>Schild M.</dc:creator><prism:publicationName>Journal of Proteomics</prism:publicationName><prism:issn>18743919</prism:issn><prism:eIssn>18767737</prism:eIssn><prism:volume>122</prism:volume><prism:pageRange>119-132</prism:pageRange><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>June 03, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jprot.2015.03.028</prism:doi><pii>S1874391915001396</pii><dc:description>© 2015 Elsevier B.V. Morphological and metabolic adaptations of the human skeletal muscle to exercise are crucial to improve performance and prevent chronic diseases and metabolic disorders. In this study we investigated human skeletal muscle protein composition in endurance trained (ET) versus untrained individuals (UT) and its modulation by an acute bout of endurance exercise. Participants were recruited based on their VO&lt;inf&gt;2&lt;/inf&gt;max and subjected to a bicycle exercise test. M. vastus lateralis biopsies were taken before and three hours after exercise. Muscle lysates were analyzed using off-gel LC-MS/MS. Relative protein abundances were compared between ET and UT at rest and after exercise. Comparing UT and ET, we identified 92 significantly changed proteins under resting conditions. Specifically, fiber-type-specific and proteins of the oxidative phosphorylation and tricarboxylic acid cycle were increased in ET. In response to acute exercise, 71 proteins in ET and 44 in UT were altered. Here, a decrease of proteins involved in energy metabolism accompanied with alterations of heat shock and proteasomal proteins could be observed. In summary, long-term endurance training increased the basal level of structural and mitochondrial proteins in skeletal muscle. In contrast, acute exercise resulted in a depletion of proteins related to substrate utilization, especially in trained athletes. Biological significance: The investigation of the human skeletal muscle proteome in response to exercise may provide novel insights into the process of muscular plasticity. It is of importance in the development of exercise-based strategies in the prevention and therapy of many chronic inflammatory and degenerative diseases which are often accompanied by muscular deconditioning. Up to date, proteomic investigations of the human muscle proteome in adaptation to exercise are mainly focused on untrained individuals and often restricted to animal studies. In the present study we compare the protein composition in endurance trained athletes and untrained individuals in the resting muscle and its modulation in response to acute exercise. To our knowledge, we present the first comprehensive analysis of skeletal muscle proteome alterations in response to acute and long-term exercise intervention.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017134</affiliation-url><afid>60017134</afid><affilname>Justus Liebig University Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016415</affiliation-url><afid>60016415</afid><affilname>Max-Planck-Institut fur Herz- und Lungenforschung</affilname><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022653</affiliation-url><afid>60022653</afid><affilname>Universitatsklinikum Tubingen Medizinische Fakultat</affilname><affiliation-city>Tubingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010819</affiliation-url><afid>60010819</afid><affilname>Universitatsklinikum Ulm</affilname><name-variant>Universitätsklinikum Ulm</name-variant><affiliation-city>Ulm</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017134</affiliation-url><afid>60017134</afid><affilname>Justus Liebig University Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024025</affiliation-url><afid>60024025</afid><affilname>Universitat zu Koln</affilname><name-variant>Universität zu Köln</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56311051000</author-url><authid>56311051000</authid><authname>Schild M.</authname><surname>Schild</surname><given-name>Marius</given-name><initials>M.</initials><afid>60017134</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55253224400</author-url><authid>55253224400</authid><authname>Ruhs A.</authname><surname>Ruhs</surname><given-name>Aaron</given-name><initials>A.</initials><afid>60016415</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35726780100</author-url><authid>35726780100</authid><authname>Beiter T.</authname><surname>Beiter</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60022653</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56592920900</author-url><authid>56592920900</authid><authname>Zügel M.</authname><surname>Zügel</surname><given-name>Martina</given-name><initials>M.</initials><afid>60010819</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37063142600</author-url><authid>37063142600</authid><authname>Hudemann J.</authname><surname>Hudemann</surname><given-name>Jens</given-name><initials>J.</initials><afid>60022653</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56592008100</author-url><authid>56592008100</authid><authname>Reimer A.</authname><surname>Reimer</surname><given-name>Anna</given-name><initials>A.</initials><afid>60017134</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56593159200</author-url><authid>56593159200</authid><authname>Krumholz-Wagner I.</authname><surname>Krumholz-Wagner</surname><given-name>Ilke</given-name><initials>I.</initials><afid>60017134</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402149068</author-url><authid>7402149068</authid><authname>Wagner C.</authname><surname>Wagner</surname><given-name>Carola</given-name><initials>C.</initials><afid>60010819</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:26422985500</author-url><authid>26422985500</authid><authname>Keller J.</authname><surname>Keller</surname><given-name>Janine</given-name><initials>J.</initials><afid>60017134</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7103034810</author-url><authid>7103034810</authid><authname>Eder K.</authname><surname>Eder</surname><given-name>Klaus</given-name><initials>K.</initials><afid>60017134</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55573216000</author-url><authid>55573216000</authid><authname>Krüger K.</authname><surname>Krüger</surname><given-name>Karsten</given-name><initials>K.</initials><afid>60017134</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7102550659</author-url><authid>7102550659</authid><authname>Krüger M.</authname><surname>Krüger</surname><given-name>Marcus</given-name><initials>M.</initials><afid>60024025</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:35432839500</author-url><authid>35432839500</authid><authname>Braun T.</authname><surname>Braun</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60016415</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003913975</author-url><authid>7003913975</authid><authname>Nieß A.</authname><surname>Nieß</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60022653</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:8947338000</author-url><authid>8947338000</authid><authname>Steinacker J.</authname><surname>Steinacker</surname><given-name>Jürgen</given-name><initials>J.</initials><afid>60010819</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:6701376686</author-url><authid>6701376686</authid><authname>Mooren F.</authname><surname>Mooren</surname><given-name>Frank C.</given-name><initials>F.C.</initials><afid>60017134</afid></author><authkeywords>Endurance exercise | Energy metabolism | Label free mass spectrometry | Muscular plasticity | Oxidative phosphorylation | Skeletal muscle proteome</authkeywords><intid>1785647847</intid><source-id>11700154304</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929962960"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929962960?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929962960&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929962960&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0040403915001604"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929962960</prism:url><dc:identifier>SCOPUS_ID:84929962960</dc:identifier><eid>2-s2.0-84929962960</eid><dc:title>Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives</dc:title><dc:creator>Richardson M.</dc:creator><prism:publicationName>Tetrahedron Letters</prism:publicationName><prism:issn>00404039</prism:issn><prism:eIssn>18733581</prism:eIssn><prism:volume>56</prism:volume><prism:issueIdentifier>23</prism:issueIdentifier><prism:pageRange>3406-3409</prism:pageRange><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>3 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.tetlet.2015.01.122</prism:doi><pii>S0040403915001604</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. Advanced glycation end-products (AGEs), unregulated modifications to host macromolecules that occur as a result of metabolic dysregulation, play a role in many diabetes related complications, inflammation and aging, and may lead to increased cardiovascular risk. Small molecules that have the ability to inhibit AGE formation, and even break preformed AGEs have enormous therapeutic potential in the treatment of these disease states. We report the screening of a series of 2-aminoimidazloles for anti-AGE activity, and the identification of a bis-2-aminoimidazole lead compound that possesses superior AGE inhibition and breaking activity compared to the known AGE inhibitor aminoguanidine.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009226</affiliation-url><afid>60009226</afid><affilname>Colorado State University</affilname><name-variant>Colorado State University</name-variant><affiliation-city>Fort Collins</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004923</affiliation-url><afid>60004923</afid><affilname>North Carolina State University</affilname><name-variant>North Carolina State University</name-variant><affiliation-city>Raleigh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56522248900</author-url><authid>56522248900</authid><authname>Richardson M.</authname><surname>Richardson</surname><given-name>Mike A.</given-name><initials>M.A.</initials><afid>60009226</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55908176300</author-url><authid>55908176300</authid><authname>Furlani R.</authname><surname>Furlani</surname><given-name>Robert E.</given-name><initials>R.E.</initials><afid>60004923</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:12796464700</author-url><authid>12796464700</authid><authname>Podell B.</authname><surname>Podell</surname><given-name>Brendan K.</given-name><initials>B.K.</initials><afid>60009226</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35848159800</author-url><authid>35848159800</authid><authname>Ackart D.</authname><surname>Ackart</surname><given-name>David F.</given-name><initials>D.F.</initials><afid>60009226</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56522737600</author-url><authid>56522737600</authid><authname>Haugen J.</authname><surname>Haugen</surname><given-name>Jessica D.</given-name><initials>J.D.</initials><afid>60009226</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56196945000</author-url><authid>56196945000</authid><authname>Melander R.</authname><surname>Melander</surname><given-name>Roberta J.</given-name><initials>R.J.</initials><afid>60004923</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603138400</author-url><authid>6603138400</authid><authname>Melander C.</authname><surname>Melander</surname><given-name>Christian</given-name><initials>C.</initials><afid>60004923</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6701555831</author-url><authid>6701555831</authid><authname>Basaraba R.</authname><surname>Basaraba</surname><given-name>Randall J.</given-name><initials>R.J.</initials><afid>60009226</afid></author><authkeywords>Advanced glycation end-products (AGEs) | Aminoguanidine | Bis-2-aminoimidazole | Diabetes</authkeywords><intid>2036036921</intid><source-id>26514</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84921966160"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84921966160?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84921966160&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84921966160&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0278584615000093"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84921966160</prism:url><dc:identifier>SCOPUS_ID:84921966160</dc:identifier><eid>2-s2.0-84921966160</eid><dc:title>Antidepressant-like effect of zinc is dependent on signaling pathways implicated in BDNF modulation</dc:title><dc:creator>Manosso L.</dc:creator><prism:publicationName>Progress in Neuro-Psychopharmacology and Biological Psychiatry</prism:publicationName><prism:issn>02785846</prism:issn><prism:eIssn>18784216</prism:eIssn><prism:volume>59</prism:volume><prism:pageRange>59-67</prism:pageRange><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>June 03, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pnpbp.2015.01.008</prism:doi><pii>S0278584615000093</pii><dc:description>© 2015. Considering that intracellular signaling pathways that modulate brain BDNF are implicated in antidepressant responses, this study investigated whether signaling pathway inhibitors upstream to BDNF might influence the antidepressant-like effect of zinc, a metal that has been shown to display antidepressant properties. To this end, the influence of i.c.v. administration of H-89 (1μg/site, PKA inhibitor), KN-62 (1μg/site, CAMKII inhibitor), chelerythrine (1μg/site, PKC inhibitor), PD98059 (5μg/site, MEK1/2 inhibitor), U0126 (5μg/site, MEK1/2 inhibitor), LY294002 (10nmol/site, PI3K inhibitor) on the reduction of immobility time in the tail suspension test (TST) elicited by ZnCl2 (10mg/kg, p.o.) was investigated. Moreover, the effect of the combination of sub-effective doses of ZnCl2 (1mg/kg, p.o.) and AR-A014418 (0.001μg/site, GSK-3β inhibitor) was evaluated. The occurrence of changes in CREB phosphorylation and BDNF immunocontent in the hippocampus and prefrontal cortex of mice following ZnCl2 treatment was also investigated. The anti-immobility effect of ZnCl2 in the TST was prevented by treatment with PKA, PKC, CAMKII, MEK1/2 or PI3K inhibitors. Furthermore, ZnCl2 in combination with AR-A014418 caused a synergistic anti-immobility effect in the TST. None of the treatments altered locomotor activity of mice. ZnCl2 treatment caused no alteration in CREB phosphorylation and BDNF immunocontent. The results extend literature data regarding the mechanisms underlying the antidepressant-like action of zinc by indicating that its antidepressant-like effect may be dependent on the activation of PKA, CAMKII, PKC, ERK, and PI3K/GSK-3β pathways. However, zinc is not able to acutely increase BDNF in the hippocampus and prefrontal cortex.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017609</affiliation-url><afid>60017609</afid><affilname>Universidade Federal de Santa Catarina</affilname><name-variant>Universidade Federal de Santa Catarina</name-variant><affiliation-city>Florianopolis</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016207</affiliation-url><afid>60016207</afid><affilname>Universidade Regional de Blumenau</affilname><name-variant>Universidade Regional de Blumenau</name-variant><affiliation-city>Blumenau</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55368424200</author-url><authid>55368424200</authid><authname>Manosso L.</authname><surname>Manosso</surname><given-name>Luana M.</given-name><initials>L.M.</initials><afid>60017609</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35148099700</author-url><authid>35148099700</authid><authname>Moretti M.</authname><surname>Moretti</surname><given-name>Morgana</given-name><initials>M.</initials><afid>60016207</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55219899100</author-url><authid>55219899100</authid><authname>Ribeiro C.</authname><surname>Ribeiro</surname><given-name>Camille M.</given-name><initials>C.M.</initials><afid>60017609</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55082108600</author-url><authid>55082108600</authid><authname>Gonçalves F.</authname><surname>Gonçalves</surname><given-name>Filipe M.</given-name><initials>F.M.</initials><afid>60017609</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006745491</author-url><authid>7006745491</authid><authname>Leal R.</authname><surname>Leal</surname><given-name>Rodrigo B.</given-name><initials>R.B.</initials><afid>60017609</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35518147800</author-url><authid>35518147800</authid><authname>Rodrigues A.</authname><surname>Rodrigues</surname><given-name>Ana Lúcia S</given-name><initials>A.L.S.</initials><afid>60017609</afid></author><authkeywords>Antidepressant | Signaling pathways | Tail suspension test | Zinc</authkeywords><intid>2034727589</intid><source-id>21767</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84921019068"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84921019068?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84921019068&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84921019068&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0278584614002486"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84921019068</prism:url><dc:identifier>SCOPUS_ID:84921019068</dc:identifier><eid>2-s2.0-84921019068</eid><dc:title>Ghrelin-reactive immunoglobulins and anxiety, depression and stress-induced cortisol response in adolescents. The TRAILS study</dc:title><dc:creator>François M.</dc:creator><prism:publicationName>Progress in Neuro-Psychopharmacology and Biological Psychiatry</prism:publicationName><prism:issn>02785846</prism:issn><prism:eIssn>18784216</prism:eIssn><prism:volume>59</prism:volume><prism:pageRange>1-7</prism:pageRange><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>June 03, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pnpbp.2014.12.011</prism:doi><pii>S0278584614002486</pii><dc:description>© 2015 Elsevier Inc. Background: Ghrelin, a hunger hormone, has been implicated in the regulation of stress-response, anxiety and depression. Ghrelin-reactive immunoglobulins (Ig) were recently identified in healthy and obese humans showing abilities to increase ghrelin's stability and orexigenic effects. Here we studied if ghrelin-reactive Ig are associated with anxiety and depression and with the stress-induced cortisol response in a general population of adolescents. Furthermore, to test the possible infectious origin of ghrelin-reactive Ig, their levels were compared with serum IgG against common viruses. Methods: We measured ghrelin-reactive IgM, IgG and IgA in serum samples of 1199 adolescents from the Dutch TRAILS study and tested their associations with 1) anxiety and depression symptoms assessed with the Youth Self-Report, 2) stress-induced salivary cortisol levels and 3) IgG against human herpesvirus 1, 2, 4 and 6 and Influenza A and B viruses. Results: Ghrelin-reactive IgM and IgG correlated positively with levels of antibodies against Influenza A virus. Ghrelin-reactive IgM correlated negatively with antibodies against Influenza B virus. Ghrelin-reactive IgM correlated positively with anxiety scores in girls and ghrelin-reactive IgG correlated with stress-induced cortisol secretion, but these associations were weak and not significant after correction for multiple testing. Conclusion: These data indicate that production of ghrelin-reactive autoantibodies could be influenced by viral infections. Serum levels of ghrelin-reactive autoantibodies probably do not play a role in regulating anxiety, depression and the stress-response in adolescents from the general population.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032922</affiliation-url><afid>60032922</afid><affilname>Universite de Rouen</affilname><name-variant>University of Rouen</name-variant><affiliation-city>Mont Saint Aignan</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032114</affiliation-url><afid>60032114</afid><affilname>Erasmus University Medical Center</affilname><name-variant>Erasmus Medical Center</name-variant><affiliation-city>Rotterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55936988600</author-url><authid>55936988600</authid><authname>François M.</authname><surname>François</surname><given-name>Marie</given-name><initials>M.</initials><afid>60032922</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55939370300</author-url><authid>55939370300</authid><authname>Schaefer J.</authname><surname>Schaefer</surname><given-name>Johanna M.</given-name><initials>J.M.</initials><afid>60032114</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55881037400</author-url><authid>55881037400</authid><authname>Bole-Feysot C.</authname><surname>Bole-Feysot</surname><given-name>Christine</given-name><initials>C.</initials><afid>60032922</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005139649</author-url><authid>7005139649</authid><authname>Déchelotte P.</authname><surname>Déchelotte</surname><given-name>Pierre</given-name><initials>P.</initials><afid>60032922</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55147513700</author-url><authid>55147513700</authid><authname>Verhulst F.</authname><surname>Verhulst</surname><given-name>Frank C.</given-name><initials>F.C.</initials><afid>60032114</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701679259</author-url><authid>6701679259</authid><authname>Fetissov S.</authname><surname>Fetissov</surname><given-name>Sergueï O.</given-name><initials>S.O.</initials><afid>60032922</afid></author><authkeywords>Anxiety | Autoantibodies | Depression | Infection | Molecular mimicry | Peptide hormones</authkeywords><intid>1784580004</intid><source-id>21767</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84921969632"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84921969632?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84921969632&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84921969632&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0278584615000056"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84921969632</prism:url><dc:identifier>SCOPUS_ID:84921969632</dc:identifier><eid>2-s2.0-84921969632</eid><dc:title>Bardoxolone methyl prevents high-fat diet-induced alterations in prefrontal cortex signalling molecules involved in recognition memory</dc:title><dc:creator>Camer D.</dc:creator><prism:publicationName>Progress in Neuro-Psychopharmacology and Biological Psychiatry</prism:publicationName><prism:issn>02785846</prism:issn><prism:eIssn>18784216</prism:eIssn><prism:volume>59</prism:volume><prism:pageRange>68-75</prism:pageRange><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>June 03, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pnpbp.2015.01.004</prism:doi><pii>S0278584615000056</pii><dc:description>© 2015 Elsevier Inc. High fat (HF) diets are known to induce changes in synaptic plasticity in the forebrain leading to learning and memory impairments. Previous studies of oleanolic acid derivatives have found that these compounds can cross the blood-brain barrier to prevent neuronal cell death. We examined the hypothesis that the oleanolic acid derivative, bardoxolone methyl (BM) would prevent diet-induced cognitive deficits in mice fed a HF diet. C57BL/6J male mice were fed a lab chow (LC) (5% of energy as fat), a HF (40% of energy as fat), or a HF diet supplemented with 10. mg/kg/day BM orally for 21. weeks. Recognition memory was assessed by performing a novel object recognition test on the treated mice. Downstream brain-derived neurotrophic factor (BDNF) signalling molecules were examined in the prefrontal cortex (PFC) and hippocampus of mice via Western blotting and N-methyl- d-aspartate (NMDA) receptor binding. BM treatment prevented HF diet-induced impairment in recognition memory (p&lt;. 0.001). In HF diet fed mice, BM administration attenuated alterations in the NMDA receptor binding density in the PFC (p&lt;. 0.05), however, no changes were seen in the hippocampus (p&gt;. 0.05). In the PFC and hippocampus of the HF diet fed mice, BM administration improved downstream BDNF signalling as indicated by increased protein levels of BDNF, phosphorylated tropomyosin related kinase B (pTrkB) and phosphorylated protein kinase B (pAkt), and increased phosphorylated AMP-activated protein kinase (pAMPK) (p&lt;. 0.05). BM administration also prevented the HF diet-induced increase in the protein levels of inflammatory molecules, phosphorylated c-Jun N-terminal kinase (pJNK) in the PFC, and protein tyrosine phosphatase 1B (PTP1B) in both the PFC and hippocampus. In summary, these findings suggest that BM prevents HF diet-induced impairments in recognition memory by improving downstream BDNF signal transduction, increasing pAMPK, and reducing inflammation in the PFC and hippocampus.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011664</affiliation-url><afid>60011664</afid><affilname>University of Wollongong</affilname><name-variant>University of Wollongong</name-variant><affiliation-city>Wollongong</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023748</affiliation-url><afid>60023748</afid><affilname>Australian Nuclear Science and Technology Organisation</affilname><name-variant>ANSTO</name-variant><affiliation-city>Lucas Heights</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011664</affiliation-url><afid>60011664</afid><affilname>University of Wollongong</affilname><name-variant>University of Wollongong</name-variant><affiliation-city>Wollongong</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109118205</affiliation-url><afid>109118205</afid><affilname>Schizophrenia Research Institute</affilname><name-variant>Schizophrenia Research Institute</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56308313600</author-url><authid>56308313600</authid><authname>Camer D.</authname><surname>Camer</surname><given-name>Danielle</given-name><initials>D.</initials><afid>60011664</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55555267100</author-url><authid>55555267100</authid><authname>Yu Y.</authname><surname>Yu</surname><given-name>Yinghua</given-name><initials>Y.</initials><afid>60011664</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201636408</author-url><authid>7201636408</authid><authname>Szabo A.</authname><surname>Szabo</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60011664</afid><afid>60023748</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201636408</author-url><authid>7201636408</authid><authname>Szabo A.</authname><surname>Szabo</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60011664</afid><afid>60023748</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15070184000</author-url><authid>15070184000</authid><authname>Fernandez F.</authname><surname>Fernandez</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60011664</afid><afid>60011664</afid><afid>109118205</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15070184000</author-url><authid>15070184000</authid><authname>Fernandez F.</authname><surname>Fernandez</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60011664</afid><afid>60011664</afid><afid>109118205</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15070184000</author-url><authid>15070184000</authid><authname>Fernandez F.</authname><surname>Fernandez</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60011664</afid><afid>60011664</afid><afid>109118205</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56498833700</author-url><authid>56498833700</authid><authname>Dinh C.</authname><surname>Dinh</surname><given-name>Chi H L</given-name><initials>C.H.L.</initials><afid>60011664</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56498021800</author-url><authid>56498021800</authid><authname>Huang X.</authname><surname>Huang</surname><given-name>Xu Feng</given-name><initials>X.F.</initials><afid>60011664</afid></author><authkeywords>Bardoxolone methyl | Hippocampus | Obesity | Prefrontal cortex | Recognition memory</authkeywords><intid>2034727956</intid><source-id>21767</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84921895050"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84921895050?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84921895050&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84921895050&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S027858461500010X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84921895050</prism:url><dc:identifier>SCOPUS_ID:84921895050</dc:identifier><eid>2-s2.0-84921895050</eid><dc:title>Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder</dc:title><dc:creator>De La Garza R.</dc:creator><prism:publicationName>Progress in Neuro-Psychopharmacology and Biological Psychiatry</prism:publicationName><prism:issn>02785846</prism:issn><prism:eIssn>18784216</prism:eIssn><prism:volume>59</prism:volume><prism:pageRange>40-48</prism:pageRange><prism:coverDate>2015-06-03</prism:coverDate><prism:coverDisplayDate>June 03, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pnpbp.2015.01.009</prism:doi><pii>S027858461500010X</pii><dc:description>© 2014 Elsevier Inc. In the present study, we tested the hypothesis that the potent and selective dopamine-β-hydroxylase (DβH) inhibitor nepicastat would have minimal effects on cardiovascular and pharmacokinetic parameters associated with cocaine administration and would reduce the positive subjective effects produced by cocaine. We conducted a double-blind, placebo-controlled, inpatient study of oral nepicastat (0, 80 and 160. mg) concurrent with intravenous (IV) cocaine (0, 10, 20 and 40. mg) in non-treatment seeking participants who metcriteria for cocaine use disorder. Safety analyses revealed that nepicastat was well-tolerated and there were no differences in adverse events observed after nepicastat plus cocaine vs. cocaine alone. In addition, the pharmacokinetic properties of cocaine administration were not altered by nepicastat treatment. Cocaine-induced cardiovascular and subjective effects were evaluated for completers in the cohort randomized to nepicastat (n. =. 13) using a within-subjects statistical analysis strategy. Specifically, the cardiovascular and subjective effects of cocaine were assessed in the presence of placebo (0. mg), 80. mg of nepicastat or 160. mg of nepicastat on study Days 4, 8 and 12, respectively. Analyses revealed a main effect of nepicastat to reduce several cocaine-induced positive subjective effects. Taken together, these data indicate that nepicastat is safe when co-administered with cocaine and may suppress its positive subjective effects, and may be viable as a pharmacotherapy for treatment of cocaine use disorder.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002441</affiliation-url><afid>60002441</afid><affilname>Baylor College of Medicine</affilname><name-variant>Baylor College of Medicine</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002476</affiliation-url><afid>60002476</afid><affilname>Virginia Commonwealth University</affilname><name-variant>Virginia Commonwealth University</name-variant><affiliation-city>Richmond</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114942779</affiliation-url><afid>114942779</afid><affilname>Biotie Therapies, Inc. (formerly Synosia Therapeutics)</affilname><name-variant>Biotie Therapies, Inc. (formerly Synosia Therapeutics)</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">23</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003906211</author-url><authid>7003906211</authid><authname>De La Garza R.</authname><surname>De La Garza</surname><given-name>Richard</given-name><initials>R.</initials><afid>60002441</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507438520</author-url><authid>6507438520</authid><authname>Bubar M.</authname><surname>Bubar</surname><given-name>Marcy J.</given-name><initials>M.J.</initials><afid>60014569</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56497615500</author-url><authid>56497615500</authid><authname>Carbone C.</authname><surname>Carbone</surname><given-name>Crystal L.</given-name><initials>C.L.</initials><afid>60014569</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006196588</author-url><authid>7006196588</authid><authname>Moeller F.</authname><surname>Moeller</surname><given-name>F. Gerard</given-name><initials>F.G.</initials><afid>60014569</afid><afid>60002476</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006196588</author-url><authid>7006196588</authid><authname>Moeller F.</authname><surname>Moeller</surname><given-name>F. Gerard</given-name><initials>F.G.</initials><afid>60014569</afid><afid>60002476</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102322515</author-url><authid>7102322515</authid><authname>Newton T.</authname><surname>Newton</surname><given-name>Thomas F.</given-name><initials>T.F.</initials><afid>60002441</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6505944150</author-url><authid>6505944150</authid><authname>Anastasio N.</authname><surname>Anastasio</surname><given-name>Noelle C.</given-name><initials>N.C.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6505944150</author-url><authid>6505944150</authid><authname>Anastasio N.</authname><surname>Anastasio</surname><given-name>Noelle C.</given-name><initials>N.C.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56497637400</author-url><authid>56497637400</authid><authname>Harper T.</authname><surname>Harper</surname><given-name>Tod A.</given-name><initials>T.A.</initials><afid>60014569</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56497633000</author-url><authid>56497633000</authid><authname>Ware D.</authname><surname>Ware</surname><given-name>David L.</given-name><initials>D.L.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56497633000</author-url><authid>56497633000</authid><authname>Ware D.</authname><surname>Ware</surname><given-name>David L.</given-name><initials>D.L.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56497536500</author-url><authid>56497536500</authid><authname>Fuller M.</authname><surname>Fuller</surname><given-name>Michael A.</given-name><initials>M.A.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56497536500</author-url><authid>56497536500</authid><authname>Fuller M.</authname><surname>Fuller</surname><given-name>Michael A.</given-name><initials>M.A.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56497973600</author-url><authid>56497973600</authid><authname>Holstein G.</authname><surname>Holstein</surname><given-name>Gaylyn J.</given-name><initials>G.J.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56497973600</author-url><authid>56497973600</authid><authname>Holstein G.</authname><surname>Holstein</surname><given-name>Gaylyn J.</given-name><initials>G.J.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6506614051</author-url><authid>6506614051</authid><authname>Jayroe J.</authname><surname>Jayroe</surname><given-name>Jason B.</given-name><initials>J.B.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6506614051</author-url><authid>6506614051</authid><authname>Jayroe J.</authname><surname>Jayroe</surname><given-name>Jason B.</given-name><initials>J.B.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56497819000</author-url><authid>56497819000</authid><authname>Bandak S.</authname><surname>Bandak</surname><given-name>Stephen I.</given-name><initials>S.I.</initials><afid>114942779</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56497925000</author-url><authid>56497925000</authid><authname>Reiman K.</authname><surname>Reiman</surname><given-name>Kirsten Z.</given-name><initials>K.Z.</initials><afid>114942779</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56497636100</author-url><authid>56497636100</authid><authname>Neale A.</authname><surname>Neale</surname><given-name>Ann C.</given-name><initials>A.C.</initials><afid>114942779</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603304194</author-url><authid>6603304194</authid><authname>Pickford L.</authname><surname>Pickford</surname><given-name>Lesley B.</given-name><initials>L.B.</initials><afid>114942779</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:35602229000</author-url><authid>35602229000</authid><authname>Cunningham K.</authname><surname>Cunningham</surname><given-name>Kathryn A.</given-name><initials>K.A.</initials><afid>60014569</afid><afid>60014569</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:35602229000</author-url><authid>35602229000</authid><authname>Cunningham K.</authname><surname>Cunningham</surname><given-name>Kathryn A.</given-name><initials>K.A.</initials><afid>60014569</afid><afid>60014569</afid></author><authkeywords>Cocaine | Dopamine-β-hydroxylase | Nepicastat | SYN117</authkeywords><intid>1784733467</intid><source-id>21767</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924599123"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924599123?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924599123&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924599123&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0168160515001300"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924599123</prism:url><dc:identifier>SCOPUS_ID:84924599123</dc:identifier><eid>2-s2.0-84924599123</eid><dc:title>Detection of Toxoplasma gondii in free-range, organic pigs in Italy using serological and molecular methods</dc:title><dc:creator>Bacci C.</dc:creator><prism:publicationName>International Journal of Food Microbiology</prism:publicationName><prism:issn>01681605</prism:issn><prism:eIssn>18793460</prism:eIssn><prism:volume>202</prism:volume><prism:pageRange>54-56</prism:pageRange><prism:coverDate>2015-06-02</prism:coverDate><prism:coverDisplayDate>June 02, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijfoodmicro.2015.03.002</prism:doi><pii>S0168160515001300</pii><dc:description>© 2015 Elsevier B.V.. Twenty-one free ranging pigs from three organically managed farms in northern Italy were examined for Toxoplasma gondii infection status by meat juice serology. DNA was extracted from all 21 animals and analysed for T. gondii by multilocus nested PCR-RFLP. Results showed a 95.2% prevalence in serology, while PCR was positive in 57.1% of infected pigs. Genotyping of amplified loci for Type I, Type II and Type I/II patterns, suggests the presence of more than one clonal genotype in circulation in these animals. Results of the present study highlight the high exposure to T. gondii in organic pig farms in Italy, indicating a potential risk for meat consumption.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004969</affiliation-url><afid>60004969</afid><affilname>Universita degli Studi di Parma</affilname><name-variant>Università di Parma</name-variant><affiliation-city>Parma</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115049727</affiliation-url><afid>115049727</afid><affilname>Istituto Zooprofilattico Sperimentale Lombardia</affilname><name-variant>Istituto Zooprofilattico Sperimentale Lombardia</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006326109</author-url><authid>7006326109</authid><authname>Bacci C.</authname><surname>Bacci</surname><given-name>C.</given-name><initials>C.</initials><afid>60004969</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56254514800</author-url><authid>56254514800</authid><authname>Vismarra A.</authname><surname>Vismarra</surname><given-name>A.</given-name><initials>A.</initials><afid>60004969</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56545431800</author-url><authid>56545431800</authid><authname>Mangia C.</authname><surname>Mangia</surname><given-name>C.</given-name><initials>C.</initials><afid>60004969</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701348172</author-url><authid>6701348172</authid><authname>Bonardi S.</authname><surname>Bonardi</surname><given-name>S.</given-name><initials>S.</initials><afid>60004969</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56545823500</author-url><authid>56545823500</authid><authname>Bruini I.</authname><surname>Bruini</surname><given-name>I.</given-name><initials>I.</initials><afid>60004969</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23988578100</author-url><authid>23988578100</authid><authname>Genchi M.</authname><surname>Genchi</surname><given-name>M.</given-name><initials>M.</initials><afid>115049727</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7201597221</author-url><authid>7201597221</authid><authname>Kramer L.</authname><surname>Kramer</surname><given-name>L.</given-name><initials>L.</initials><afid>60004969</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603448606</author-url><authid>6603448606</authid><authname>Brindani F.</authname><surname>Brindani</surname><given-name>F.</given-name><initials>F.</initials><afid>60004969</afid></author><authkeywords>Meat juice | Organically raised | PCR | Pig | Toxoplasma gondii</authkeywords><intid>1035163025</intid><source-id>19760</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929075019"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929075019?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929075019&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929075019&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929075019</prism:url><dc:identifier>SCOPUS_ID:84929075019</dc:identifier><eid>2-s2.0-84929075019</eid><dc:title>Management of Advanced Heart Failure due to Cancer Therapy: the Present Role of Mechanical Circulatory Support and Cardiac Transplantation</dc:title><dc:creator>Deo S.</dc:creator><prism:publicationName>Current Treatment Options in Cardiovascular Medicine</prism:publicationName><prism:issn>10928464</prism:issn><prism:eIssn>15343189</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1-13</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11936-015-0388-8</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Rapid improvement in antineoplastic therapy is increasing not only cancer survivorship but also the incidence of end-stage heart failure among breast and childhood cancer survivors. Anthracyclines and newer targeted therapies, including trastuzumab and tyrosine kinase inhibitors, are important agents implemented in clinical practice that carry cardiotoxic risk. While acute heart failure is often self-limited and reversible, delayed-onset heart failure significantly reduces survival. Extremes of age, renal dysfunction, pre-existing coronary artery disease, HER2 positivity, and multi-drug therapy are predictors of irreversible heart failure after chemotherapy. Left ventricular assist device (LVAD) implantation and cardiac transplantation can be performed safely in patients with end-stage heart failure (HF) from chemotherapy. However, co-existing right ventricular dysfunction, hepatic congestion, and increased risk of bleeding make LVAD therapy challenging and dependent on careful patient selection. Cardiac transplantation in patients with chemotherapy-induced heart failure can be performed with good 10-year survival, but requires 5 years of cancer freedom and post-transplant infections remain a problem. Improvements in LVAD therapy and the expanding role of the total artificial heart and other durable biventricular support devices will likely provide more reliable surgical options for the management of end-stage HF after chemotherapy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021578</affiliation-url><afid>60021578</afid><affilname>University Hospitals Case Medical Center</affilname><name-variant>University Hospitals Case Medical Center</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637887500</author-url><authid>56637887500</authid><authname>Deo S.</authname><surname>Deo</surname><given-name>Salil V.</given-name><initials>S.V.</initials><afid>60021578</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:38960915100</author-url><authid>38960915100</authid><authname>Al-Kindi S.</authname><surname>Al-Kindi</surname><given-name>Sadeer G.</given-name><initials>S.G.</initials><afid>60021578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006423103</author-url><authid>7006423103</authid><authname>Oliveira G.</authname><surname>Oliveira</surname><given-name>Guilherme H.</given-name><initials>G.H.</initials><afid>60021578</afid></author><authkeywords>Anthracyclines | Chemotherapy-induced cardiomyopathy | Heart failure | Mechanical circulatory support | Right ventricular failure | Trastuzumab</authkeywords><intid>35900795</intid><source-id>23154</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928993137"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928993137?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928993137&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928993137&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928993137</prism:url><dc:identifier>SCOPUS_ID:84928993137</dc:identifier><eid>2-s2.0-84928993137</eid><dc:title>Derivation of baseline lung impedance in chronic heart failure patients: use for monitoring pulmonary congestion and predicting admissions for decompensation</dc:title><dc:creator>Shochat M.</dc:creator><prism:publicationName>Journal of Clinical Monitoring and Computing</prism:publicationName><prism:issn>13871307</prism:issn><prism:eIssn>15732614</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>341-349</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10877-014-9610-6</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. The instantaneous lung impedance (ILI) is one of the methods to assess pulmonary congestion or edema (PCE) in chronic heart failure (CHF) patients. Due to usually existing PCE in CHF patients when evaluated, baseline lung impedance (BLI) is unknown. Therefore, the relation of ILI to BLI is unknown. Our aim was to evaluate methods to calculate and appraise BLI or its derivative as reflecting the clinical status of CHF patients. ILI and New York Heart Association (NYHA) class were assessed in 222 patients (67 ± 11 years, LVEF &lt;35 %) during 32 months of frequent outpatient clinic visits. ILI, measured in 120 asymptomatic patients at NYHA class I, with no congestion on the chest X-ray and a low-normal 6-min walk, was defined as BLI. Using measured BLI and ILI values in these patients, formulas for BLI calculation were derived based on logistic regression analysis or on the disparity between BLI and ILI values at different NYHA stages. Both models were equally reliable with &lt;3 % difference between measured and calculated BLI (p = NS). ΔLIR = (ILI/BLI − 1) × 100 % reflected the degree of PCE, or deviation from baseline, correlated with NYHA class (r = −0.9, p &lt; 0.001) and could serve for monitoring. Of study patients, 123 were re-hospitalized for PCE during follow up. Their ΔLIR decreased gradually from −21.7 ± 8.2 % 4 weeks pre-admission to −37.8 ± 9.3 % on admission (p &lt; 0.001). Patients improved during hospital stay (NYHA 3.7 ± 0.5 to 2.9 ± 0.8, p &lt; 0.0001) with ΔLIR increasing to −29.1 ± 12.0 % (p &lt; 0.001). ΔLIR based on calculated BLI correlated with the clinical status of CHF patients and allowed the prediction of hospitalizations for PCE.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028306</affiliation-url><afid>60028306</afid><affilname>Hille Yaffe Medical Center Israel</affilname><name-variant>Hillel-Yaffe Medical Center</name-variant><affiliation-city>Hadera</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022403</affiliation-url><afid>60022403</afid><affilname>Technion - Israel Institute of Technology</affilname><name-variant>Technion</name-variant><affiliation-city>Haifa</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029655</affiliation-url><afid>60029655</afid><affilname>Edith Wolfson Medical Center Israel</affilname><name-variant>Wolfson Medical Center</name-variant><affiliation-city>Tel Aviv-Yafo</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005681</affiliation-url><afid>60005681</afid><affilname>Tel Aviv University</affilname><name-variant>Tel-Aviv University</name-variant><affiliation-city>Tel Aviv-Yafo</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">20</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8916466700</author-url><authid>8916466700</authid><authname>Shochat M.</authname><surname>Shochat</surname><given-name>Michael</given-name><initials>M.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8916466700</author-url><authid>8916466700</authid><authname>Shochat M.</authname><surname>Shochat</surname><given-name>Michael</given-name><initials>M.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603751467</author-url><authid>6603751467</authid><authname>Shotan A.</authname><surname>Shotan</surname><given-name>Avraham</given-name><initials>A.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603751467</author-url><authid>6603751467</authid><authname>Shotan A.</authname><surname>Shotan</surname><given-name>Avraham</given-name><initials>A.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602857398</author-url><authid>6602857398</authid><authname>Blondheim D.</authname><surname>Blondheim</surname><given-name>David S.</given-name><initials>D.S.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602857398</author-url><authid>6602857398</authid><authname>Blondheim D.</authname><surname>Blondheim</surname><given-name>David S.</given-name><initials>D.S.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:16444720400</author-url><authid>16444720400</authid><authname>Kazatsker M.</authname><surname>Kazatsker</surname><given-name>Mark</given-name><initials>M.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:16444720400</author-url><authid>16444720400</authid><authname>Kazatsker M.</authname><surname>Kazatsker</surname><given-name>Mark</given-name><initials>M.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56647945900</author-url><authid>56647945900</authid><authname>Dahan I.</authname><surname>Dahan</surname><given-name>Iris</given-name><initials>I.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56647945900</author-url><authid>56647945900</authid><authname>Dahan I.</authname><surname>Dahan</surname><given-name>Iris</given-name><initials>I.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16444132000</author-url><authid>16444132000</authid><authname>Asif A.</authname><surname>Asif</surname><given-name>Aya</given-name><initials>A.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16444132000</author-url><authid>16444132000</authid><authname>Asif A.</authname><surname>Asif</surname><given-name>Aya</given-name><initials>A.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55158247900</author-url><authid>55158247900</authid><authname>Shochat I.</authname><surname>Shochat</surname><given-name>Ilia</given-name><initials>I.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55158247900</author-url><authid>55158247900</authid><authname>Shochat I.</authname><surname>Shochat</surname><given-name>Ilia</given-name><initials>I.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8285615600</author-url><authid>8285615600</authid><authname>Frimerman A.</authname><surname>Frimerman</surname><given-name>Aaron</given-name><initials>A.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8285615600</author-url><authid>8285615600</authid><authname>Frimerman A.</authname><surname>Frimerman</surname><given-name>Aaron</given-name><initials>A.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7007129149</author-url><authid>7007129149</authid><authname>Rozenman Y.</authname><surname>Rozenman</surname><given-name>Yoseph</given-name><initials>Y.</initials><afid>60029655</afid><afid>60005681</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7007129149</author-url><authid>7007129149</authid><authname>Rozenman Y.</authname><surname>Rozenman</surname><given-name>Yoseph</given-name><initials>Y.</initials><afid>60029655</afid><afid>60005681</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7006629215</author-url><authid>7006629215</authid><authname>Meisel S.</authname><surname>Meisel</surname><given-name>Simcha R.</given-name><initials>S.R.</initials><afid>60028306</afid><afid>60022403</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7006629215</author-url><authid>7006629215</authid><authname>Meisel S.</authname><surname>Meisel</surname><given-name>Simcha R.</given-name><initials>S.R.</initials><afid>60028306</afid><afid>60022403</afid></author><authkeywords>Congestive heart failure | Lung impedance | Pulmonary congestion | Pulmonary edema</authkeywords><intid>1785885265</intid><source-id>15872</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928394312"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928394312?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928394312&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928394312&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0891584915001124"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928394312</prism:url><dc:identifier>SCOPUS_ID:84928394312</dc:identifier><eid>2-s2.0-84928394312</eid><dc:title>Differential involvement of various sources of reactive oxygen species in thyroxin-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles</dc:title><dc:creator>Elnakish M.</dc:creator><prism:publicationName>Free Radical Biology and Medicine</prism:publicationName><prism:issn>08915849</prism:issn><prism:eIssn>18734596</prism:eIssn><prism:volume>83</prism:volume><prism:pageRange>252-261</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.freeradbiomed.2015.02.035</prism:doi><pii>S0891584915001124</pii><dc:description>© 2015 Elsevier Inc. Thyroid hormones are key regulators of basal metabolic state and oxidative metabolism. Hyperthyroidism has been reported to cause significant alterations in hemodynamics, and in cardiac and diaphragm muscle functions, all of which have been linked to increased oxidative stress. However, the definite source of increased reactive oxygen species (ROS) in each of these phenotypes is still unknown. The goal of the current study was to test the hypothesis that thyroxin (T4) may produce distinct hemodynamic, cardiac, and diaphragm muscle abnormalities by differentially affecting various sources of ROS. Wild-type and T4 mice with and without 2-week treatments with allopurinol (xanthine oxidase inhibitor), apocynin (NADPH oxidase inhibitor), L-NIO (nitric oxide synthase inhibitor), or MitoTEMPO (mitochondria-targeted antioxidant) were studied. Blood pressure and echocardiography were noninvasively evaluated, followed by ex vivo assessments of isolated heart and diaphragm muscle functions. Treatment with L-NIO attenuated the T4-induced hypertension in mice. However, apocynin improved the left-ventricular (LV) dysfunction without preventing the cardiac hypertrophy in these mice. Both allopurinol and MitoTEMPO reduced the T4-induced fatigability of the diaphragm muscles. In conclusion, we show here for the first time that T4 exerts differential effects on various sources of ROS to induce distinct cardiovascular and skeletal muscle phenotypes. Additionally, we find that T4-induced LV dysfunction is independent of cardiac hypertrophy and NADPH oxidase is a key player in this process. Furthermore, we prove the significance of both xanthine oxidase and mitochondrial ROS pathways in T4-induced fatigability of diaphragm muscles. Finally, we confirm the importance of the nitric oxide pathway in T4-induced hypertension.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108614608</affiliation-url><afid>108614608</afid><affilname>College of Medicine</affilname><name-variant>College of Medicine</name-variant><affiliation-city>Swansea</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090016</affiliation-url><afid>60090016</afid><affilname>Dorothy M. Davis Heart and Lung Research Institute</affilname><name-variant>Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029258</affiliation-url><afid>60029258</afid><affilname>Helwan University</affilname><name-variant>Helwan University</name-variant><affiliation-city>Cairo</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36164034100</author-url><authid>36164034100</authid><authname>Elnakish M.</authname><surname>Elnakish</surname><given-name>Mohammad T.</given-name><initials>M.T.</initials><afid>108614608</afid><afid>60090016</afid><afid>60029258</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36164034100</author-url><authid>36164034100</authid><authname>Elnakish M.</authname><surname>Elnakish</surname><given-name>Mohammad T.</given-name><initials>M.T.</initials><afid>108614608</afid><afid>60090016</afid><afid>60029258</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36164034100</author-url><authid>36164034100</authid><authname>Elnakish M.</authname><surname>Elnakish</surname><given-name>Mohammad T.</given-name><initials>M.T.</initials><afid>108614608</afid><afid>60090016</afid><afid>60029258</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56061718500</author-url><authid>56061718500</authid><authname>Schultz E.</authname><surname>Schultz</surname><given-name>Eric J.</given-name><initials>E.J.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56061718500</author-url><authid>56061718500</authid><authname>Schultz E.</authname><surname>Schultz</surname><given-name>Eric J.</given-name><initials>E.J.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56605047800</author-url><authid>56605047800</authid><authname>Gearinger R.</authname><surname>Gearinger</surname><given-name>Rachel L.</given-name><initials>R.L.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56605047800</author-url><authid>56605047800</authid><authname>Gearinger R.</authname><surname>Gearinger</surname><given-name>Rachel L.</given-name><initials>R.L.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56604753100</author-url><authid>56604753100</authid><authname>Saad N.</authname><surname>Saad</surname><given-name>Nancy S.</given-name><initials>N.S.</initials><afid>108614608</afid><afid>60090016</afid><afid>60029258</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56604753100</author-url><authid>56604753100</authid><authname>Saad N.</authname><surname>Saad</surname><given-name>Nancy S.</given-name><initials>N.S.</initials><afid>108614608</afid><afid>60090016</afid><afid>60029258</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56604753100</author-url><authid>56604753100</authid><authname>Saad N.</authname><surname>Saad</surname><given-name>Nancy S.</given-name><initials>N.S.</initials><afid>108614608</afid><afid>60090016</afid><afid>60029258</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55520213800</author-url><authid>55520213800</authid><authname>Rastogi N.</authname><surname>Rastogi</surname><given-name>Neha</given-name><initials>N.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55520213800</author-url><authid>55520213800</authid><authname>Rastogi N.</authname><surname>Rastogi</surname><given-name>Neha</given-name><initials>N.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:26321333500</author-url><authid>26321333500</authid><authname>Ahmed A.</authname><surname>Ahmed</surname><given-name>Amany A E</given-name><initials>A.A.E.</initials><afid>60029258</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56638718200</author-url><authid>56638718200</authid><authname>Mohler P.</authname><surname>Mohler</surname><given-name>Peter J.</given-name><initials>P.J.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56638718200</author-url><authid>56638718200</authid><authname>Mohler P.</authname><surname>Mohler</surname><given-name>Peter J.</given-name><initials>P.J.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56648322800</author-url><authid>56648322800</authid><authname>Janssen P.</authname><surname>Janssen</surname><given-name>Paul M L</given-name><initials>P.M.L.</initials><afid>108614608</afid><afid>60090016</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56648322800</author-url><authid>56648322800</authid><authname>Janssen P.</authname><surname>Janssen</surname><given-name>Paul M L</given-name><initials>P.M.L.</initials><afid>108614608</afid><afid>60090016</afid></author><authkeywords>Allopurinol | Apocynin | Cardiac muscle | Diaphragm | Free radicals | L-NIO | MitoTEMPO | Thyroxin</authkeywords><intid>35779005</intid><source-id>15095</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928317765"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928317765?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928317765&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928317765&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928317765</prism:url><dc:identifier>SCOPUS_ID:84928317765</dc:identifier><eid>2-s2.0-84928317765</eid><dc:title>Biomarker testing and pre-emptive therapy in preventing heart failure</dc:title><dc:creator>McDonald K.</dc:creator><prism:publicationName>Current Cardiovascular Risk Reports</prism:publicationName><prism:issn>19329520</prism:issn><prism:eIssn>19329563</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12170-015-0456-3</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. In an attempt to reduce the heart failure epidemic, screening and prevention will become an increasing focus of management in the wider at-risk population. Refining risk prediction through the use of biomarkers in isolation or in combination is emerging as a critical step in this process. The utility of biomarkers to identify disease manifestations before the onset of symptoms and detrimental myocardial damage is proving to be valuable. In addition, biomarkers that predict the likelihood and rate of disease progression over time will help streamline and focus clinical efforts and therapeutic strategies. Importantly, several recent early intervention studies using biomarker strategies are promising and indicate that not only can new-onset heart failure be reduced but also the development of other cardiovascular conditions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008643</affiliation-url><afid>60008643</afid><affilname>St Vincent's University Hospital</affilname><name-variant>St. Vincent's University Hospital</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005141</affiliation-url><afid>60005141</afid><affilname>University College Dublin</affilname><name-variant>University College</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56105934600</author-url><authid>56105934600</authid><authname>McDonald K.</authname><surname>McDonald</surname><given-name>Ken</given-name><initials>K.</initials><afid>60008643</afid><afid>60005141</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56105934600</author-url><authid>56105934600</authid><authname>McDonald K.</authname><surname>McDonald</surname><given-name>Ken</given-name><initials>K.</initials><afid>60008643</afid><afid>60005141</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602597150</author-url><authid>6602597150</authid><authname>Ledwidge M.</authname><surname>Ledwidge</surname><given-name>Mark</given-name><initials>M.</initials><afid>60008643</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25926470400</author-url><authid>25926470400</authid><authname>Gallagher J.</authname><surname>Gallagher</surname><given-name>Joe</given-name><initials>J.</initials><afid>60008643</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55553732872</author-url><authid>55553732872</authid><authname>Watson C.</authname><surname>Watson</surname><given-name>Chris</given-name><initials>C.</initials><afid>60008643</afid><afid>60005141</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55553732872</author-url><authid>55553732872</authid><authname>Watson C.</authname><surname>Watson</surname><given-name>Chris</given-name><initials>C.</initials><afid>60008643</afid><afid>60005141</afid></author><authkeywords>Biomarkers | Cardiovascular disease prediction and prevention | Heart failure</authkeywords><intid>1035763653</intid><source-id>19500157062</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928333499"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928333499?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928333499&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928333499&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928333499</prism:url><dc:identifier>SCOPUS_ID:84928333499</dc:identifier><eid>2-s2.0-84928333499</eid><dc:title>Peri-operative kidney injury and long-term chronic kidney disease following orthotopic heart transplantation in children</dc:title><dc:creator>Hoskote A.</dc:creator><prism:publicationName>Pediatric Nephrology</prism:publicationName><prism:issn>0931041X</prism:issn><prism:eIssn>1432198X</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>905-918</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00467-014-2878-4</prism:doi><dc:description>© 2014, The Author(s). Significant advances in cardiac intensive care including extracorporeal life support have enabled children with complex congenital heart disease and end-stage heart failure to be supported while awaiting transplantation. With an increasing number of survivors after heart transplantation in children, the complications from long-term immunosuppression, including renal insufficiency, are becoming more apparent. Severe renal dysfunction after heart transplant is defined by a serum creatinine level &gt;2.5 mg/dL (221 μmol/L), and/or need for dialysis or renal transplant. The degree of renal dysfunction is variable and is progressive over time. About 3–10 % of heart transplant recipients will go on to develop severe renal dysfunction within the first 10 years post-transplantation. Multiple risk factors for chronic kidney disease post-transplant have been identified, which include pre-transplant worsening renal function, recipient demographics and morbidity, peri-transplant haemodynamics and long-term exposure to calcineurin inhibitors. Renal insufficiency increases the risk of post-transplant morbidity and mortality. Hence, screening for renal dysfunction pre-, peri- and post-transplantation is important. Early and timely detection of renal insufficiency may help minimize renal insults, and allow prompt implementation of renoprotective strategies. Close monitoring and pre-emptive management of renal dysfunction is an integral aspect of peri-transplant and subsequent post-transplant long-term care.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012662</affiliation-url><afid>60012662</afid><affilname>UCL Institute of Child Health</affilname><name-variant>UCL Institute of Child Health</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507851178</author-url><authid>6507851178</authid><authname>Hoskote A.</authname><surname>Hoskote</surname><given-name>Aparna</given-name><initials>A.</initials><afid>60012662</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005588453</author-url><authid>7005588453</authid><authname>Burch M.</authname><surname>Burch</surname><given-name>Michael</given-name><initials>M.</initials><afid>60022148</afid></author><authkeywords>Bridging to transplant | Calcineurin inhibitor | Chronic kidney disease | Complications | Creatinine clearance | Renal failure | Renal insufficiency</authkeywords><intid>35767748</intid><source-id>20471</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926334623"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926334623?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926334623&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926334623&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S003193841500181X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926334623</prism:url><dc:identifier>SCOPUS_ID:84926334623</dc:identifier><eid>2-s2.0-84926334623</eid><dc:title>Placebo 'serotonin' increases heart rate variability in recovery from psychosocial stress</dc:title><dc:creator>Darragh M.</dc:creator><prism:publicationName>Physiology and Behavior</prism:publicationName><prism:issn>00319384</prism:issn><prism:eIssn>1873507X</prism:eIssn><prism:volume>145</prism:volume><prism:pageRange>45-49</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.physbeh.2015.03.043</prism:doi><pii>S003193841500181X</pii><dc:description>© 2015 Elsevier Inc. Objective: To investigate placebo effects on heart rate (HR) and heart rate variability (HRV) in recovery from a psychosocial stressor. Methods: A healthy sample underwent two mental arithmetic stress tests in one experimental session. After undergoing the baseline test, participants were randomized into control or placebo groups. Prior to the second stress test, the placebo group received an intranasal dose of 'serotonin' (placebo) with the suggestion that it would enhance recovery. HR and HRV were assessed throughout procedures. Results: There was an increase in vagally-mediated HRV in the placebo group. The change in HR did not differ between groups. Conclusions: Placebo suggestion can enhance autonomic recovery after psychosocial stress. Findings are consistent with the notion of top-down mechanisms of placebo effects, but further research would need to specifically examine the role of top-down regulatory pathways as possible mediators of placebo-induced changes in autonomic function.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005686</affiliation-url><afid>60005686</afid><affilname>University of Auckland</affilname><name-variant>University of Auckland</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55561241600</author-url><authid>55561241600</authid><authname>Darragh M.</authname><surname>Darragh</surname><given-name>Margot</given-name><initials>M.</initials><afid>60005686</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56582336400</author-url><authid>56582336400</authid><authname>Vanderboor T.</authname><surname>Vanderboor</surname><given-name>Teresa</given-name><initials>T.</initials><afid>60005686</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202615403</author-url><authid>7202615403</authid><authname>Booth R.</authname><surname>Booth</surname><given-name>Roger J.</given-name><initials>R.J.</initials><afid>60005686</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55929847700</author-url><authid>55929847700</authid><authname>Sollers J.</authname><surname>Sollers</surname><given-name>John J.</given-name><initials>J.J.</initials><afid>60005686</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603374365</author-url><authid>6603374365</authid><authname>Consedine N.</authname><surname>Consedine</surname><given-name>Nathan S.</given-name><initials>N.S.</initials><afid>60005686</afid></author><authkeywords>Autonomic nervous system | Heart rate variability | Neurovisceral integration model | Placebo effect | Stress</authkeywords><intid>35430511</intid><source-id>24007</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924952098"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924952098?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924952098&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924952098&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928493115001915"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924952098</prism:url><dc:identifier>SCOPUS_ID:84924952098</dc:identifier><eid>2-s2.0-84924952098</eid><dc:title>Engineering of a polymer layered bio-hybrid heart valve scaffold</dc:title><dc:creator>Jahnavi S.</dc:creator><prism:publicationName>Materials Science and Engineering C</prism:publicationName><prism:issn>09284931</prism:issn><prism:volume>51</prism:volume><prism:pageRange>263-273</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.msec.2015.03.009</prism:doi><pii>S0928493115001915</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Abstract Current treatment strategy for end stage valve disease involves either valvular repair or replacement with homograft/mechanical/bioprosthetic valves. In cases of recurrent stenosis/ regurgitation, valve replacement is preferred choice of treatment over valvular repair. Currently available mechanical valves primarily provide durability whereas bioprosthetic valves have superior tissue compatibility but both lack remodelling and regenerative properties making their utility limited in paediatric patients. With advances in tissue engineering, attempts have been made to fabricate valves with regenerative potential using various polymers, decellularized tissues and hybrid scaffolds. To engineer an ideal heart valve, decellularized bovine pericardium extracellular matrix (DBPECM) is an attractive biocompatible scaffold but has weak mechanical properties and rapid degradation. However, DBPECM can be modified with synthetic polymers to enhance its mechanical properties. In this study, we developed a Bio-Hybrid scaffold with non-cross linked DBPECM in its native structure coated with a layer of Polycaprolactone-Chitosan (PCL-CH) nanofibers that displayed superior mechanical properties. Surface and functional studies demonstrated integration of PCL-CH to the DBPECM with enhanced bio and hemocompatibility. This engineered Bio-Hybrid scaffold exhibited most of the physical, biochemical and functional properties of the native valve that makes it an ideal scaffold for fabrication of cardiac valve with regenerative potential.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Indian Institute of Technology</affilname><name-variant>Stem Cell and Molecular Biology Laboratory</name-variant><name-variant>Department of Biotechnology</name-variant><affiliation-city>Madras, Chennai, TN</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Sree Chitra Tirunal Institute for Medical Sciences and Technology</affilname><name-variant>Tissue Culture Laboratory</name-variant><name-variant>Biomedical Technology Wing</name-variant><affiliation-city>Poojappura, Trivandrum, Kerala</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Indian Institute of Technology Madras</affilname><name-variant>Trivitron Innovation Centre</name-variant><name-variant>Department of Engineering Design</name-variant><affiliation-city>Chennai, TN</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Indian Institute of Technology</affilname><name-variant>Conducting Polymer laboratory</name-variant><name-variant>Department of Physics</name-variant><affiliation-city>Madras, Chennai, TN</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56630108800</author-url><authid>56630108800</authid><authname>Jahnavi S.</authname><surname>Jahnavi</surname><given-name>S.</given-name><initials>S.</initials><afid/><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56630108800</author-url><authid>56630108800</authid><authname>Jahnavi S.</authname><surname>Jahnavi</surname><given-name>S.</given-name><initials>S.</initials><afid/><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506407353</author-url><authid>6506407353</authid><authname>Kumary T.</authname><surname>Kumary</surname><given-name>T. V.</given-name><initials>T.V.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603067943</author-url><authid>6603067943</authid><authname>Bhuvaneshwar G.</authname><surname>Bhuvaneshwar</surname><given-name>G. S.</given-name><initials>G.S.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005426339</author-url><authid>7005426339</authid><authname>Natarajan T.</authname><surname>Natarajan</surname><given-name>T. S.</given-name><initials>T.S.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7402268487</author-url><authid>7402268487</authid><authname>Verma R.</authname><surname>Verma</surname><given-name>R. S.</given-name><initials>R.S.</initials><afid/></author><authkeywords>Bio-Hybrid | Decellularized bovine pericardium extracellular matrix (DBPECM) and Polycaprolactone-Chitosan (PCL-CH) | Heart valve | Tissue engineering of heart valve (TEHV)</authkeywords><intid>35230858</intid><article-number>5332</article-number><source-id>17813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922653448"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922653448?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922653448&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922653448&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1095643315000306"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922653448</prism:url><dc:identifier>SCOPUS_ID:84922653448</dc:identifier><eid>2-s2.0-84922653448</eid><dc:title>Does the right muscular atrioventricular valve in the avian heart perform two functions?</dc:title><dc:creator>Prosheva V.</dc:creator><prism:publicationName>Comparative Biochemistry and Physiology -Part A : Molecular and Integrative Physiology</prism:publicationName><prism:issn>10956433</prism:issn><prism:eIssn>15314332</prism:eIssn><prism:volume>184</prism:volume><prism:pageRange>41-45</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbpa.2015.02.001</prism:doi><pii>S1095643315000306</pii><dc:description>© 2015. The right atrioventricular valve of adult birds is a muscular unicuspid structure and unlike the right atrioventricular valve in the adult mammalian heart. The aim of this study is to test the hypothesis that the avian muscular valve (MV) is a part of the cardiac wall during systole and contributes to the right ventricle pump function. Six adult hens Gallus gallus domesticus were examined with a focus on MV structure and function. The thickness of the right ventricle (RV) wall and MV were examined post-mortem. RV wall and MV end-systolic thickness were estimated echocardiographically. The frame-by-frame processing of RV images was applied for the analysis of MV and RV free wall motion. According to the post-mortem measurements, no significant difference in the thickness between RV free wall and MV (1.8. ±. 0.3 and 1.6. ±. 0.4. mm, respectively) was found. In the course of the entire cardiac cycle, MV demonstrated the excursion of 10.3. ±. 0.9. mm. To the end of RV systole, MV thickness was increased roughly by a factor of two (2.9. ±. 0.57. mm), and reached almost the same value (3.0. ±. 0.25. mm) in RV free wall. Based on the findings obtained, we concluded that the MV may play specific and non-specific roles in the avian heart. First, MV determines the blood flow separation between the right heart chambers. Second, MV performs contractility to support for RV pump function.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072266</affiliation-url><afid>60072266</afid><affilname>Ural Branch, Russian Academy of Sciences</affilname><name-variant>Russian Academy of Sciences</name-variant><affiliation-city>Yekaterinburg</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106983485</affiliation-url><afid>106983485</afid><affilname>Urals State Medical Academy</affilname><name-variant>Urals State Medical Academy</name-variant><affiliation-city>Yekaterinburg</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103702</affiliation-url><afid>60103702</afid><affilname>Ural Federal University</affilname><name-variant>Ural Federal University</name-variant><affiliation-city>Yekaterinburg</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6601994633</author-url><authid>6601994633</authid><authname>Prosheva V.</authname><surname>Prosheva</surname><given-name>Valentina</given-name><initials>V.</initials><afid>60072266</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56514140900</author-url><authid>56514140900</authid><authname>Dernovoj B.</authname><surname>Dernovoj</surname><given-name>Bronislav</given-name><initials>B.</initials><afid>60072266</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:10340931900</author-url><authid>10340931900</authid><authname>Kharin S.</authname><surname>Kharin</surname><given-name>Sergey</given-name><initials>S.</initials><afid>60072266</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56514019700</author-url><authid>56514019700</authid><authname>Kaseva N.</authname><surname>Kaseva</surname><given-name>Natalya</given-name><initials>N.</initials><afid>60072266</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603192790</author-url><authid>6603192790</authid><authname>Shklyar T.</authname><surname>Shklyar</surname><given-name>Tatyana</given-name><initials>T.</initials><afid>106983485</afid><afid>60103702</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603192790</author-url><authid>6603192790</authid><authname>Shklyar T.</authname><surname>Shklyar</surname><given-name>Tatyana</given-name><initials>T.</initials><afid>106983485</afid><afid>60103702</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6601994496</author-url><authid>6601994496</authid><authname>Blyakhman F.</authname><surname>Blyakhman</surname><given-name>Felix</given-name><initials>F.</initials><afid>106983485</afid><afid>60103702</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6601994496</author-url><authid>6601994496</authid><authname>Blyakhman F.</authname><surname>Blyakhman</surname><given-name>Felix</given-name><initials>F.</initials><afid>106983485</afid><afid>60103702</afid></author><authkeywords>Avian heart | Echocardiography | Muscular atrioventricular valve mechanics | Post-mortem examinations | Right ventricle structure and function</authkeywords><intid>1534842593</intid><source-id>3500148021</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928750246"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928750246?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928750246&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928750246&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0277953615002440"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928750246</prism:url><dc:identifier>SCOPUS_ID:84928750246</dc:identifier><eid>2-s2.0-84928750246</eid><dc:title>Increased incidence of coronary heart disease associated with "double burden" in a cohort of Italian women</dc:title><dc:creator>D'Ovidio F.</dc:creator><prism:publicationName>Social Science and Medicine</prism:publicationName><prism:issn>02779536</prism:issn><prism:eIssn>18735347</prism:eIssn><prism:volume>135</prism:volume><prism:pageRange>40-46</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.socscimed.2015.04.015</prism:doi><pii>S0277953615002440</pii><dc:description>© 2015 Elsevier Ltd. Objective of this study was to assess the risk of coronary heart disease (CHD) associated with the combination of employment status and child care among women of working age, also examining the sex of the offspring. Only two previous studies investigated the effect of double burden on CHD, observing an increased risk among employed women with high domestic burden or providing child care, although the relative risks were marginally or not significant.The study population was composed of all women 25-50 years old at 2001 census, living in Turin in families composed only by individuals or couples, with or without children (N=109,358). Subjects were followed up during 2002-2010 for CHD incidence and mortality through record-linkage of the cohort with the local archives of mortality and hospital admissions. CHD risk was estimated by multivariate Poisson regression models.Among employed women, CHD risk increased significantly by 29% for each child in the household (IRR=1.29) and by 39% for each son (IRR=1.39), whereas no association with the presence of children was found among non-employed women or among employed women with daughters. When categorized, the presence of two or more sons significantly increased CHD risk among employed women (IRR=2.23), compared to those without children.The study found a significant increase in CHD risk associated with the presence of two or more sons in the household, but not daughters, among employed women. This is a new finding, which should be confirmed in other studies, conducted also in countries where the division of domestic duties between males and females is more balanced, such as the European Nordic countries.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012259</affiliation-url><afid>60012259</afid><affilname>Universita degli Studi di Torino</affilname><name-variant>University of Torino</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106956169</affiliation-url><afid>106956169</afid><affilname>ASL TO3</affilname><name-variant>ASL TO 3</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112928316</affiliation-url><afid>112928316</afid><affilname>ARPA Piedmont</affilname><name-variant>ARPA Piedmont</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012259</affiliation-url><afid>60012259</afid><affilname>Universita degli Studi di Torino</affilname><name-variant>University of Torino</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56549704900</author-url><authid>56549704900</authid><authname>D'Ovidio F.</authname><surname>D'Ovidio</surname><given-name>Fabrizio</given-name><initials>F.</initials><afid>60012259</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006644528</author-url><authid>7006644528</authid><authname>d'Errico A.</authname><surname>d'Errico</surname><given-name>Angelo</given-name><initials>A.</initials><afid>106956169</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16647140200</author-url><authid>16647140200</authid><authname>Scarinzi C.</authname><surname>Scarinzi</surname><given-name>Cecilia</given-name><initials>C.</initials><afid>112928316</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202995366</author-url><authid>7202995366</authid><authname>Costa G.</authname><surname>Costa</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60012259</afid></author><authkeywords>Children | Coronary heart disease | Double burden | Employment | Epidemiology | Women</authkeywords><intid>535840750</intid><source-id>18983</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930179359"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930179359?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930179359&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930179359&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1878540915000213"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930179359</prism:url><dc:identifier>SCOPUS_ID:84930179359</dc:identifier><eid>2-s2.0-84930179359</eid><dc:title>Additional heart sounds during early diastole in a patient with hypertrophic cardiomyopathy and atrioventricular block</dc:title><dc:creator>Konishi E.</dc:creator><prism:publicationName>Journal of Cardiology Cases</prism:publicationName><prism:issn>18785409</prism:issn><prism:eIssn>18785409</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>171-174</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jccase.2015.02.010</prism:doi><pii>S1878540915000213</pii><dc:description>© 2015 Japanese College of Cardiology. A third heart sound (S3) and a fourth heart sound (S4) are similarly perceived as low-pitched sounds and can be difficult to distinguish in some conditions, such as tachycardia or arrhythmia. We report a case with hypertrophic cardiomyopathy and Wenckebach second-degree atrioventricular block, in which the S4 was initially misdiagnosed as an S3 on auscultation and later confirmed using a phonocardiogram with an apexcardiogram. Interestingly, the amplitude of the S4 dynamically and regularly fluctuated in proportion to the interval between the S4 and the preceding ventricular contraction. These findings were associated with transmitral inflow patterns assessed by Doppler echocardiography, highlighting the importance of not only transmitral A but also E waves for the amplitude of S4 in patients with arrhythmias.&lt;. Learning objective: A fourth heart sound could be difficult to diagnose and dynamically fluctuate in amplitude in patients with arrhythmias, such as Wenckebach second-degree atrioventricular block. These findings are likely to be associated with changes in transmitral inflow patterns assessed by Doppler echocardiography.&gt;.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082691</affiliation-url><afid>60082691</afid><affilname>Matsushita Memorial Hospital</affilname><name-variant>Matsushita Memorial Hospital</name-variant><affiliation-city>Moriguchi</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082691</affiliation-url><afid>60082691</afid><affilname>Matsushita Memorial Hospital</affilname><name-variant>Matsushita Memorial Hospital</name-variant><affiliation-city>Moriguchi</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030588</affiliation-url><afid>60030588</afid><affilname>Kyoto Prefectural University of Medicine</affilname><name-variant>Kyoto Pref. University of Medicine</name-variant><affiliation-city>Kyoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56577767900</author-url><authid>56577767900</authid><authname>Konishi E.</authname><surname>Konishi</surname><given-name>Eiko</given-name><initials>E.</initials><afid>60082691</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56577168200</author-url><authid>56577168200</authid><authname>Kawasaki T.</authname><surname>Kawasaki</surname><given-name>Tatsuya</given-name><initials>T.</initials><afid>60082691</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56577474900</author-url><authid>56577474900</authid><authname>Shiraishi H.</authname><surname>Shiraishi</surname><given-name>Hirokazu</given-name><initials>H.</initials><afid>60030588</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56572332700</author-url><authid>56572332700</authid><authname>Yamano M.</authname><surname>Yamano</surname><given-name>Michiyo</given-name><initials>M.</initials><afid>60082691</afid><afid>60030588</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56572332700</author-url><authid>56572332700</authid><authname>Yamano M.</authname><surname>Yamano</surname><given-name>Michiyo</given-name><initials>M.</initials><afid>60082691</afid><afid>60030588</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004827376</author-url><authid>7004827376</authid><authname>Kamitani T.</authname><surname>Kamitani</surname><given-name>Tadaaki</given-name><initials>T.</initials><afid>60082691</afid></author><authkeywords>Apexcardiogram | Atrioventricular block | Fourth heart sound | Hypertrophic cardiomyopathy | Phonocardiogram</authkeywords><intid>1786079862</intid><source-id>19600156852</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925066477"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925066477?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925066477&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925066477&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2214647415000197"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925066477</prism:url><dc:identifier>SCOPUS_ID:84925066477</dc:identifier><eid>2-s2.0-84925066477</eid><dc:title>Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study</dc:title><dc:creator>Mackey R.</dc:creator><prism:publicationName>BBA Clinical</prism:publicationName><prism:issn>22146474</prism:issn><prism:volume>3</prism:volume><prism:pageRange>243-250</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbacli.2015.03.005</prism:doi><pii>S2214647415000197</pii><dc:description>© 2015 The Authors. Background: We hypothesized that higher concentrations of LDL particles (LDL-P) and leptin, and lower concentrations of HDL particles (HDL-P), and total and high molecular weight (HMW) adiponectin, would predict incident coronary heart disease (CHD) among severely obese postmenopausal women. Methods: In a case-cohort study nested in the Women's Health Initiative Observational Study, we sampled 677 of the 1852 white or black women with body mass index (BMI) ≥40kg/m2 and no prevalent cardiovascular disease (CVD), including all 124 cases of incident CHD over mean 5.0year follow-up. Biomarkers were assayed on stored blood samples. Results: In multivariable-adjusted weighted Cox models, higher baseline levels of total and small LDL-P, and lower levels of total and medium HDL-P, and smaller mean HDL-P size were significantly associated with incident CHD. In contrast, large HDL-P levels were inversely associated with CHD only for women without diabetes, and higher total and HMW adiponectin levels and lower leptin levels were associated with CHD only for women with diabetes. Higher total LDL-P and lower HDL-P were associated with CHD risk independently of confounders including CV risk factors and other lipoprotein measures, with adjusted HR (95% CIs) of 1.55 (1.28, 1.88) and 0.70 (0.57, 0.85), respectively, and similar results for medium HDL-P. Conclusions: Higher CHD risk among severely obese postmenopausal women is strongly associated with modifiable concentrations of LDL-P and HDL-P, independent of diabetes, smoking, hypertension, physical activity, BMI and waist circumference. General significance: Severely obese postmenopausal women should be considered high risk candidates for lipid lowering therapy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015543</affiliation-url><afid>60015543</afid><affilname>University of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015543</affiliation-url><afid>60015543</afid><affilname>University of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015543</affiliation-url><afid>60015543</afid><affilname>University of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003625</affiliation-url><afid>60003625</afid><affilname>Fred Hutchinson Cancer Research Center</affilname><name-variant>Fred Hutchinson Cancer Research Center</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027086</affiliation-url><afid>60027086</afid><affilname>University of Alabama at Birmingham</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city>Birmingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032838</affiliation-url><afid>60032838</afid><affilname>Stanford University School of Medicine</affilname><name-variant>Stanford University School of Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031387</affiliation-url><afid>60031387</afid><affilname>MedStar Health</affilname><name-variant>Medstar Health Research Institute</name-variant><affiliation-city>Columbia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002339</affiliation-url><afid>60002339</afid><affilname>Emory University School of Medicine</affilname><name-variant>Emory University School of Medicine</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011460</affiliation-url><afid>60011460</afid><affilname>Brown University</affilname><name-variant>Brown University</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026952</affiliation-url><afid>60026952</afid><affilname>Mayo Clinic Scottsdale-Phoenix, Arizona</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Scottsdale</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005035067</author-url><authid>7005035067</authid><authname>Mackey R.</authname><surname>Mackey</surname><given-name>Rachel H.</given-name><initials>R.H.</initials><afid>60015543</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602602216</author-url><authid>6602602216</authid><authname>McTigue K.</authname><surname>McTigue</surname><given-name>Kathleen M.</given-name><initials>K.M.</initials><afid>60015543</afid><afid>60015543</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602602216</author-url><authid>6602602216</authid><authname>McTigue K.</authname><surname>McTigue</surname><given-name>Kathleen M.</given-name><initials>K.M.</initials><afid>60015543</afid><afid>60015543</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56558901600</author-url><authid>56558901600</authid><authname>Chang Y.</authname><surname>Chang</surname><given-name>Yuefang F.</given-name><initials>Y.F.</initials><afid>60015543</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603318812</author-url><authid>6603318812</authid><authname>Barinas-Mitchell E.</authname><surname>Barinas-Mitchell</surname><given-name>Emma</given-name><initials>E.</initials><afid>60015543</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55226447900</author-url><authid>55226447900</authid><authname>Evans R.</authname><surname>Evans</surname><given-name>Rhobert W.</given-name><initials>R.W.</initials><afid>60015543</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003283550</author-url><authid>7003283550</authid><authname>Tinker L.</authname><surname>Tinker</surname><given-name>Lesley F.</given-name><initials>L.F.</initials><afid>60003625</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35372126200</author-url><authid>35372126200</authid><authname>Lewis C.</authname><surname>Lewis</surname><given-name>Cora E.</given-name><initials>C.E.</initials><afid>60027086</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55500445500</author-url><authid>55500445500</authid><authname>Manson J.</authname><surname>Manson</surname><given-name>JoAnn E.</given-name><initials>J.E.</initials><afid>60016782</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006150650</author-url><authid>7006150650</authid><authname>Stefanick M.</authname><surname>Stefanick</surname><given-name>Marcia L.</given-name><initials>M.L.</initials><afid>60032838</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7202678559</author-url><authid>7202678559</authid><authname>Howard B.</authname><surname>Howard</surname><given-name>Barbara V.</given-name><initials>B.V.</initials><afid>60031387</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7402638005</author-url><authid>7402638005</authid><authname>Phillips L.</authname><surname>Phillips</surname><given-name>Lawrence S.</given-name><initials>L.S.</initials><afid>60014232</afid><afid>60026952</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7402638005</author-url><authid>7402638005</authid><authname>Phillips L.</authname><surname>Phillips</surname><given-name>Lawrence S.</given-name><initials>L.S.</initials><afid>60014232</afid><afid>60026952</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56638762800</author-url><authid>56638762800</authid><authname>Liu S.</authname><surname>Liu</surname><given-name>Simin</given-name><initials>S.</initials><afid>60002339</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:35751139700</author-url><authid>35751139700</authid><authname>Kulick D.</authname><surname>Kulick</surname><given-name>Doina</given-name><initials>D.</initials><afid>60011460</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7202315657</author-url><authid>7202315657</authid><authname>Kuller L.</authname><surname>Kuller</surname><given-name>Lewis H.</given-name><initials>L.H.</initials><afid>60015543</afid></author><authkeywords>Adiponectin | Coronary heart disease | Extreme obesity | Lipoproteins | Postmenopausal women | Severe obesity</authkeywords><intid>535268864</intid><source-id>21100317907</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927137371"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927137371?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927137371&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927137371&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1532045615000381"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927137371</prism:url><dc:identifier>SCOPUS_ID:84927137371</dc:identifier><eid>2-s2.0-84927137371</eid><dc:title>The effects of cocaine on heart rate and electrocardiogram in zebrafish (Danio rerio)</dc:title><dc:creator>Mersereau E.</dc:creator><prism:publicationName>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</prism:publicationName><prism:issn>15320456</prism:issn><prism:eIssn>18781659</prism:eIssn><prism:volume>172-173</prism:volume><prism:pageRange>1-6</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbpc.2015.03.007</prism:doi><pii>S1532045615000381</pii><dc:description>© 2015 Elsevier Inc. Zebrafish (Danio rerio) have been used as a model organism to explore the genetic basis for responsiveness to addictive drugs like cocaine. However, very little is known about how the physiological response to cocaine is mediated in zebrafish. In the present study electrocardiograms (ECGs) were recorded from adult zebrafish treated with cocaine. Treatment with cocaine resulted in a bell-shaped dose response curve with a maximal change in heart rate seen using 5 mg/L cocaine. Higher doses resulted in a higher percentage of fish showing bradycardia. The cocaine-induced tachycardia was blocked by co-treatment with propranolol, a β-adrenergic antagonist, but potentiated by co-treatment with phentolamine, an α-adrenergic antagonist. Co-treatment with atropine, a classic cholinergic antagonist, had no effect on cocaine-induced tachycardia. Cocaine treatment of adult fish changed the ECG of treated fish, inducing a dose-dependent increase in QT interval after adjusting for heart rate (QTc), while not affecting the PR or QRS intervals. The acute effects of cocaine on heart rate were examined in 5-day old embryos to see if zebrafish might serve as a suitable model organism to study possible links of embryonic physiological response to subsequent adult behavioral response to the drug. Cocaine treatment of 5-day old zebrafish embryos also resulted in a bell-shaped dose response curve, with maximal tachycardia achieved with 10 mg/L. The response in embryonic fish was thus comparable to that in adults and raises the possibility that the effects of embryonic exposure to cocaine on the developing cardiovascular system can be effectively modeled in zebrafish.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026161</affiliation-url><afid>60026161</afid><affilname>University of North Dakota</affilname><name-variant>University of North Dakota</name-variant><affiliation-city>Grand Forks</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010065</affiliation-url><afid>60010065</afid><affilname>University of Arizona</affilname><name-variant>University of Arizona</name-variant><affiliation-city>Tucson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024438</affiliation-url><afid>60024438</afid><affilname>University of North Texas</affilname><name-variant>University of North Texas</name-variant><affiliation-city>Denton</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56588041600</author-url><authid>56588041600</authid><authname>Mersereau E.</authname><surname>Mersereau</surname><given-name>Erik J.</given-name><initials>E.J.</initials><afid>60026161</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56587967900</author-url><authid>56587967900</authid><authname>Poitra S.</authname><surname>Poitra</surname><given-name>Shelby L.</given-name><initials>S.L.</initials><afid>60026161</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56587600100</author-url><authid>56587600100</authid><authname>Espinoza A.</authname><surname>Espinoza</surname><given-name>Ana</given-name><initials>A.</initials><afid>60010065</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005190710</author-url><authid>7005190710</authid><authname>Crossley D.</authname><surname>Crossley</surname><given-name>Dane A.</given-name><initials>D.A.</initials><afid>60024438</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603200361</author-url><authid>6603200361</authid><authname>Darland T.</authname><surname>Darland</surname><given-name>Tristan</given-name><initials>T.</initials><afid>60026161</afid></author><authkeywords>Adrenergic compounds | Cocaine | Electrocardiogram | Heart rate | Zebrafish</authkeywords><intid>2035565592</intid><source-id>9000153111</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923025824"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923025824?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923025824&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923025824&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1095643315000148"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923025824</prism:url><dc:identifier>SCOPUS_ID:84923025824</dc:identifier><eid>2-s2.0-84923025824</eid><dc:title>Temperature acclimation of mitochondria function from the hearts of a temperate wrasse (Notolabrus celidotus)</dc:title><dc:creator>Iftikar F.</dc:creator><prism:publicationName>Comparative Biochemistry and Physiology -Part A : Molecular and Integrative Physiology</prism:publicationName><prism:issn>10956433</prism:issn><prism:eIssn>15314332</prism:eIssn><prism:volume>184</prism:volume><prism:pageRange>46-55</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbpa.2015.01.017</prism:doi><pii>S1095643315000148</pii><dc:description>© 2015 Elsevier Inc. Understanding how mitochondrial function alters with acclimation may provide insight to the limits these organelles place on temperate fish hearts facing seasonal temperature fluctuations. This investigation determined if compromised cardiac mitochondrial function contributed to heart failure (HF) in the New Zealand wrasse Notolabrus celidotus acclimated at their mean summer and winter ocean temperatures. To test this hypothesis, fish were acclimated to cold (CA, 15°C) and warm (WA, 21°C) temperatures. The temperature of HF was determined by Doppler sonography and mitochondrial function in permeabilised cardiac fibres was tested using high resolution respirometry. Heat stress mediated HF occurred at a THF of 26.7±0.4°C for CA fish, and at 28.2±0.6°C for WA fish. Biochemical analyses also revealed that WA fish had elevated resting plasma lactate indicating an increased dependence on anaerobic pathways. When cardiac fibres were tested with increasing temperatures, apparent breakpoints in the respiratory control ratio (RCR-I) with substrates supporting complex I (CI) oxygen flux occurred below the THF for both acclimated groups. While WA cardiac mitochondria were less sensitive to increasing temperature for respirational flux supported by CI, Complex II, and chemically uncoupled flux, CA fish maintained higher RCRs at higher temperatures. We conclude that while acclimation to summer temperatures does alter cardiac mitochondrial function in N. celidotus, these changes need not be beneficial in terms of oxidative phosphorylation efficiency and may come at an energetic cost, which would be detrimental in the face of further habitat warming.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005686</affiliation-url><afid>60005686</afid><affilname>University of Auckland</affilname><name-variant>University of Auckland</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016744</affiliation-url><afid>60016744</afid><affilname>CSIRO Marine and Atmospheric Research</affilname><name-variant>CSIRO Marine Research</name-variant><affiliation-city>Hobart</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106562527</affiliation-url><afid>106562527</afid><affilname>Plant and Food Research</affilname><name-variant>Plant and Food Research</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005686</affiliation-url><afid>60005686</afid><affilname>University of Auckland</affilname><name-variant>University of Auckland</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24341154600</author-url><authid>24341154600</authid><authname>Iftikar F.</authname><surname>Iftikar</surname><given-name>F. I.</given-name><initials>F.I.</initials><afid>60005686</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25628427800</author-url><authid>25628427800</authid><authname>Morash A.</authname><surname>Morash</surname><given-name>A. J.</given-name><initials>A.J.</initials><afid>60016744</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56518938100</author-url><authid>56518938100</authid><authname>Cook D.</authname><surname>Cook</surname><given-name>D. G.</given-name><initials>D.G.</initials><afid>106562527</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701803197</author-url><authid>6701803197</authid><authname>Herbert N.</authname><surname>Herbert</surname><given-name>N. A.</given-name><initials>N.A.</initials><afid>60005686</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006559720</author-url><authid>7006559720</authid><authname>Hickey A.</authname><surname>Hickey</surname><given-name>A. J R</given-name><initials>A.J.R.</initials><afid>60005686</afid></author><authkeywords>Acclimation | Cardiac mitochondria | Fish | Heart failure | RCR</authkeywords><intid>34908907</intid><source-id>3500148021</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925057676"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925057676?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925057676&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925057676&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0731708515001466"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925057676</prism:url><dc:identifier>SCOPUS_ID:84925057676</dc:identifier><eid>2-s2.0-84925057676</eid><dc:title>Simultaneous determination of selected eicosanoids by reversed-phase HPLC method using fluorescence detection and application to rat and human plasma, and rat heart and kidney samples</dc:title><dc:creator>Aghazadeh-Habashi A.</dc:creator><prism:publicationName>Journal of Pharmaceutical and Biomedical Analysis</prism:publicationName><prism:issn>07317085</prism:issn><prism:eIssn>1873264X</prism:eIssn><prism:volume>110</prism:volume><prism:pageRange>12-19</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jpba.2015.02.041</prism:doi><pii>S0731708515001466</pii><dc:description>© 2015 Elsevier B.V. Eicosanoids are biologically active lipid-derived oxidative metabolites of arachidonic acid. We, herein, present an improved sensitive, selective and robust high performance liquid chromatography (HPLC)-fluorescence assay for simultaneous quantification of eicosanoids in human plasma and rat tissues. Aliquots of 200μL of plasma or 30mg of heart or kidney tissues were spiked with 16-hydroxydecanoic acid as internal standard, and extracted with anhydrous acetonitrile using solid phase cartridges. The eluted samples were dried, reconstituted in anhydrous acetonitrile and labeled with 2-(2,3-naphthalimino)ethyl-trifluoromethanesulphonate in the presence of saturated potassium fluoride solution in anhydrous acetonitrile and N,N-diiospropylethylamine as catalyst. The derivatized eicosanoids were extracted with anhydrous acetonitrile using solid phase cartridges. Chromatographic separation was achieved on a C18 reversed phase column using gradient mobile phase of 0.05% of formic acid:acetonitrile:water at 0.8mL/min flow rate. The analytes were detected at excitation and emission wavelength of 260 and 396nm, respectively. The assay was linear (r2≥0.98) in the concentration range of 0.01-2.5μg/mL. The intra-day and inter-day coefficients variation was less than 19.8%. Using this assay, we were able to quantify arachidonic acid metabolites simultaneously in human and rat biological samples.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030835</affiliation-url><afid>60030835</afid><affilname>University of Alberta</affilname><name-variant>University of Alberta</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507713735</author-url><authid>6507713735</authid><authname>Aghazadeh-Habashi A.</authname><surname>Aghazadeh-Habashi</surname><given-name>Ali</given-name><initials>A.</initials><afid>60030835</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:33567472600</author-url><authid>33567472600</authid><authname>Asghar W.</authname><surname>Asghar</surname><given-name>Waheed</given-name><initials>W.</initials><afid>60030835</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006530215</author-url><authid>7006530215</authid><authname>Jamali F.</authname><surname>Jamali</surname><given-name>Fakhreddin</given-name><initials>F.</initials><afid>60030835</afid></author><authkeywords>Eicosanoids | Fluorescence detection | High performance liquid chromatography | Human | Rat</authkeywords><intid>1785268168</intid><source-id>23061</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198114"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198114?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198114&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198114&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198114</prism:url><dc:identifier>SCOPUS_ID:84930198114</dc:identifier><eid>2-s2.0-84930198114</eid><dc:title>Optimal use of echocardiography in valvular heart disease evaluation</dc:title><dc:creator>Siegel R.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>977-986</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-306293</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016173</affiliation-url><afid>60016173</afid><affilname>Cedars-Sinai Medical Center</affilname><name-variant>Cedars-Sinai Medical Center</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011766</affiliation-url><afid>60011766</afid><affilname>Chaim Sheba Medical Center Israel</affilname><name-variant>Chaim Sheba Medical Center</name-variant><affiliation-city>Tel Aviv-Yafo</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005037</affiliation-url><afid>60005037</afid><affilname>Tel Aviv University, Sackler Faculty of Medicine</affilname><name-variant>Tel Aviv University</name-variant><affiliation-city>Ramal Aviv</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55614151200</author-url><authid>55614151200</authid><authname>Siegel R.</authname><surname>Siegel</surname><given-name>Robert J.</given-name><initials>R.J.</initials><afid>60016173</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56650427900</author-url><authid>56650427900</authid><authname>Luo H.</authname><surname>Luo</surname><given-name>Huai</given-name><initials>H.</initials><afid>60016173</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55497607200</author-url><authid>55497607200</authid><authname>Makar M.</authname><surname>Makar</surname><given-name>Moody</given-name><initials>M.</initials><afid>60016173</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:9637772600</author-url><authid>9637772600</authid><authname>Beigel R.</authname><surname>Beigel</surname><given-name>Roy</given-name><initials>R.</initials><afid>60016173</afid><afid>60011766</afid><afid>60005037</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:9637772600</author-url><authid>9637772600</authid><authname>Beigel R.</authname><surname>Beigel</surname><given-name>Roy</given-name><initials>R.</initials><afid>60016173</afid><afid>60011766</afid><afid>60005037</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:9637772600</author-url><authid>9637772600</authid><authname>Beigel R.</authname><surname>Beigel</surname><given-name>Roy</given-name><initials>R.</initials><afid>60016173</afid><afid>60011766</afid><afid>60005037</afid></author><intid>536086968</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929340311"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929340311?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929340311&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929340311&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929340311</prism:url><dc:identifier>SCOPUS_ID:84929340311</dc:identifier><eid>2-s2.0-84929340311</eid><dc:title>Visualizing vascular structure in the adult newt (Notophthalmus viridescens) heart</dc:title><dc:creator>Singh B.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030125</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55348564600</author-url><authid>55348564600</authid><authname>Singh B.</authname><surname>Singh</surname><given-name>Bhairab N.</given-name><initials>B.N.</initials><afid>60005745</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23062551000</author-url><authid>23062551000</authid><authname>Weaver C.</authname><surname>Weaver</surname><given-name>Cyprian</given-name><initials>C.</initials><afid>60005745</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56560227700</author-url><authid>56560227700</authid><authname>Koyano-Nakagawa N.</authname><surname>Koyano-Nakagawa</surname><given-name>Naoko</given-name><initials>N.</initials><afid>60005745</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006865345</author-url><authid>7006865345</authid><authname>Garry D.</authname><surname>Garry</surname><given-name>Daniel J.</given-name><initials>D.J.</initials><afid>60005745</afid></author><intid>1535945494</intid><article-number>020917</article-number><source-id>11700154387</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928812594"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928812594?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928812594&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928812594&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928812594</prism:url><dc:identifier>SCOPUS_ID:84928812594</dc:identifier><eid>2-s2.0-84928812594</eid><dc:title>ICD and CRT Use in Ischemic Heart Disease in Women</dc:title><dc:creator>Mehta N.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0512-y</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Although the role of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) in improving outcomes in ischemic cardiomyopathy (ICM) has been described, the data regarding gender-based survival outcomes are limited. There is a higher preponderance of non-ischemic cardiomyopathy (NICM) in women, and most of the ICM literature is derived from sub-study analysis. This review summarizes the current body of literature on prognosis, pathophysiology, and the present clinical practice for device implantation in women with ICM.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115209273</affiliation-url><afid>115209273</afid><affilname>Division of Cardiovascular Medicine</affilname><name-variant>Division of Cardiovascular Medicine</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56648334400</author-url><authid>56648334400</authid><authname>Mehta N.</authname><surname>Mehta</surname><given-name>Nishaki Kiran</given-name><initials>N.K.</initials><afid>60003500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56648307000</author-url><authid>56648307000</authid><authname>Abraham W.</authname><surname>Abraham</surname><given-name>William T.</given-name><initials>W.T.</initials><afid>115209273</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8979747400</author-url><authid>8979747400</authid><authname>Maytin M.</authname><surname>Maytin</surname><given-name>Melanie</given-name><initials>M.</initials><afid>60016782</afid></author><authkeywords>Cardiac resynchronization therapy | Gender differences | Implantable cardioverter defibrillator | Ischemic cardiomyopathy</authkeywords><intid>1535850331</intid><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84916882856"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84916882856?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84916882856&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84916882856&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2214647414000324"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84916882856</prism:url><dc:identifier>SCOPUS_ID:84916882856</dc:identifier><eid>2-s2.0-84916882856</eid><dc:title>The predictive role of circulating microparticles in patients with chronic heart failure</dc:title><dc:creator>Berezin A.</dc:creator><prism:publicationName>BBA Clinical</prism:publicationName><prism:issn>22146474</prism:issn><prism:volume>3</prism:volume><prism:pageRange>18-24</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbacli.2014.11.006</prism:doi><pii>S2214647414000324</pii><dc:description>© 2014. Aim: The study aim was to evaluate whether circulating microparticles with apoptotic or non-apoptotic phenotypes are useful for risk assessment of 3-year cumulative fatal and non-fatal cardiovascular events in CHF patients. Methods: The incidence of fatal and non-fatal cardiovascular events, as well as the frequency of occurrence of death from any cause in a cohort of 388 patients with CHF during 3. years of observation was studied prospectively. Circulating levels of NT-pro brain natriuretic peptide (NT-pro-BNP), high-sensitivity C-reactive protein (hs-CRP), and endothelial apoptotic microparticles (EMPs) were measured at baseline. Results: Median follow-up was 2.32. years (IQR = 1.8-3.1). During follow-up, 110 cardiovascular events (including 43 fatal cases) were determined. Additionally, 74 subjects were hospitalized repetitively due to worsening CHF and also 16 subjects were readmitted in the hospital due to other cardiovascular reasons. In the univariate logistic regression analysis, the main factors independently related with cumulative endpoints were creatinine, fasting glucose, HbA1c, total cholesterol, uric acid, various types of EPMs, NT-pro-BNP, hs-CRP, NYHA class, decreased left ventricular ejection fraction (LVEF) less 45%, and type 2 diabetes mellitus. In multivariate model NYHA class, decreased LVEF (less 45%), NT-pro-BNP, hs-CRP, CD144. +/CD31. +/annexin V. + EMPs, and CD31. +/annexin V. + EMPs remained statistically significant for cumulative endpoint. Adding of CD144. +/CD31. +/annexin V. + EMCs and CD31. +/annexin V. + EMCs to the standard ABC model may improve the relative IDI for cumulative endpoint by 11.4% and 10.5% respectively. Conclusion: Apoptotic phenotype of circulating microparticles may relate 3-year combined clinical outcomes in CHF patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011630</affiliation-url><afid>60011630</afid><affilname>Zaporozhye State Medical University</affilname><name-variant>Zaporozhe State Medical University</name-variant><affiliation-city>Zaporizhia</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011630</affiliation-url><afid>60011630</afid><affilname>Zaporozhye State Medical University</affilname><name-variant>Zaporozhe State Medical University</name-variant><affiliation-city>Zaporizhia</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011630</affiliation-url><afid>60011630</afid><affilname>Zaporozhye State Medical University</affilname><name-variant>Zaporozhe State Medical University</name-variant><affiliation-city>Zaporizhia</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114556114</affiliation-url><afid>114556114</afid><affilname>Private Medical Center Vita-Center</affilname><name-variant>Private Medical Center Vita-Center</name-variant><affiliation-city>Zaporizhia</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102064370</author-url><authid>7102064370</authid><authname>Berezin A.</authname><surname>Berezin</surname><given-name>Alexander E.</given-name><initials>A.E.</initials><afid>60011630</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55681524700</author-url><authid>55681524700</authid><authname>Kremzer A.</authname><surname>Kremzer</surname><given-name>Alexander A.</given-name><initials>A.A.</initials><afid>60011630</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56155882700</author-url><authid>56155882700</authid><authname>Martovitskaya Y.</authname><surname>Martovitskaya</surname><given-name>Yulia V.</given-name><initials>Y.V.</initials><afid>60011630</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56155608200</author-url><authid>56155608200</authid><authname>Samura T.</authname><surname>Samura</surname><given-name>Tatyana A.</given-name><initials>T.A.</initials><afid>60011630</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56304923000</author-url><authid>56304923000</authid><authname>Berezina T.</authname><surname>Berezina</surname><given-name>Tatyana A.</given-name><initials>T.A.</initials><afid>114556114</afid></author><authkeywords>Cardiovascular outcomes | Chronic heart failure | Microparticles | Predictive value</authkeywords><intid>33890842</intid><source-id>21100317907</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930177474"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930177474?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930177474&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930177474&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1878540915000250"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930177474</prism:url><dc:identifier>SCOPUS_ID:84930177474</dc:identifier><eid>2-s2.0-84930177474</eid><dc:title>The story of the lost needle: Foreign body embolization to the heart</dc:title><dc:creator>Ghatak A.</dc:creator><prism:publicationName>Journal of Cardiology Cases</prism:publicationName><prism:issn>18785409</prism:issn><prism:eIssn>18785409</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>175-177</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jccase.2015.03.004</prism:doi><pii>S1878540915000250</pii><dc:description>© 2015 Japanese College of Cardiology. A 61-year-old female was evaluated because of severe symptomatic mitral regurgitation. She was found to have a foreign body in the heart by cardiac catheterization. Through a retrospective review of serial imaging studies, we found that a hypodermic needle had been retained in the body from a prior abdominal wall surgery and had subsequently migrated to the heart. During surgical mitral valve replacement the needle was identified and removed. We demonstrate the trajectory of this foreign body from the abdominal wall into the heart.&lt;. Learning objective: Foreign bodies can migrate from the subcutaneous tissue into the venous circulation and subsequently into the heart. A thorough surgical history is important in the evaluation of foreign bodies in the heart. An assessment of symptoms and future risk of complications should guide the removal of cardiac foreign bodies.&gt;.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021519</affiliation-url><afid>60021519</afid><affilname>University of Miami Leonard M. Miller School of Medicine</affilname><name-variant>University of Miami</name-variant><affiliation-city>Miami</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021519</affiliation-url><afid>60021519</afid><affilname>University of Miami Leonard M. Miller School of Medicine</affilname><name-variant>University of Miami</name-variant><affiliation-city>Miami</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16679269400</author-url><authid>16679269400</authid><authname>Ghatak A.</authname><surname>Ghatak</surname><given-name>Abhijit</given-name><initials>A.</initials><afid>60021519</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56580346100</author-url><authid>56580346100</authid><authname>Baik P.</authname><surname>Baik</surname><given-name>Peter</given-name><initials>P.</initials><afid>60021519</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56161779300</author-url><authid>56161779300</authid><authname>Cardoso R.</authname><surname>Cardoso</surname><given-name>Rhanderson</given-name><initials>R.</initials><afid>60021519</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56580113100</author-url><authid>56580113100</authid><authname>Dobrinsky J.</authname><surname>Dobrinsky</surname><given-name>Jonathan</given-name><initials>J.</initials><afid>60021519</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54779836200</author-url><authid>54779836200</authid><authname>Kaynak H.</authname><surname>Kaynak</surname><given-name>Husnu</given-name><initials>H.</initials><afid>60021519</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36646540200</author-url><authid>36646540200</authid><authname>Marzouka G.</authname><surname>Marzouka</surname><given-name>George</given-name><initials>G.</initials><afid>60021519</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56584908700</author-url><authid>56584908700</authid><authname>Stang R.</authname><surname>Stang</surname><given-name>Robert</given-name><initials>R.</initials><afid>60021519</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56586303200</author-url><authid>56586303200</authid><authname>Carrillo R.</authname><surname>Carrillo</surname><given-name>Roger</given-name><initials>R.</initials><afid>60021519</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56586299600</author-url><authid>56586299600</authid><authname>Williams D.</authname><surname>Williams</surname><given-name>Donald</given-name><initials>D.</initials><afid>60021519</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56584901200</author-url><authid>56584901200</authid><authname>Heldman A.</authname><surname>Heldman</surname><given-name>Alan W.</given-name><initials>A.W.</initials><afid>60021519</afid></author><authkeywords>Embolization | Foreign body | Mitral regurgitation</authkeywords><intid>536080038</intid><source-id>19600156852</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926647175"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926647175?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926647175&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926647175&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2212968515000082"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926647175</prism:url><dc:identifier>SCOPUS_ID:84926647175</dc:identifier><eid>2-s2.0-84926647175</eid><dc:title>Investigation of heart proteome of different consomic mouse strains. Testing the effect of polymorphisms on the proteome-wide trans-variation of proteins</dc:title><dc:creator>Forler S.</dc:creator><prism:publicationName>EuPA Open Proteomics</prism:publicationName><prism:issn>22129685</prism:issn><prism:eIssn>22129685</prism:eIssn><prism:volume>7</prism:volume><prism:pageRange>27-42</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.euprot.2015.03.002</prism:doi><pii>S2212968515000082</pii><dc:description>© 2015 The Authors. We investigated to which extent polymorphisms of an individual affect the proteomic network. Consomic mouse strains (CS) were used to study the trans-effect of the cis-variant (polymorphic) proteins of the strain PWD/Ph on the proteins of the host strain C57BL/6J. The cardiac proteome of ten CSs was analyzed by 2-DE and MS. Cis-variant PWD proteins altered a high number of C57BL/6J proteins, but the number of trans-variant proteins differed considerably between different CSs. Cardiac hypertrophy was induced in CSs. We found that high variability of the proteome, as induced by polymorphisms in CS14, acts protective against the complex disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030619</affiliation-url><afid>60030619</afid><affilname>Max Planck Institute for Molecular Genetics</affilname><name-variant>Max Planck Institute for Molecular Genetics</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024629</affiliation-url><afid>60024629</afid><affilname>Max Delbruck Center for Molecular Medicine</affilname><name-variant>Max Delbruck Center for Molecular Medicine</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55240200600</author-url><authid>55240200600</authid><authname>Forler S.</authname><surname>Forler</surname><given-name>Stefanie</given-name><initials>S.</initials><afid>60026245</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006311259</author-url><authid>7006311259</authid><authname>Klein O.</authname><surname>Klein</surname><given-name>Oliver</given-name><initials>O.</initials><afid>60026245</afid><afid>60026245</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006311259</author-url><authid>7006311259</authid><authname>Klein O.</authname><surname>Klein</surname><given-name>Oliver</given-name><initials>O.</initials><afid>60026245</afid><afid>60026245</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23980415100</author-url><authid>23980415100</authid><authname>Köhler S.</authname><surname>Köhler</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60026245</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36809318300</author-url><authid>36809318300</authid><authname>Robinson P.</authname><surname>Robinson</surname><given-name>Peter N.</given-name><initials>P.N.</initials><afid>60026245</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102891244</author-url><authid>7102891244</authid><authname>Witt H.</authname><surname>Witt</surname><given-name>Henning</given-name><initials>H.</initials><afid>60030619</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7101677328</author-url><authid>7101677328</authid><authname>Sultan M.</authname><surname>Sultan</surname><given-name>Marc</given-name><initials>M.</initials><afid>60030619</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602614178</author-url><authid>6602614178</authid><authname>Eravci M.</authname><surname>Eravci</surname><given-name>Murat</given-name><initials>M.</initials><afid>60024629</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006921582</author-url><authid>7006921582</authid><authname>Regitz-Zagrosek V.</authname><surname>Regitz-Zagrosek</surname><given-name>Vera</given-name><initials>V.</initials><afid>60026245</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:36047778300</author-url><authid>36047778300</authid><authname>Lehrach H.</authname><surname>Lehrach</surname><given-name>Hans</given-name><initials>H.</initials><afid>60030619</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7007034010</author-url><authid>7007034010</authid><authname>Klose J.</authname><surname>Klose</surname><given-name>Joachim</given-name><initials>J.</initials><afid>60026245</afid><afid>60026245</afid><afid>60026245</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7007034010</author-url><authid>7007034010</authid><authname>Klose J.</authname><surname>Klose</surname><given-name>Joachim</given-name><initials>J.</initials><afid>60026245</afid><afid>60026245</afid><afid>60026245</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7007034010</author-url><authid>7007034010</authid><authname>Klose J.</authname><surname>Klose</surname><given-name>Joachim</given-name><initials>J.</initials><afid>60026245</afid><afid>60026245</afid><afid>60026245</afid></author><authkeywords>2-D electrophoresis | Heart hypertrophy | Heart proteome | Mass spectrometry | Mouse chromosomal substitution strains</authkeywords><intid>1535483570</intid><source-id>21100258759</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929339304"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929339304?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929339304&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929339304&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929339304</prism:url><dc:identifier>SCOPUS_ID:84929339304</dc:identifier><eid>2-s2.0-84929339304</eid><dc:title>Material Selection and Performance Index for Polymeric Prosthetic Heart Valve Design</dc:title><dc:creator>Brubert J.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>1-2</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030194</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031101</affiliation-url><afid>60031101</afid><affilname>University of Cambridge</affilname><name-variant>University of Cambridge</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56296667400</author-url><authid>56296667400</authid><authname>Brubert J.</authname><surname>Brubert</surname><given-name>J. Jacob</given-name><initials>J.J.</initials><afid>60031101</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602877207</author-url><authid>6602877207</authid><authname>Moggridge G.</authname><surname>Moggridge</surname><given-name>Geoff</given-name><initials>G.</initials><afid>60031101</afid></author><intid>2035940724</intid><source-id>11700154387</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929299030"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929299030?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929299030&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929299030&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929299030</prism:url><dc:identifier>SCOPUS_ID:84929299030</dc:identifier><eid>2-s2.0-84929299030</eid><dc:title>An Access-Closure Device for Percutaneous Beating Heart Surgery</dc:title><dc:creator>Malka R.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>1-3</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030118</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60077572</affiliation-url><afid>60077572</afid><affilname>Harvard School of Engineering and Applied Sciences</affilname><name-variant>Harvard University</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106633548</affiliation-url><afid>106633548</afid><affilname>Wyss Institute for Biologically Inspired Engineering</affilname><name-variant>Wyss Institute for Biologically Inspired Engineering</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105636543</affiliation-url><afid>105636543</afid><affilname>Boston Children's Hospital</affilname><name-variant>Boston Children's Hospital</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644553700</author-url><authid>56644553700</authid><authname>Malka R.</authname><surname>Malka</surname><given-name>Ronit E.</given-name><initials>R.E.</initials><afid>60077572</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643825600</author-url><authid>56643825600</authid><authname>Rosen M.</authname><surname>Rosen</surname><given-name>Michelle H.</given-name><initials>M.H.</initials><afid>60077572</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644139100</author-url><authid>56644139100</authid><authname>Ku S.</authname><surname>Ku</surname><given-name>Seul</given-name><initials>S.</initials><afid>60077572</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644781900</author-url><authid>56644781900</authid><authname>Thornycroft P.</authname><surname>Thornycroft</surname><given-name>Patrick</given-name><initials>P.</initials><afid>60077572</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55303553000</author-url><authid>55303553000</authid><authname>Gafford J.</authname><surname>Gafford</surname><given-name>Joshua B.</given-name><initials>J.B.</initials><afid>60077572</afid><afid>106633548</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55303553000</author-url><authid>55303553000</authid><authname>Gafford J.</authname><surname>Gafford</surname><given-name>Joshua B.</given-name><initials>J.B.</initials><afid>60077572</afid><afid>106633548</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55858526200</author-url><authid>55858526200</authid><authname>Holland D.</authname><surname>Holland</surname><given-name>Donal</given-name><initials>D.</initials><afid>60077572</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14066683700</author-url><authid>14066683700</authid><authname>Vasilyev N.</authname><surname>Vasilyev</surname><given-name>Nikolay</given-name><initials>N.</initials><afid>105636543</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006881026</author-url><authid>7006881026</authid><authname>del Nido P.</authname><surname>del Nido</surname><given-name>Pedro</given-name><initials>P.</initials><afid>105636543</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:12646107000</author-url><authid>12646107000</authid><authname>Walsh C.</authname><surname>Walsh</surname><given-name>Conor J.</given-name><initials>C.J.</initials><afid>60077572</afid><afid>106633548</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:12646107000</author-url><authid>12646107000</authid><authname>Walsh C.</authname><surname>Walsh</surname><given-name>Conor J.</given-name><initials>C.J.</initials><afid>60077572</afid><afid>106633548</afid></author><intid>535946907</intid><source-id>11700154387</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226123"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226123?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226123&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226123&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226123</prism:url><dc:identifier>SCOPUS_ID:84930226123</dc:identifier><eid>2-s2.0-84930226123</eid><dc:title>Almanac 2014: Aortic valve disease</dc:title><dc:creator>Otto C.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>929-935</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-306027</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. The past few years have seen major advances in the diagnosis of aortic valve disease and in our understanding of the pathophysiology of disease. In addition, transcatheter aortic valve implantation has transformed our clinical management options. This article summarises new aortic valve disease research published in Heart in 2013 and 2014, within the context of other major studies published in general medical journals, including a discussion of the potential impact of these new research findings on the clinical approach to management of adults with aortic valve disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028548</affiliation-url><afid>60028548</afid><affilname>University of Washington School of Medicine</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202696525</author-url><authid>7202696525</authid><authname>Otto C.</authname><surname>Otto</surname><given-name>Catherine M.</given-name><initials>C.M.</initials><afid>60028548</afid></author><intid>36086461</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928341072"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928341072?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928341072&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928341072&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928341072</prism:url><dc:identifier>SCOPUS_ID:84928341072</dc:identifier><eid>2-s2.0-84928341072</eid><dc:title>Tools for cardiovascular risk assessment in clinical practice</dc:title><dc:creator>Cainzos-Achirica M.</dc:creator><prism:publicationName>Current Cardiovascular Risk Reports</prism:publicationName><prism:issn>19329520</prism:issn><prism:eIssn>19329563</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12170-015-0455-4</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Precise risk stratification of atherosclerotic cardiovascular disease guides best management and therefore is a public health priority. In addition to risk estimation using traditional risk factors, tools such as coronary artery calcium, high-sensitivity C-reactive protein, ankle-brachial index and carotid imaging, and clinical features such as family history of premature coronary heart disease may offer opportunities for a more personalized risk assessment. In this review, we discuss the strengths and limitations of each of these tools, focusing on the evidence provided by the latest studies relevant to the field. Among them, coronary artery calcium currently stands out as the most powerful tool for cardiovascular risk assessment, as recognized by the 2013 ACC/AHA Risk Assessment Guideline. Recent studies have expanded our knowledge regarding its value for improving the detection of both low and high absolute risk within clinically relevant subgroups, as well as for cost-effectively guiding preventive therapy allocation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024002</affiliation-url><afid>60024002</afid><affilname>Welch Center for Prevention Epidemiology and Clinical Research</affilname><name-variant>Johns Hopkins Bloomberg School of Public Health</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003443</affiliation-url><afid>60003443</afid><affilname>Johns Hopkins Medical Institutions</affilname><name-variant>Johns Hopkins Medical Institutions</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55549963700</author-url><authid>55549963700</authid><authname>Cainzos-Achirica M.</authname><surname>Cainzos-Achirica</surname><given-name>Miguel</given-name><initials>M.</initials><afid>60024002</afid><afid>60003443</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55549963700</author-url><authid>55549963700</authid><authname>Cainzos-Achirica M.</authname><surname>Cainzos-Achirica</surname><given-name>Miguel</given-name><initials>M.</initials><afid>60024002</afid><afid>60003443</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56604003000</author-url><authid>56604003000</authid><authname>Eissler K.</authname><surname>Eissler</surname><given-name>Kieran</given-name><initials>K.</initials><afid>60003443</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14012509900</author-url><authid>14012509900</authid><authname>Blaha M.</authname><surname>Blaha</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60024002</afid><afid>60003443</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14012509900</author-url><authid>14012509900</authid><authname>Blaha M.</authname><surname>Blaha</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60024002</afid><afid>60003443</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:18333255600</author-url><authid>18333255600</authid><authname>Blumenthal R.</authname><surname>Blumenthal</surname><given-name>Roger S.</given-name><initials>R.S.</initials><afid>60003443</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55450099100</author-url><authid>55450099100</authid><authname>Martin S.</authname><surname>Martin</surname><given-name>Seth S.</given-name><initials>S.S.</initials><afid>60024002</afid><afid>60003443</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55450099100</author-url><authid>55450099100</authid><authname>Martin S.</authname><surname>Martin</surname><given-name>Seth S.</given-name><initials>S.S.</initials><afid>60024002</afid><afid>60003443</afid></author><authkeywords>Absolute cardiovascular risk | Ankle-brachial index | Atherosclerosis | Cardiovascular disease | Carotid intima-media thickness | Carotid plaque | Coronary artery calcium | Family history | High-sensitivity C-reactive protein | Prevention | Risk assessment | Risk management | Risk scores | Serum biomarkers | Traditional risk factors</authkeywords><intid>2035761757</intid><source-id>19500157062</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929990691"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929990691?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929990691&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929990691&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929990691</prism:url><dc:identifier>SCOPUS_ID:84929990691</dc:identifier><eid>2-s2.0-84929990691</eid><dc:title>Management of Severe Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery</dc:title><dc:creator>Davila C.</dc:creator><prism:publicationName>Current Treatment Options in Cardiovascular Medicine</prism:publicationName><prism:issn>10928464</prism:issn><prism:eIssn>15343189</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1-11</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11936-015-0382-1</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Pulmonary hypertension (PH) is simply defined as a mean pulmonary artery pressure greater than 25 mmHg at rest; however, may result from varying combinations of abnormal pulmonary artery (PA) blood flow, pulmonary vascular resistance (PVR), PA compliance, and pulmonary venous pressure. Mitral regurgitation (MR) allows for partial transmission of systemic arterial pressure into the pulmonary venous system. Mitral stenosis (MS) prevents pulmonary venous drainage into the left ventricle. In either case, the direct result is marked pressurization of the pulmonary venous system, with the primary cause of PH in significant mitral valve disease (PH&lt;inf&gt;MVD&lt;/inf&gt;) being pulmonary venous hypertension (PVH). Chronic and severe PVH may then lead to muscularization of the pulmonary arterial bed, with a rise in PVR and loss of pulmonary arterial compliance that follows (“reactive” pulmonary vascular disease). Right heart dysfunction ensues once the PVR rises and the compliance falls to a point in which the right ventricle (RV) cannot overcome the increased afterload. However, it is worth emphasizing that in the setting of PH&lt;inf&gt;MVD&lt;/inf&gt;, no matter the degree of mismatch between RV afterload and RV function, the root condition in the patient and cause of the PH remains severe MV disease. Without correction of the primary condition, the patient’s heart failure (HF), PH, PVR, and RV dysfunction will remain or progress. Moreover, direct PH medical therapies are ineffective and may actually worsen left heart congestion in the setting of unremediated MVD. Therefore, although surgery may be a higher risk in some patients with PH&lt;inf&gt;MVD&lt;/inf&gt;, the potential benefits justify the risks in the majority of cases. If needed, direct medical management of PH is far simpler and more effective once the MVD is corrected, given the degree of left heart congestion often improves dramatically. Therefore, corrective mitral valve intervention should be considered as the main and definitive treatment for these patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105862464</affiliation-url><afid>105862464</afid><affilname>Einstein Medical Center</affilname><name-variant>Einstein Medical Center</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021187</affiliation-url><afid>60021187</afid><affilname>Temple University Hospital</affilname><name-variant>Temple University Hospital</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021187</affiliation-url><afid>60021187</afid><affilname>Temple University Hospital</affilname><name-variant>Temple University Hospital</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55995395700</author-url><authid>55995395700</authid><authname>Davila C.</authname><surname>Davila</surname><given-name>Carlos D.</given-name><initials>C.D.</initials><afid>105862464</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36958031900</author-url><authid>36958031900</authid><authname>Forfia P.</authname><surname>Forfia</surname><given-name>Paul R.</given-name><initials>P.R.</initials><afid>60021187</afid><afid>60021187</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36958031900</author-url><authid>36958031900</authid><authname>Forfia P.</authname><surname>Forfia</surname><given-name>Paul R.</given-name><initials>P.R.</initials><afid>60021187</afid><afid>60021187</afid></author><authkeywords>Heart failure | Mitral valve disease | Pulmonary hypertension | Surgery</authkeywords><intid>1036044703</intid><source-id>23154</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928664962"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928664962?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928664962&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928664962&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928664962</prism:url><dc:identifier>SCOPUS_ID:84928664962</dc:identifier><eid>2-s2.0-84928664962</eid><dc:title>Cardiac Magnetic Resonance Imaging in Ventricular Remodelling</dc:title><dc:creator>Ellims A.</dc:creator><prism:publicationName>Current Cardiovascular Imaging Reports</prism:publicationName><prism:issn>19419066</prism:issn><prism:eIssn>19419074</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12410-015-9335-z</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Ventricular remodelling is characterised by changes in ventricular structure and/or function in response to haemodynamic load and/or cardiac injury. Several cardiovascular conditions, including ischaemic heart disease, inherited cardiomyopathies, systemic hypertension and valvular heart disease, may cause ventricular remodelling and, over time, progression to heart failure. Cardiac magnetic resonance (CMR) imaging is increasingly utilised to provide gold standard assessments of ventricular structure and function, and also non-invasively evaluate myocardial fibrosis. An enhanced understanding of the mechanisms and natural history of ventricular remodelling by the application of CMR may facilitate therapies to halt or regress maladaptive ventricular remodelling responses.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008014</affiliation-url><afid>60008014</afid><affilname>Alfred Hospital</affilname><name-variant>Alfred Hospital</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112593182</affiliation-url><afid>112593182</afid><affilname>Baker IDI Heart and Diabetes Research Institute</affilname><name-variant>Baker IDI Heart and Diabetes Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36157641600</author-url><authid>36157641600</authid><authname>Ellims A.</authname><surname>Ellims</surname><given-name>Andris H.</given-name><initials>A.H.</initials><afid>60008014</afid><afid>112593182</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36157641600</author-url><authid>36157641600</authid><authname>Ellims A.</authname><surname>Ellims</surname><given-name>Andris H.</given-name><initials>A.H.</initials><afid>60008014</afid><afid>112593182</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55432818700</author-url><authid>55432818700</authid><authname>Taylor A.</authname><surname>Taylor</surname><given-name>Andrew J.</given-name><initials>A.J.</initials><afid>60008014</afid><afid>112593182</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55432818700</author-url><authid>55432818700</authid><authname>Taylor A.</authname><surname>Taylor</surname><given-name>Andrew J.</given-name><initials>A.J.</initials><afid>60008014</afid><afid>112593182</afid></author><authkeywords>Cardiac magnetic resonance | Cardiomyopathy | Heart failure | Late gadolinium enhancement | Myocardial fibrosis | Ventricular remodelling</authkeywords><intid>1035819830</intid><source-id>19600157307</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226122"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226122?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226122&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226122&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226122</prism:url><dc:identifier>SCOPUS_ID:84930226122</dc:identifier><eid>2-s2.0-84930226122</eid><dc:title>Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease</dc:title><dc:creator>Patel V.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>961-966</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-306782</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. Background: Anderson-Fabry Disease (AFD) is an X linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene. Some mutations are associated with prominent and, in many cases, exclusive cardiac involvement. The primary aims of this study were to determine the incidence of major cardiac events in AFD and to identify clinical and genetic predictors of adverse outcomes. Methods and results: We studied 207 patients with AFD (47% male, mean age 44 years, mean follow-up 7.1 years). Fifty-eight (28%) individuals carried mutations that have been previously associated with a cardiac predominant phenotype. Twenty-one (10%) developed severe heart failure (New York Heart Association functional class (NYHA) ≥3), 13 (6%) developed atrial fibrillation (AF), 13 (6%) received devices for the treatment of bradycardia; there were a total of 7 (3%) cardiac deaths. The incidence of the primary endpoint (a composite of new onset AF, NYHA ≥ 3 symptoms, device insertion for bradycardia and cardiac death) was 2.64 per 100 person-years (CI 1.78 to 3.77). Age (HR 1.04, CI 1.01 to 1.08, p=0.004), Mainz Severity Score Index score (HR 1.05, CI 1.01 to 1.09, p=0.012) and QRS duration (HR 1.03, CI 1.00 to 1.05, p=0.020) were significant independent predictors of the primary endpoint. The presence of a cardiac genetic variant did not predict the primary end point. Conclusions: AFD is associated with a high burden of cardiac morbidity and mortality. Adverse cardiac outcomes are associated with age, global disease severity and advanced cardiac disease but not the presence of cardiac genetic variants.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029950</affiliation-url><afid>60029950</afid><affilname>UCL Medical School</affilname><name-variant>UCL Medical School</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014714</affiliation-url><afid>60014714</afid><affilname>University of Dhaka</affilname><name-variant>University of Dhaka</name-variant><affiliation-city>Dhaka</affiliation-city><affiliation-country>Bangladesh</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36914277700</author-url><authid>36914277700</authid><authname>Patel V.</authname><surname>Patel</surname><given-name>Vimal</given-name><initials>V.</initials><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26644292900</author-url><authid>26644292900</authid><authname>O'Mahony C.</authname><surname>O'Mahony</surname><given-name>Constantinos</given-name><initials>C.</initials><afid>60022148</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7403462852</author-url><authid>7403462852</authid><authname>Hughes D.</authname><surname>Hughes</surname><given-name>Derralynn</given-name><initials>D.</initials><afid>60029950</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662614800</author-url><authid>56662614800</authid><authname>Rahman M.</authname><surname>Rahman</surname><given-name>Mohammad Shafiqur</given-name><initials>M.S.</initials><afid>60014714</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:25027144700</author-url><authid>25027144700</authid><authname>Coats C.</authname><surname>Coats</surname><given-name>Caroline</given-name><initials>C.</initials><afid>60022148</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:49962091400</author-url><authid>49962091400</authid><authname>Murphy E.</authname><surname>Murphy</surname><given-name>Elaine</given-name><initials>E.</initials><afid>60022148</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003596979</author-url><authid>7003596979</authid><authname>Lachmann R.</authname><surname>Lachmann</surname><given-name>Robin</given-name><initials>R.</initials><afid>60022148</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402756333</author-url><authid>7402756333</authid><authname>Mehta A.</authname><surname>Mehta</surname><given-name>Atul</given-name><initials>A.</initials><afid>60029950</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7202244843</author-url><authid>7202244843</authid><authname>Elliott P.</authname><surname>Elliott</surname><given-name>Perry M.</given-name><initials>P.M.</initials><afid>60022148</afid></author><intid>1536088032</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226121"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226121?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226121&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226121&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226121</prism:url><dc:identifier>SCOPUS_ID:84930226121</dc:identifier><eid>2-s2.0-84930226121</eid><dc:title>Prognostic value of cardiac time intervals measured by tissue Doppler imaging M-mode in the general population</dc:title><dc:creator>Biering-Sørensen T.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>954-960</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-307137</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. Objective: Tissue Doppler imaging (TDI) M-mode through the mitral leaflet is an easy and precise method to estimate the cardiac time intervals. The aim was to evaluate the usability of the cardiac time intervals in predicting major cardiovascular events (MACE) in the general population. Methods: In a large prospective community-based study, cardiac function was evaluated in 1915 participants by both conventional echocardiography and TDI. The cardiac time intervals, including the isovolumic relaxation time (IVRT), isovolumic contraction time (IVCT) and ejection time (ET), were obtained by TDI M-mode through the mitral leaflet. IVCT/ET, IVRT/ET and the myocardial performance index (MPI=(IVRT+IVCT)/ET) were calculated. Results: During follow-up (median 10.8 years), 383 (20%) participants reached the combined endpoint MACE (ischaemic heart disease, heart failure or cardiac death). After multivariable adjustment for clinical predictors and conventional echocardiography, only the combined indexes, including information on both systolic and diastolic performance (IVRT/ET and MPI), remained significant prognosticators (p&lt;0.05 for both). Adding IVRT/ET or MPI to a model already including all other echocardiographic parameters resulted in a significant increase in the c-statistics (0.76 vs 0.75 p&lt;0.01 for both). IVRT/ET or MPI improved reclassification significantly when added to the clinical predictors (p&lt;0.05 for both). Conclusions: In the general population, the combined cardiac time intervals that include information on both systolic and diastolic function in one index (IVRT/ET and MPI) are not only powerful and independent predictors of future MACE, but provide additional prognostic information to clinical and conventional echocardiographic measures of systolic and diastolic function.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25637106800</author-url><authid>25637106800</authid><authname>Biering-Sørensen T.</authname><surname>Biering-Sørensen</surname><given-name>Tor</given-name><initials>T.</initials><afid>60030840</afid><afid>60030840</afid><afid>60030840</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25637106800</author-url><authid>25637106800</authid><authname>Biering-Sørensen T.</authname><surname>Biering-Sørensen</surname><given-name>Tor</given-name><initials>T.</initials><afid>60030840</afid><afid>60030840</afid><afid>60030840</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25637106800</author-url><authid>25637106800</authid><authname>Biering-Sørensen T.</authname><surname>Biering-Sørensen</surname><given-name>Tor</given-name><initials>T.</initials><afid>60030840</afid><afid>60030840</afid><afid>60030840</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15725926700</author-url><authid>15725926700</authid><authname>Mogelvang R.</authname><surname>Mogelvang</surname><given-name>Rasmus</given-name><initials>R.</initials><afid>60030840</afid><afid>60030840</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15725926700</author-url><authid>15725926700</authid><authname>Mogelvang R.</authname><surname>Mogelvang</surname><given-name>Rasmus</given-name><initials>R.</initials><afid>60030840</afid><afid>60030840</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35463622600</author-url><authid>35463622600</authid><authname>Jensen J.</authname><surname>Jensen</surname><given-name>Jan Skov</given-name><initials>J.S.</initials><afid>60030840</afid><afid>60030840</afid><afid>60030840</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35463622600</author-url><authid>35463622600</authid><authname>Jensen J.</authname><surname>Jensen</surname><given-name>Jan Skov</given-name><initials>J.S.</initials><afid>60030840</afid><afid>60030840</afid><afid>60030840</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35463622600</author-url><authid>35463622600</authid><authname>Jensen J.</authname><surname>Jensen</surname><given-name>Jan Skov</given-name><initials>J.S.</initials><afid>60030840</afid><afid>60030840</afid><afid>60030840</afid></author><intid>36086532</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929483904"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929483904?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929483904&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929483904&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929483904</prism:url><dc:identifier>SCOPUS_ID:84929483904</dc:identifier><eid>2-s2.0-84929483904</eid><dc:title>New Insights from Major Prospective Cohort Studies with Cardiovascular Magnetic Resonance (CMR)</dc:title><dc:creator>Arai A.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0599-3</prism:doi><dc:description>© 2015, The Author(s). Since 1948, epidemiology studies played an important role in understanding cardiovascular disease and afforded an opportunity to learn about newer diagnostic tests. In 2000, the MESA Study incorporated several advanced cardiovascular imaging modalities including cardiac magnetic resonance imaging (MRI) and coronary artery calcium scans. The decade of follow-up enabled prognosis studies, an important step beyond association studies. In brief, left ventricular hypertrophy by cardiac MRI predicted incident heart failure and stroke. In the MESA Study, coronary artery calcium was a better predictor of coronary artery disease end points than the non-contrast-enhanced MRI scan. In the ICELAND MI substudy of the AGES-Reykjavik Study, a contrast-enhanced MRI scan detected many more unrecognized myocardial infarctions (MIs) (UMIs) than detected by electrocardiography and documented these UMI had adverse prognostic significance. Thus, cardiac MRI has been successfully incorporated into large population studies and shown added value over conventional measurements of cardiovascular disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006577</affiliation-url><afid>60006577</afid><affilname>National Institutes of Health, Bethesda</affilname><name-variant>National Institute of Health</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7103347595</author-url><authid>7103347595</authid><authname>Arai A.</authname><surname>Arai</surname><given-name>Andrew E.</given-name><initials>A.E.</initials><afid>60006577</afid></author><authkeywords>Cardiomyopathy | Cardiovascular | Epidemiology | Left ventricular hypertrophy | MRI (magnetic resonance imaging) | Myocardial infarction</authkeywords><intid>2035959226</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212158"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212158?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212158&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212158&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212158</prism:url><dc:identifier>SCOPUS_ID:84930212158</dc:identifier><eid>2-s2.0-84930212158</eid><dc:title>MicroRNAs in cardiovascular disease: An introduction for clinicians</dc:title><dc:creator>Romaine S.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>921-928</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2013-305402</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. MicroRNAs (miRNAs) are small, non-coding, RNA molecules approximately 22 nucleotides in length which act as post-transcriptional regulators of gene expression. Individual miRNAs have been shown to regulate the expression of multiple genes. Conversely, the expression of individual genes can be regulated by multiple miRNAs. Consequently, since their discovery just over 20 years ago, miRNAs have been identified as key regulators of complex biological processes linked to multiple cardiovascular pathologies, including left ventricular hypertrophy, ischaemic heart disease, heart failure, hypertension and arrhythmias. Furthermore, since the finding that miRNAs are present in the circulation, they have been investigated as novel biomarkers, especially in the context of acute myocardial infarction (AMI) and heart failure. While there is little convincing evidence that miRNAs can outperform traditional biomarkers, such as cardiac troponins, in the diagnosis of AMI, there is potential for miRNAs to complement existing risk prediction models and act as valuable markers of post-AMI prognosis. Encouragingly, the concept of miRNA-based therapeutics is developing, with synthetic antagonists of miRNAs (antagomiRs) currently in phase II trials for the treatment of chronic hepatitis C virus infection. In the cardiovascular field, promising preclinical studies suggest that they could be useful in treating disorders ranging from heart failure to dyslipidaemia, although several challenges related to specificity and targeted delivery remain to be overcome. Through this review, we provide clinicians with a brief overview of the ever-expanding world of miRNAs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033125</affiliation-url><afid>60033125</afid><affilname>University of Leicester</affilname><name-variant>University of Leicester</name-variant><affiliation-city>Leicester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108519584</affiliation-url><afid>108519584</afid><affilname>NIHR Leicester Cardiovascular Biomedical Research Unit</affilname><name-variant>Leicester NIHR Biomedical Research Unit in Cardiovascular Disease</name-variant><affiliation-city>Leicester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030318</affiliation-url><afid>60030318</afid><affilname>Universita degli Studi di Milano</affilname><name-variant>University of Milan</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56650822800</author-url><authid>56650822800</authid><authname>Romaine S.</authname><surname>Romaine</surname><given-name>Simon P R</given-name><initials>S.P.R.</initials><afid>60033125</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006672694</author-url><authid>7006672694</authid><authname>Tomaszewski M.</authname><surname>Tomaszewski</surname><given-name>Maciej</given-name><initials>M.</initials><afid>60033125</afid><afid>108519584</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006672694</author-url><authid>7006672694</authid><authname>Tomaszewski M.</authname><surname>Tomaszewski</surname><given-name>Maciej</given-name><initials>M.</initials><afid>60033125</afid><afid>108519584</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005775844</author-url><authid>7005775844</authid><authname>Condorelli G.</authname><surname>Condorelli</surname><given-name>Gianluigi</given-name><initials>G.</initials><afid>60033125</afid><afid>108519584</afid><afid>60030318</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005775844</author-url><authid>7005775844</authid><authname>Condorelli G.</authname><surname>Condorelli</surname><given-name>Gianluigi</given-name><initials>G.</initials><afid>60033125</afid><afid>108519584</afid><afid>60030318</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005775844</author-url><authid>7005775844</authid><authname>Condorelli G.</authname><surname>Condorelli</surname><given-name>Gianluigi</given-name><initials>G.</initials><afid>60033125</afid><afid>108519584</afid><afid>60030318</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004345054</author-url><authid>7004345054</authid><authname>Samani N.</authname><surname>Samani</surname><given-name>Nilesh J.</given-name><initials>N.J.</initials><afid>60033125</afid><afid>108519584</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004345054</author-url><authid>7004345054</authid><authname>Samani N.</authname><surname>Samani</surname><given-name>Nilesh J.</given-name><initials>N.J.</initials><afid>60033125</afid><afid>108519584</afid></author><intid>1536088283</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924917622"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924917622?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924917622&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924917622&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1043466615000630"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924917622</prism:url><dc:identifier>SCOPUS_ID:84924917622</dc:identifier><eid>2-s2.0-84924917622</eid><dc:title>Soluble interleukin 6 receptor levels are associated with reduced myocardial reperfusion after percutaneous coronary intervention for acute myocardial infarction</dc:title><dc:creator>Groot H.</dc:creator><prism:publicationName>Cytokine</prism:publicationName><prism:issn>10434666</prism:issn><prism:eIssn>10960023</prism:eIssn><prism:volume>73</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>207-212</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cyto.2015.02.004</prism:doi><pii>S1043466615000630</pii><dc:description>© 2015 Elsevier Ltd. Aims: Interleukin-6 receptor (IL-6R) signalling has been suggested to play a causal role in the development and outcome of coronary heart disease (CHD). The aim of this study was to investigate the association of sIL-6R levels with myocardial reperfusion after percutaneous coronary intervention (PCI) for acute ST-elevated myocardial infarction (STEMI). Methods: Blood was sampled from 70 patients presenting with STEMI at 6 different time-points (baseline, post-PCI, t=. 1. h, t=. 6. h, t=. 24. h, t=. 2w). Coronary angiograms post-PCI were analysed for myocardial blush grade (MBG) as indicator of myocardial reperfusion. Serum IL-6 and sIL-6R were measured using IL-6 and sIL-6R enzyme-linked immunosorbent assays (ELISA). Results: sIL-6R levels fluctuated biphasic during the two weeks after STEMI. Reduced MBG was associated with a larger change in sIL-6R levels between baseline and post-PCI compared to optimal MBG (-13.40; SEM 2.78. ng/ml vs -1.99; SEM 2.35. ng/ml, respectively; p&lt;. 0.001). Patients with reduced MBG also showed a larger increase in sIL-6R levels after PCI and 1. h after myocardial infarction (MI) compared to optimal MBG (respectively 11.56; SEM 2.68. ng/ml vs 3.02; SEM 2.39. ng/ml; p=. 0.018). IL-6/sIL-6R ratio was also more increased in patients with reduced MBG at 24. h after myocardial infarction (0.23; SEM 0.08-0.51 vs 0.10; SEM 0.05-0.21; p=. 0.024). An optimal MBG was associated with a 10. ng increase in sIL-6R level between baseline and post-PCI (OR 1.687, CI 1.095-2.598; p=. 0.018). Conclusions: sIL-6R levels fluctuate biphasic during the two weeks after MI with larger changes and increased IL-6/sIL-6R ratio in patients with reduced MBG. Further research is needed to increase our understanding of the possible causality of these associations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006027</affiliation-url><afid>60006027</afid><affilname>Universitair Medisch Centrum Groningen</affilname><name-variant>University Medical Center Groningen</name-variant><affiliation-city>Groningen</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070245</affiliation-url><afid>60070245</afid><affilname>Meander Medical Center</affilname><name-variant>Meander Medical Center</name-variant><affiliation-city>Amersfoort</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002794</affiliation-url><afid>60002794</afid><affilname>Interuniversity Cardiology Institute of the Netherlands ICIN - KNAW</affilname><name-variant>Interuniversity Cardiology Institute of the Netherlands</name-variant><affiliation-city>Utrecht</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56553936000</author-url><authid>56553936000</authid><authname>Groot H.</authname><surname>Groot</surname><given-name>Hilde E.</given-name><initials>H.E.</initials><afid>60006027</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56553756400</author-url><authid>56553756400</authid><authname>Hartman M.</authname><surname>Hartman</surname><given-name>Minke H T</given-name><initials>M.H.T.</initials><afid>60006027</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:13611238000</author-url><authid>13611238000</authid><authname>Gu Y.</authname><surname>Gu</surname><given-name>Youlan L.</given-name><initials>Y.L.</initials><afid>60006027</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701847257</author-url><authid>6701847257</authid><authname>de Smet B.</authname><surname>de Smet</surname><given-name>Bart J G L</given-name><initials>B.J.G.L.</initials><afid>60070245</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003935271</author-url><authid>7003935271</authid><authname>van den Heuvel A.</authname><surname>van den Heuvel</surname><given-name>Ad F M</given-name><initials>A.F.M.</initials><afid>60006027</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8513068600</author-url><authid>8513068600</authid><authname>Lipsic E.</authname><surname>Lipsic</surname><given-name>Erik</given-name><initials>E.</initials><afid>60006027</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602378288</author-url><authid>6602378288</authid><authname>van der Harst P.</authname><surname>van der Harst</surname><given-name>Pim</given-name><initials>P.</initials><afid>60006027</afid><afid>60002794</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602378288</author-url><authid>6602378288</authid><authname>van der Harst P.</authname><surname>van der Harst</surname><given-name>Pim</given-name><initials>P.</initials><afid>60006027</afid><afid>60002794</afid></author><authkeywords>Myocardial reperfusion | Soluble interleukin-6 receptor</authkeywords><intid>1035212327</intid><source-id>22083</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929071605"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929071605?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929071605&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929071605&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929071605</prism:url><dc:identifier>SCOPUS_ID:84929071605</dc:identifier><eid>2-s2.0-84929071605</eid><dc:title>Functional and Biomechanical Effects of the Edge-to-Edge Repair in the Setting of Mitral Regurgitation: Consolidated Knowledge and Novel Tools to Gain Insight into Its Percutaneous Implementation</dc:title><dc:creator>Sturla F.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>117-140</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-014-0208-4</prism:doi><dc:description>© 2014, Biomedical Engineering Society. Mitral regurgitation is the most prevalent heart valve disease in the western population. When severe, it requires surgical treatment, repair being the preferred option. The edge-to-edge repair technique treats mitral regurgitation by suturing the leaflets together and creating a double-orifice valve. Due to its relative simplicity and versatility, it has become progressively more widespread. Recently, its percutaneous version has become feasible, and has raised interest thanks to the positive results of the Mitraclip&lt;sup&gt;®&lt;/sup&gt; device. Edge-to-edge features and evolution have stimulated debate and multidisciplinary research by both clinicians and engineers. After providing an overview of representative studies in the field, here we propose a novel computational approach to the most recent percutaneous evolution of the edge-to-edge technique. Image-based structural finite element models of three mitral valves affected by posterior prolapse were derived from cine-cardiac magnetic resonance imaging. The models accounted for the patient-specific 3D geometry of the valve, including leaflet compound curvature pattern, patient-specific motion of annulus and papillary muscles, and hyperelastic and anisotropic mechanical properties of tissues. The biomechanics of the three valves throughout the entire cardiac cycle was simulated before and after Mitraclip&lt;sup&gt;®&lt;/sup&gt; implantation, assessing the biomechanical impact of the procedure. For all three simulated MVs, Mitraclip&lt;sup&gt;®&lt;/sup&gt; implantation significantly improved systolic leaflets coaptation, without inducing major alterations in systolic peak stresses. Diastolic orifice area was decreased, by up to 58.9%, and leaflets diastolic stresses became comparable, although lower, to systolic ones. Despite established knowledge on the edge-to-edge surgical repair, latest technological advances make its percutanoues implementation a challenging field of research. The modeling approach herein proposed may be expanded to analyze clinical scenarios that are currently critical for Mitraclip&lt;sup&gt;®&lt;/sup&gt; implantation, helping the search for possible solutions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023256</affiliation-url><afid>60023256</afid><affilname>Politecnico di Milano</affilname><name-variant>Politecnico di Milano</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032256</affiliation-url><afid>60032256</afid><affilname>Universita degli Studi di Verona</affilname><name-variant>University of Verona</name-variant><affiliation-city>Verona</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55837209500</author-url><authid>55837209500</authid><authname>Sturla F.</authname><surname>Sturla</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60023256</afid><afid>60032256</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55837209500</author-url><authid>55837209500</authid><authname>Sturla F.</authname><surname>Sturla</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60023256</afid><afid>60032256</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005302872</author-url><authid>7005302872</authid><authname>Redaelli A.</authname><surname>Redaelli</surname><given-name>Alberto</given-name><initials>A.</initials><afid>60023256</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6601970572</author-url><authid>6601970572</authid><authname>Puppini G.</authname><surname>Puppini</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60032256</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35579670300</author-url><authid>35579670300</authid><authname>Onorati F.</authname><surname>Onorati</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60032256</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004905834</author-url><authid>7004905834</authid><authname>Faggian G.</authname><surname>Faggian</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60032256</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602264012</author-url><authid>6602264012</authid><authname>Votta E.</authname><surname>Votta</surname><given-name>Emiliano</given-name><initials>E.</initials><afid>60023256</afid></author><authkeywords>Edge-to-edge | Finite element model | Heart valve biomechanics | Mitraclip | Mitral regurgitation | Mitral valve</authkeywords><intid>1785901806</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930227010"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930227010?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930227010&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930227010&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930227010</prism:url><dc:identifier>SCOPUS_ID:84930227010</dc:identifier><eid>2-s2.0-84930227010</eid><dc:title>Residual pulmonary vasodilative reserve predicts outcome in idiopathic pulmonary hypertension</dc:title><dc:creator>Leuchte H.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>972-976</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2015-307529</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. Objective: Idiopathic pulmonary arterial hypertension (IPAH) remains a devastating and incurable, albeit treatable condition. Treatment response is not uniform and parameters that help to anticipate a rather benign or a malignant course of the disease are warranted. Acute pulmonary vasoreactivity testing during right heart catheterisation is recommended to identify a minority of patients with IPAH with sustained response to calcium channel blocker therapy. This study aimed to evaluate the prognostic significance of a residual pulmonary vasodilative reserve in patients with IPAH not meeting current vasoresponder criteria. Design: Observational right heart catheter study in 66 (n=66) patients with IPAH not meeting current vasoresponse criteria. Pulmonary vasodilative reserve was assessed by inhalation of 5 μg iloprost-aerosol. Results: Sixty-six (n=66) of 72 (n=72) patients with IPAH did not meet current definition criteria assessed during vasodilator testing to assess pulmonary vasodilatory reserve. In those, iloprost-aerosol caused a reduction of mean pulmonary artery pressure (Δ pulmonary artery pressure - 11.4%; p&lt;0.001) and increased cardiac output (Δ cardiac output +16.7%; p&lt;0.001), resulting in a reduction of pulmonary vascular resistance (Δ pulmonary vascular resistance - 25%; p&lt;0.001). The magnitude of this response was pronounced in surviving patients. A pulmonary vascular resistance reduction of ≥30% turned out to predict outcome in patients with IPAH. Conclusions: Residual pulmonary vasodilative reserve during acute vasodilator testing is of prognostic relevance in patients with IPAH not meeting current definitions of acute vasoreactivity. Therefore vasoreactivity testing holds more information than currently used.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028717</affiliation-url><afid>60028717</afid><affilname>Ludwig-Maximilians-Universitat Munchen</affilname><name-variant>University of Munich</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000291</affiliation-url><afid>60000291</afid><affilname>Klinikum der Universitat Munchen</affilname><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6601967854</author-url><authid>6601967854</authid><authname>Leuchte H.</authname><surname>Leuchte</surname><given-name>Hanno H.</given-name><initials>H.H.</initials><afid>60028717</afid><afid>60000291</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6601967854</author-url><authid>6601967854</authid><authname>Leuchte H.</authname><surname>Leuchte</surname><given-name>Hanno H.</given-name><initials>H.H.</initials><afid>60028717</afid><afid>60000291</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26022856400</author-url><authid>26022856400</authid><authname>Baezner C.</authname><surname>Baezner</surname><given-name>Carlos</given-name><initials>C.</initials><afid>60000291</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202309979</author-url><authid>7202309979</authid><authname>Baumgartner R.</authname><surname>Baumgartner</surname><given-name>Rainer A.</given-name><initials>R.A.</initials><afid>60028717</afid><afid>60000291</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202309979</author-url><authid>7202309979</authid><authname>Baumgartner R.</authname><surname>Baumgartner</surname><given-name>Rainer A.</given-name><initials>R.A.</initials><afid>60028717</afid><afid>60000291</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602302549</author-url><authid>6602302549</authid><authname>Muehling O.</authname><surname>Muehling</surname><given-name>Olaf</given-name><initials>O.</initials><afid>60000291</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6508182224</author-url><authid>6508182224</authid><authname>Neurohr C.</authname><surname>Neurohr</surname><given-name>Claus</given-name><initials>C.</initials><afid>60000291</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7101784631</author-url><authid>7101784631</authid><authname>Behr J.</authname><surname>Behr</surname><given-name>Juergen</given-name><initials>J.</initials><afid>60000291</afid></author><intid>36085986</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929500839"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929500839?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929500839&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929500839&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929500839</prism:url><dc:identifier>SCOPUS_ID:84929500839</dc:identifier><eid>2-s2.0-84929500839</eid><dc:title>Sex Differences in the Pathophysiology, Treatment, and Outcomes in IHD</dc:title><dc:creator>Sanghavi M.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0511-z</prism:doi><dc:description>© 2015, The Author(s). Heart disease is the number one killer of women. Although there are many similarities between men and women, the evolving understanding of ischemic heart disease in women allow us to emphasize the important differences that need to be recognized. These differences, including symptoms at presentation, importance of particular risk factors, pathophysiology of disease, and treatments/outcomes, will be discussed in this review.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026695</affiliation-url><afid>60026695</afid><affilname>UT Southwestern Medical Center</affilname><name-variant>University of Texas Southwestern Medical Center</name-variant><affiliation-city>Dallas</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56605547900</author-url><authid>56605547900</authid><authname>Sanghavi M.</authname><surname>Sanghavi</surname><given-name>Monika</given-name><initials>M.</initials><afid>60026695</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56648319400</author-url><authid>56648319400</authid><authname>Gulati M.</authname><surname>Gulati</surname><given-name>Martha</given-name><initials>M.</initials><afid>60003500</afid></author><authkeywords>Cardiovascular disease | Ischemic heart disease | Microvascular dysfunction | Risk factors | Women</authkeywords><intid>35963856</intid><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929085025"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929085025?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929085025&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929085025&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929085025</prism:url><dc:identifier>SCOPUS_ID:84929085025</dc:identifier><eid>2-s2.0-84929085025</eid><dc:title>A Technical Review of Minimally Invasive Mitral Valve Replacements</dc:title><dc:creator>Preston-Maher G.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>174-184</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-014-0203-9</prism:doi><dc:description>© 2014, The Author(s). Mitral regurgitation is one of the most common forms of heart valve disorder, which may result in heart failure. Due to the rapid ageing of the population, surgical repair and replacement treatments, which have represented an effective treatment in the past, are now unsuitable for about half of symptomatic patients, who are judged high-risk. Encouraged by the positive experience with transcatheter aortic valves and percutaneous reconstructive mitral treatments, a number of research groups are currently engaged in the development of minimally invasive approaches for the functional replacement of the mitral valve. The first experiences have clearly demonstrated that the approach is feasible and promising, though significant progress is still required in the prostheses design and implantation procedures before the treatment can establish as a safe and effective solution. This review analyses the devices currently at a most advanced stage of development, describing their main features and the technical solutions that they adopt in order to respond to the functional requirements of the most challenging of the heart valves.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56638546100</author-url><authid>56638546100</authid><authname>Preston-Maher G.</authname><surname>Preston-Maher</surname><given-name>Georgia L.</given-name><initials>G.L.</initials><afid>60022148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005835193</author-url><authid>7005835193</authid><authname>Torii R.</authname><surname>Torii</surname><given-name>Ryo</given-name><initials>R.</initials><afid>60022148</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506017118</author-url><authid>6506017118</authid><authname>Burriesci G.</authname><surname>Burriesci</surname><given-name>Gaetano</given-name><initials>G.</initials><afid>60022148</afid></author><authkeywords>Mitral valve | TAVI | TMVI | Transcatheter heart valve replacement</authkeywords><intid>1785903459</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929071739"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929071739?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929071739&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929071739&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929071739</prism:url><dc:identifier>SCOPUS_ID:84929071739</dc:identifier><eid>2-s2.0-84929071739</eid><dc:title>Bench Models for Assessing the Mechanics of Mitral Valve Repair and Percutaneous Surgery</dc:title><dc:creator>Siefert A.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>193-207</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-014-0196-4</prism:doi><dc:description>© 2014, Biomedical Engineering Society. Rapid preclinical evaluations of mitral valve (MV) mechanics are currently best facilitated by bench models of the left ventricle (LV). This review aims to provide a comprehensive assessment of these models to aid interpretation of their resulting data, inform future experimental evaluations, and further the translation of results to procedure and device development. For this review, two types of experimental bench models were evaluated. Rigid LV models were characterized as fluid-mechanical systems capable of testing explanted MVs under static and or pulsatile left heart hemodynamics. Passive LV models were characterized as explanted hearts whose left side is placed in series with a static or pulsatile flow-loop. In both systems, MV function and mechanics can be quantitatively evaluated. Rigid and passive LV models were characterized and evaluated. The materials and methods involved in their construction, function, quantitative capabilities, and disease modeling were described. The advantages and disadvantages of each model are compared to aid the interpretation of their resulting data and inform future experimental evaluations. Repair and percutaneous studies completed in these models were additionally summarized with perspective on future advances discussed. Bench models of the LV provide excellent platforms for quantifying MV repair mechanics and function. While exceptional work has been reported, more research and development is necessary to improve techniques and devices for repair and percutaneous surgery. Continuing efforts in this field will significantly contribute to the further development of procedures and devices, predictions of long-term performance, and patient safety.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008326</affiliation-url><afid>60008326</afid><affilname>Failure Analysis Associates</affilname><name-variant>Failure Analysis Associates, Inc</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55164523300</author-url><authid>55164523300</authid><authname>Siefert A.</authname><surname>Siefert</surname><given-name>Andrew W.</given-name><initials>A.W.</initials><afid>60008326</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56638356300</author-url><authid>56638356300</authid><authname>Siskey R.</authname><surname>Siskey</surname><given-name>Ryan L.</given-name><initials>R.L.</initials><afid>60008326</afid></author><authkeywords>Experimental methods | Heart | Heart valve | Mechanics | Simulation</authkeywords><intid>1785902311</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929630009"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929630009?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929630009&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929630009&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929630009</prism:url><dc:identifier>SCOPUS_ID:84929630009</dc:identifier><eid>2-s2.0-84929630009</eid><dc:title>DTI template-based estimation of cardiac fiber orientations from 3D ultrasound</dc:title><dc:creator>Qin X.</dc:creator><prism:publicationName>Medical Physics</prism:publicationName><prism:issn>00942405</prism:issn><prism:volume>42</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>2915-2924</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1118/1.4921121</prism:doi><dc:description>© 2015 American Association of Physicists in Medicine. Purpose: Cardiac muscle fibers directly affect the mechanical, physiological, and pathological properties of the heart. Patient-specific quantification of cardiac fiber orientations is an important but difficult problem in cardiac imaging research. In this study, the authors proposed a cardiac fiber orientation estimation method based on three-dimensional (3D) ultrasound images and a cardiac fiber template that was obtained from magnetic resonance diffusion tensor imaging (DTI). Methods: A DTI template-based framework was developed to estimate cardiac fiber orientations from 3D ultrasound images using an animal model. It estimated the cardiac fiber orientations of the target heart by deforming the fiber orientations of the template heart, based on the deformation field of the registration between the ultrasound geometry of the target heart and the MRI geometry of the template heart. In the experiments, the animal hearts were imaged by high-frequency ultrasound, T1-weighted MRI, and high-resolution DTI. Results: The proposed method was evaluated by four different parameters: Dice similarity coefficient (DSC), target errors, acute angle error (AAE), and inclination angle error (IAE). Its ability of estimating cardiac fiber orientations was first validated by a public database. Then, the performance of the proposed method on 3D ultrasound data was evaluated by an acquired database. Their average values were 95.4%±2.0% for the DSC of geometric registrations, 21.0°±0.76° for AAE, and 19.4°±1.2° for IAE of fiber orientation estimations. Furthermore, the feasibility of this framework was also performed on 3D ultrasound images of a beating heart. Conclusions: The proposed framework demonstrated the feasibility of using 3D ultrasound imaging to estimate cardiac fiber orientation of in vivo beating hearts and its further improvements could contribute to understanding the dynamic mechanism of the beating heart and has the potential to help diagnosis and therapy of heart disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002339</affiliation-url><afid>60002339</afid><affilname>Emory University School of Medicine</affilname><name-variant>Emory University School of Medicine</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000928</affiliation-url><afid>60000928</afid><affilname>Emory University</affilname><name-variant>Emory University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002339</affiliation-url><afid>60002339</afid><affilname>Emory University School of Medicine</affilname><name-variant>Emory University School of Medicine</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000928</affiliation-url><afid>60000928</afid><affilname>Emory University</affilname><name-variant>Emory University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56651536700</author-url><authid>56651536700</authid><authname>Qin X.</authname><surname>Qin</surname><given-name>Xulei</given-name><initials>X.</initials><afid>60002339</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005499116</author-url><authid>7005499116</authid><authname>Fei B.</authname><surname>Fei</surname><given-name>Baowei</given-name><initials>B.</initials><afid>60002339</afid><afid>60000928</afid><afid>60002339</afid><afid>60000928</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005499116</author-url><authid>7005499116</authid><authname>Fei B.</authname><surname>Fei</surname><given-name>Baowei</given-name><initials>B.</initials><afid>60002339</afid><afid>60000928</afid><afid>60002339</afid><afid>60000928</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005499116</author-url><authid>7005499116</authid><authname>Fei B.</authname><surname>Fei</surname><given-name>Baowei</given-name><initials>B.</initials><afid>60002339</afid><afid>60000928</afid><afid>60002339</afid><afid>60000928</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005499116</author-url><authid>7005499116</authid><authname>Fei B.</authname><surname>Fei</surname><given-name>Baowei</given-name><initials>B.</initials><afid>60002339</afid><afid>60000928</afid><afid>60002339</afid><afid>60000928</afid></author><authkeywords>3D ultrasound imaging | cardiac fiber orientation | deformable image registration | heart failure | magnetic resonance diffusion tensor imaging (MR-DTI)</authkeywords><intid>535990571</intid><source-id>17871</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926378480"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926378480?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926378480&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926378480&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S001448001500060X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926378480</prism:url><dc:identifier>SCOPUS_ID:84926378480</dc:identifier><eid>2-s2.0-84926378480</eid><dc:title>Increased TRPM6 expression in atrial fibrillation patients contribute to atrial fibrosis</dc:title><dc:creator>Zhang Y.</dc:creator><prism:publicationName>Experimental and Molecular Pathology</prism:publicationName><prism:issn>00144800</prism:issn><prism:eIssn>10960945</prism:eIssn><prism:volume>98</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>486-490</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yexmp.2015.03.025</prism:doi><pii>S001448001500060X</pii><dc:description>© 2015 Elsevier Inc. Background: Transient receptor potential (TRP) family plays important roles in cardiovascular system. We investigated the relationship between transient receptor potential channel subfamily M6 (TRPM6) and atrial fibrosis in rheumatic heart disease patients with atrial fibrillation (AF). Methods: The right atrial tissue samples were obtained from 64 patients with rheumatic heart diseases who underwent heart valve replacement surgery, and composed of 34 sinus rhythm (SR) patients and 30 AF patients. Hematoxylin and Eosin (HE) staining was used to observe cross-sectional area (CSA) of myocardial cell. Masson staining and measurement of connective tissue growth factor (CTGF), transforming growth factor beta 1 (TGF-β 1), and collagen type I/III (Collagen I/III) were performed to determine atrial fibrosis. The mRNA and protein levels of TRPM6 were detected by real-time quantitative polymerase chain reaction (RT-PCR) and western blotting, respectively. Results: Marked increases were observed in CSA of myocardial cell and myocardial collagen volume fraction in AF group compared with the SR group (all P&lt; 0.05). The mRNA levels of myocardial fibrosis markers (CTGF, TGF-beta 1, Collagen I/III) in AF group increased significantly compared to the SR group (all P&lt; 0.05). TRPM6 mRNA and protein levels in AF group were elevated markedly in comparison with SR group (P&lt; 0.01). Conclusion: These findings revealed that increased TRPM6 mRNA and protein levels may contribute to atrial fibrosis, and suggested that TRPM6 might be involved in AF development by promoting fibrogenesis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025084</affiliation-url><afid>60025084</afid><affilname>Shanghai Jiaotong University</affilname><name-variant>Shanghai Jiaotong University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36116132400</author-url><authid>36116132400</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yun Jiao</given-name><initials>Y.J.</initials><afid>60025084</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56450102500</author-url><authid>56450102500</authid><authname>Ma N.</authname><surname>Ma</surname><given-name>Nan</given-name><initials>N.</initials><afid>60025084</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56581191800</author-url><authid>56581191800</authid><authname>Su F.</authname><surname>Su</surname><given-name>Feng</given-name><initials>F.</initials><afid>60025084</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56182999100</author-url><authid>56182999100</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hao</given-name><initials>H.</initials><afid>60025084</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102430406</author-url><authid>7102430406</authid><authname>Mei J.</authname><surname>Mei</surname><given-name>Ju</given-name><initials>J.</initials><afid>60025084</afid></author><authkeywords>Atrial fibrillation | Atrial fibrosis | MRNA level | Myocardial fibrosis markers | Protein level | Rheumatic heart disease | Sinus rhythm | Transient receptor potential channel subfamily M6 | Transient receptor potential family</authkeywords><intid>1535429050</intid><source-id>13247</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927746374"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927746374?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927746374&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927746374&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0010482515000967"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927746374</prism:url><dc:identifier>SCOPUS_ID:84927746374</dc:identifier><eid>2-s2.0-84927746374</eid><dc:title>A model-based approach to stability analysis of autonomic-cardiac regulation</dc:title><dc:creator>Ataee P.</dc:creator><prism:publicationName>Computers in Biology and Medicine</prism:publicationName><prism:issn>00104825</prism:issn><prism:eIssn>18790534</prism:eIssn><prism:volume>61</prism:volume><prism:pageRange>119-126</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.compbiomed.2015.03.018</prism:doi><pii>S0010482515000967</pii><dc:description>© 2015 Elsevier Ltd. This paper presents a model-based approach to analyze the stability of autonomic-cardiac regulation. In the proposed approach, a low-order lumped parameter model of autonomic-cardiac regulation is used to derive the system equilibria based on the measurements of heart rate and blood pressure, and then the stability margin associated with the equilibria is quantified via the Lyapunov's stability analysis method. A unique strength of the proposed approach is that it provides a quantitative measure of autonomic-cardiac stability via a computationally efficient analysis. Therefore, by integrating it with system identification techniques to derive autonomic-cardiac regulation model tuned to each individual, the proposed approach is able to assess subject-specific autonomic-cardiac stability. Indeed, our initial in-silico investigation showed that the proposed approach could estimate the system equilibria accurately, and the associated stability margin behaved consistently with widely accepted physiologic knowledge. The proposed approach may be useful in identifying physiological conditions that can lead to instability in autonomic-cardiac regulation, quantifying the margin of stability and distance to instability related to autonomic-cardiac regulation, and developing interventions to prevent autonomic-cardiac instability.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115157608</affiliation-url><afid>115157608</afid><affilname>Thalmic Labs Inc</affilname><name-variant>Thalmic Labs Inc</name-variant><affiliation-city/><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020304</affiliation-url><afid>60020304</afid><affilname>University of Maryland</affilname><name-variant>University of Maryland</name-variant><affiliation-city>College Park</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010365</affiliation-url><afid>60010365</afid><affilname>The University of British Columbia</affilname><name-variant>University of British Columbia</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022927</affiliation-url><afid>60022927</afid><affilname>University of Tehran</affilname><name-variant>University of Tehran</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010365</affiliation-url><afid>60010365</afid><affilname>The University of British Columbia</affilname><name-variant>University of British Columbia</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23391919800</author-url><authid>23391919800</authid><authname>Ataee P.</authname><surname>Ataee</surname><given-name>Pedram</given-name><initials>P.</initials><afid>115157608</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202494227</author-url><authid>7202494227</authid><authname>Hahn J.</authname><surname>Hahn</surname><given-name>Jin Oh</given-name><initials>J.O.</initials><afid>60020304</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102872794</author-url><authid>7102872794</authid><authname>Dumont G.</authname><surname>Dumont</surname><given-name>Guy A.</given-name><initials>G.A.</initials><afid>60010365</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23392935600</author-url><authid>23392935600</authid><authname>Noubari H.</authname><surname>Noubari</surname><given-name>Hossein A.</given-name><initials>H.A.</initials><afid>60010365</afid><afid>60022927</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23392935600</author-url><authid>23392935600</authid><authname>Noubari H.</authname><surname>Noubari</surname><given-name>Hossein A.</given-name><initials>H.A.</initials><afid>60010365</afid><afid>60022927</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7103194108</author-url><authid>7103194108</authid><authname>Boyce W.</authname><surname>Boyce</surname><given-name>W. Thomas</given-name><initials>W.T.</initials><afid>60010365</afid></author><authkeywords>Autonomic-cardiac regulation | Autonomic-cardiac stability | Lyapunov's stability analysis method | Stability margin | System identification</authkeywords><intid>35664904</intid><source-id>17957</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930197792"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930197792?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930197792&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930197792&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930197792</prism:url><dc:identifier>SCOPUS_ID:84930197792</dc:identifier><eid>2-s2.0-84930197792</eid><dc:title>Structural apelin analogues: Mitochondrial ROS inhibition and cardiometabolic protection in myocardial ischaemia reperfusion injury</dc:title><dc:creator>Pisarenko O.</dc:creator><prism:publicationName>British Journal of Pharmacology</prism:publicationName><prism:issn>00071188</prism:issn><prism:eIssn>14765381</prism:eIssn><prism:volume>172</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>2933-2945</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/bph.13038</prism:doi><dc:description>© 2014 The Authors. British Journal of Pharmacology published by John Wiley &amp; Sons Ltd on behalf of The British Pharmacological Society. Background and Purpose Mitochondria-derived oxidative stress is believed to be crucially involved in cardiac ischaemia reperfusion (I/R) injury, although currently no therapies exist that specifically target mitochondrial reactive oxygen species (ROS) production. The present study was designed to evaluate the potential effects of the structural analogues of apelin-12, an adipocyte-derived peptide, on mitochondrial ROS generation, cardiomyocyte apoptosis, and metabolic and functional recovery to myocardial I/R injury. Experimental Approach In cultured H9C2 cardiomyoblasts and adult cardiomyocytes, oxidative stress was induced by hypoxia reoxygenation. Isolated rat hearts were subjected to 35 min of global ischaemia and 30 min of reperfusion. Apelin-12, apelin-13 and structural apelin-12 analogues, AI and AII, were infused during 5 min prior to ischaemia. Key Results In cardiac cells, mitochondrial ROS production was inhibited by the structural analogues of apelin, AI and AII, in comparison with the natural peptides, apelin-12 and apelin-13. Treatment of cardiomyocytes with AI and AII decreased cell apoptosis concentration-dependently. In a rat model of I/R injury, pre-ischaemic infusion of AI and AII markedly reduced ROS formation in the myocardial effluent and attenuated cell membrane damage. Prevention of oxidative damage by AI and AII was associated with the improvement of functional and metabolic recovery after I/R in the heart. Conclusions and Implications These data provide the evidence for the potential of the structural apelin analogues in selective reduction of mitochondrial ROS generation and myocardial apoptosis and form the basis for a promising therapeutic strategy in the treatment of oxidative stress-related heart disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101042998</affiliation-url><afid>101042998</afid><affilname>Russian Cardiology Research and Production Complex</affilname><name-variant>Russian Cardiology Research-and-Production Complex</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000905</affiliation-url><afid>60000905</afid><affilname>Inserm</affilname><name-variant>INSERM</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102124</affiliation-url><afid>60102124</afid><affilname>Universite de Toulouse</affilname><name-variant>University of Toulouse</name-variant><affiliation-city>Toulouse</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35458259200</author-url><authid>35458259200</authid><authname>Pisarenko O.</authname><surname>Pisarenko</surname><given-name>Oleg</given-name><initials>O.</initials><afid>101042998</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602329464</author-url><authid>6602329464</authid><authname>Shulzhenko V.</authname><surname>Shulzhenko</surname><given-name>Valentin</given-name><initials>V.</initials><afid>101042998</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003300583</author-url><authid>7003300583</authid><authname>Studneva I.</authname><surname>Studneva</surname><given-name>Irina</given-name><initials>I.</initials><afid>101042998</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55813245000</author-url><authid>55813245000</authid><authname>Pelogeykina Y.</authname><surname>Pelogeykina</surname><given-name>Yulia</given-name><initials>Y.</initials><afid>101042998</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006408022</author-url><authid>7006408022</authid><authname>Timoshin A.</authname><surname>Timoshin</surname><given-name>Alexander</given-name><initials>A.</initials><afid>101042998</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:27567540300</author-url><authid>27567540300</authid><authname>Anesia R.</authname><surname>Anesia</surname><given-name>Rodica</given-name><initials>R.</initials><afid>60000905</afid><afid>60102124</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:27567540300</author-url><authid>27567540300</authid><authname>Anesia R.</authname><surname>Anesia</surname><given-name>Rodica</given-name><initials>R.</initials><afid>60000905</afid><afid>60102124</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004547174</author-url><authid>7004547174</authid><authname>Valet P.</authname><surname>Valet</surname><given-name>Philippe</given-name><initials>P.</initials><afid>60000905</afid><afid>60102124</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004547174</author-url><authid>7004547174</authid><authname>Valet P.</authname><surname>Valet</surname><given-name>Philippe</given-name><initials>P.</initials><afid>60000905</afid><afid>60102124</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005062259</author-url><authid>7005062259</authid><authname>Parini A.</authname><surname>Parini</surname><given-name>Angelo</given-name><initials>A.</initials><afid>60000905</afid><afid>60102124</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005062259</author-url><authid>7005062259</authid><authname>Parini A.</authname><surname>Parini</surname><given-name>Angelo</given-name><initials>A.</initials><afid>60000905</afid><afid>60102124</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:16646252600</author-url><authid>16646252600</authid><authname>Kunduzova O.</authname><surname>Kunduzova</surname><given-name>Oksana</given-name><initials>O.</initials><afid>60000905</afid><afid>60102124</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:16646252600</author-url><authid>16646252600</authid><authname>Kunduzova O.</authname><surname>Kunduzova</surname><given-name>Oksana</given-name><initials>O.</initials><afid>60000905</afid><afid>60102124</afid></author><intid>1786087208</intid><source-id>20084</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928978803"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928978803?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928978803&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928978803&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928978803</prism:url><dc:identifier>SCOPUS_ID:84928978803</dc:identifier><eid>2-s2.0-84928978803</eid><dc:title>Pulmonary Embolism Response Teams</dc:title><dc:creator>Reza N.</dc:creator><prism:publicationName>Current Treatment Options in Cardiovascular Medicine</prism:publicationName><prism:issn>10928464</prism:issn><prism:eIssn>15343189</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11936-015-0387-9</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Pulmonary embolism (PE) is a complex and multidimensional pathophysiology, the diagnosis and management of which spans multiple disciplines. The high morbidity and associated mortality of “massive” and “submassive” acute PE may require prompt, definitive management; however, current consensus guidelines in this domain are not supported by high-level evidence. Randomized clinical trials comparing available pharmacologic and invasive treatment modalities—including anticoagulation, thrombolysis, and embolectomy—have not been conducted and continue to be challenging to conceptualize, design, and execute. Consequently, time-sensitive therapeutic determinations are largely not standardized, and rendered on a case-by-case basis in part depending on institutional practices and expertises. Chronic sequelae of PE, such as chronic thromboembolic pulmonary hypertension and right heart failure, are increasingly identified as conditions necessitating longitudinal specialty care. These and other challenges have created a niche for a multidisciplinary team which can respond rapidly to unstable patient scenarios, appropriately deploy resources, and offer highly specialized acute and chronic management of PE. The Massachusetts General Hospital Pulmonary Embolism Response Team (PERT), modeled after existing rapid response and collaborative care teams, is a novel approach that combines this clinical service with the development of an educational and research framework to advance the care of patients with PE.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56624574600</author-url><authid>56624574600</authid><authname>Reza N.</authname><surname>Reza</surname><given-name>Nosheen</given-name><initials>N.</initials><afid>60029929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12545895500</author-url><authid>12545895500</authid><authname>Dudzinski D.</authname><surname>Dudzinski</surname><given-name>David M.</given-name><initials>D.M.</initials><afid>60029929</afid><afid>60029929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12545895500</author-url><authid>12545895500</authid><authname>Dudzinski D.</authname><surname>Dudzinski</surname><given-name>David M.</given-name><initials>D.M.</initials><afid>60029929</afid><afid>60029929</afid></author><authkeywords>Heart team | Massive PE | Multidisciplinary | Pulmonary embolism | Pulmonary embolism response team | Rapid response teams</authkeywords><intid>1785877095</intid><source-id>23154</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209135"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209135?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209135&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209135&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209135</prism:url><dc:identifier>SCOPUS_ID:84930209135</dc:identifier><eid>2-s2.0-84930209135</eid><dc:title>Pharmacological modulation of autophagy to protect cardiomyocytes according to the time windows of ischaemia/reperfusion</dc:title><dc:creator>Xu Q.</dc:creator><prism:publicationName>British Journal of Pharmacology</prism:publicationName><prism:issn>00071188</prism:issn><prism:eIssn>14765381</prism:eIssn><prism:volume>172</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>3072-3085</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/bph.13111</prism:doi><dc:description>© 2015 The British Pharmacological Society. Background and Purpose Targeted modulation of autophagy induced by myocardial ischaemia/reperfusion has been the subject of intensive investigation, but it is debatable whether autophagy is beneficial or harmful. Hence, we evaluated the effects of pharmacological manipulation of autophagy on the survival of cardiomyocytes in different time windows of ischaemia/reperfusion. Experimental Approach We examined the autophagy and apoptosis in cardiomyocytes subjected to different durations of anoxia/re-oxygenation or ischaemia/reperfusion, and evaluated the effects of the autophagic enhancer rapamycin and inhibitor wortmannin on cell survival. Key Results In neonatal rat cardiomyocytes (NRCs) or murine hearts, autophagy was increased in response to anoxia/reoxygenation or ischaemia/reperfusion in a time-dependent manner. Rapamycin-enhanced autophagy in NRCs led to higher cell viability and less apoptosis when anoxia was sustained for 蠐6 h. When anoxia was prolonged to 12 h, rapamycin did not increase cell viability, induced less apoptosis and more autophagic cell death. When anoxia was prolonged to 24 h, rapamycin increased autophagic cell death, while wortmannin reduced autophagic cell death and apoptosis. Similar results were obtained in mice subjected to ischaemia/reperfusion. Rapamycin inhibited the opening of mitochondrial transition pore in NRCs exposed to 6 h anoxia/4 h re-oxygenation but did not exert any effect when anoxia was extended to 24 h. Similarly, rapamycin reduced the myocardial expression of Bax in mice subjected to short-time ischaemia, but this effect disappeared when ischaemia was extended to 24 h. Conclusions and Implications The cardioprotection of autophagy is context-dependent and therapies involving the modification of autophagy should be determined according to the duration of ischaemia/reperfusion.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002593</affiliation-url><afid>60002593</afid><affilname>Southern Medical University</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>TongHe</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073529</affiliation-url><afid>60073529</afid><affilname>Guangzhou General Hospital of Guangzhou Command</affilname><name-variant>Guangzhou General Hospital of Guangzhou Military Command</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115014898</affiliation-url><afid>115014898</afid><affilname>Huabo Bio-pharmaceutical Research Institute</affilname><name-variant>Huabo Bio-pharmaceutical Research Institute</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56302940200</author-url><authid>56302940200</authid><authname>Xu Q.</authname><surname>Xu</surname><given-name>Qiulin</given-name><initials>Q.</initials><afid>60002593</afid><afid>60073529</afid><afid>115014898</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56302940200</author-url><authid>56302940200</authid><authname>Xu Q.</authname><surname>Xu</surname><given-name>Qiulin</given-name><initials>Q.</initials><afid>60002593</afid><afid>60073529</afid><afid>115014898</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56302940200</author-url><authid>56302940200</authid><authname>Xu Q.</authname><surname>Xu</surname><given-name>Qiulin</given-name><initials>Q.</initials><afid>60002593</afid><afid>60073529</afid><afid>115014898</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56202879200</author-url><authid>56202879200</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xixian</given-name><initials>X.</initials><afid>60002593</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56535546800</author-url><authid>56535546800</authid><authname>Lu Y.</authname><surname>Lu</surname><given-name>Yongkang</given-name><initials>Y.</initials><afid>60002593</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56201931300</author-url><authid>56201931300</authid><authname>Shen L.</authname><surname>Shen</surname><given-name>Liang</given-name><initials>L.</initials><afid>60002593</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56259386700</author-url><authid>56259386700</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jingwen</given-name><initials>J.</initials><afid>60002593</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55842076600</author-url><authid>55842076600</authid><authname>Cao S.</authname><surname>Cao</surname><given-name>Shiping</given-name><initials>S.</initials><afid>60002593</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55500301100</author-url><authid>55500301100</authid><authname>Huang X.</authname><surname>Huang</surname><given-name>Xiaobo</given-name><initials>X.</initials><afid>60002593</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004504690</author-url><authid>7004504690</authid><authname>Bin J.</authname><surname>Bin</surname><given-name>Jianping</given-name><initials>J.</initials><afid>60002593</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7403026929</author-url><authid>7403026929</authid><authname>Liao Y.</authname><surname>Liao</surname><given-name>Yulin</given-name><initials>Y.</initials><afid>60002593</afid></author><intid>36086484</intid><source-id>20084</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928345935"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928345935?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928345935&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928345935&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0022191015000785"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928345935</prism:url><dc:identifier>SCOPUS_ID:84928345935</dc:identifier><eid>2-s2.0-84928345935</eid><dc:title>Temperate Drosophila preserve cardiac function at low temperature</dc:title><dc:creator>Andersen J.</dc:creator><prism:publicationName>Journal of Insect Physiology</prism:publicationName><prism:issn>00221910</prism:issn><prism:volume>77</prism:volume><prism:pageRange>26-32</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jinsphys.2015.03.016</prism:doi><pii>S0022191015000785</pii><dc:description>© 2015 Elsevier Ltd. Most insects are chill susceptible and will enter a coma if exposed to sufficiently low temperature. This chill coma has been associated with a failure of the neuromuscular system. Insect heart rate (HR) is determined by intrinsic regulation (muscle pacemaker) with extrinsic (nervous and humoral) input. By examining the continually active heart of five Drosophila species with markedly different cold tolerance, we investigated whether cardiac performance is related to the whole animal critical thermal minimum (CT&lt;inf&gt;min&lt;/inf&gt;). Further, to separate the effects of cold on extrinsic and intrinsic regulators of HR, we measured HR under similar conditions in decapitated flies as well as amputated abdomens of Drosophila montana. Cardiac performance was assessed from break points in HR-temperature relationship (Arrhenius break point, ABP) and from the HR cessation temperature. Among the five species, we found strong relationships for both the HR-ABP and HR cessation temperatures to whole animal CT&lt;inf&gt;min&lt;/inf&gt;, such that temperate Drosophila species maintained cardiac function at considerably lower temperatures than their tropical congeners. Hearts of amputated abdomens, with reduced extrinsic input, had a higher thermal sensitivity and a significantly lower break point temperature, suggesting that central neuronal input is important for stimulating HR at low temperatures.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029616</affiliation-url><afid>60029616</afid><affilname>Aarhus Universitet</affilname><name-variant>University of Aarhus</name-variant><affiliation-city>Aarhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:44860919400</author-url><authid>44860919400</authid><authname>Andersen J.</authname><surname>Andersen</surname><given-name>Jonas Lembcke</given-name><initials>J.L.</initials><afid>60029616</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25958781800</author-url><authid>25958781800</authid><authname>MacMillan H.</authname><surname>MacMillan</surname><given-name>Heath Andrew</given-name><initials>H.A.</initials><afid>60029616</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56276192400</author-url><authid>56276192400</authid><authname>Overgaard J.</authname><surname>Overgaard</surname><given-name>Johannes</given-name><initials>J.</initials><afid>60029616</afid></author><authkeywords>Central nervous system | Chill tolerance | Decapitated flies | Drosophila heart rate | Muscle function</authkeywords><intid>535768144</intid><source-id>20487</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929157816"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929157816?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929157816&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929157816&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929157816</prism:url><dc:identifier>SCOPUS_ID:84929157816</dc:identifier><eid>2-s2.0-84929157816</eid><dc:title>Impact of clinical and sociodemographic patient characteristics on the outcome of cardiac rehabilitation in older patients</dc:title><dc:creator>Salzwedel A.</dc:creator><prism:publicationName>Aging Clinical and Experimental Research</prism:publicationName><prism:issn>15940667</prism:issn><prism:eIssn>17208319</prism:eIssn><prism:volume>27</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>315-321</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40520-014-0283-2</prism:doi><dc:description>© 2014, Springer International Publishing Switzerland. Methods: The impact of baseline characteristics on the success of CR, measured by MOC, was analysed using a mixed model for 1,220 older patients (70.9 ± 7.0 years, 78.3 % men) who enrolled in 12 CR clinics. A multitude of potentially influential baseline patient characteristics was considered including sociodemographic variables, comorbidity, duration of hospital stay, exercise capacity, cardiovascular risk factors, emotional status, and laboratory and echocardiographic data. Background: Cardiac rehabilitation (CR) seeks to simultaneously improve several outcome parameters related to patient risk factors, exercise capacity and subjective health. A single score, the multiple outcome criterion (MOC), comprised of alterations in 13 outcome variables was used to measure the overall success of CR in an older population. As this success depends on the older patient’s characteristics at the time of admission to CR, we attempted to determine the most important influences. Results: Overall, CR was successful, as indicated by the mean value of the MOC (0.6 ± 0.45; min −1.0, max 2.0; positive values denoting improvement, negative ones deterioration). Examples of association with negative MOC values included smoking (MOC −0.15, p &lt; 0.001), female gender (MOC −0.07, p = 0.049), and a longer hospital stay (MOC −0.03, p = 0.03). An example of association with positive MOC value was depression score (MOC 0.06, p = 0.003). Further associations included maximal exercise capacity, blood pressure, heart rate and the rehabilitation centre attended. Conclusion: Our results emphasize the necessity to take into consideration baseline characteristics when evaluating the success of CR and setting treatment targets for older patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115231139</affiliation-url><afid>115231139</afid><affilname>Klinik Am See</affilname><name-variant>Klinik am See</name-variant><affiliation-city>Potsdam</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021763</affiliation-url><afid>60021763</afid><affilname>Universitat Potsdam</affilname><name-variant>University of Potsdam</name-variant><affiliation-city>Potsdam</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005036</affiliation-url><afid>60005036</afid><affilname>Universitatsklinikum Hamburg-Eppendorf und Medizinische Fakultat</affilname><name-variant>University Medical Center Hamburg-Eppendorf</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024025</affiliation-url><afid>60024025</afid><affilname>Universitat zu Koln</affilname><name-variant>Universität zu Köln</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101064690</affiliation-url><afid>101064690</afid><affilname>Techniker Krankenkasse</affilname><name-variant>Technikes Krankenkasse</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37038334700</author-url><authid>37038334700</authid><authname>Salzwedel A.</authname><surname>Salzwedel</surname><given-name>Annett</given-name><initials>A.</initials><afid>60026245</afid><afid>115231139</afid><afid>60021763</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37038334700</author-url><authid>37038334700</authid><authname>Salzwedel A.</authname><surname>Salzwedel</surname><given-name>Annett</given-name><initials>A.</initials><afid>60026245</afid><afid>115231139</afid><afid>60021763</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37038334700</author-url><authid>37038334700</authid><authname>Salzwedel A.</authname><surname>Salzwedel</surname><given-name>Annett</given-name><initials>A.</initials><afid>60026245</afid><afid>115231139</afid><afid>60021763</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55270657700</author-url><authid>55270657700</authid><authname>Wegscheider K.</authname><surname>Wegscheider</surname><given-name>Karl</given-name><initials>K.</initials><afid>60005036</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:44861165800</author-url><authid>44861165800</authid><authname>Herich L.</authname><surname>Herich</surname><given-name>Lena</given-name><initials>L.</initials><afid>60005036</afid><afid>60024025</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:44861165800</author-url><authid>44861165800</authid><authname>Herich L.</authname><surname>Herich</surname><given-name>Lena</given-name><initials>L.</initials><afid>60005036</afid><afid>60024025</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56641232700</author-url><authid>56641232700</authid><authname>Rieck A.</authname><surname>Rieck</surname><given-name>Angelika</given-name><initials>A.</initials><afid>60021763</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55918692400</author-url><authid>55918692400</authid><authname>Strandt G.</authname><surname>Strandt</surname><given-name>Gert</given-name><initials>G.</initials><afid>101064690</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004756762</author-url><authid>7004756762</authid><authname>Völler H.</authname><surname>Völler</surname><given-name>Heinz</given-name><initials>H.</initials><afid>60026245</afid><afid>115231139</afid><afid>60021763</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004756762</author-url><authid>7004756762</authid><authname>Völler H.</authname><surname>Völler</surname><given-name>Heinz</given-name><initials>H.</initials><afid>60026245</afid><afid>115231139</afid><afid>60021763</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004756762</author-url><authid>7004756762</authid><authname>Völler H.</authname><surname>Völler</surname><given-name>Heinz</given-name><initials>H.</initials><afid>60026245</afid><afid>115231139</afid><afid>60021763</afid></author><authkeywords>Cardiac rehabilitation | Composite outcome measure | Older patients | Predictors | Rehabilitation success</authkeywords><intid>1035913990</intid><source-id>28496</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929470424"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929470424?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929470424&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929470424&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929470424</prism:url><dc:identifier>SCOPUS_ID:84929470424</dc:identifier><eid>2-s2.0-84929470424</eid><dc:title>Metabolomics analysis reveals insights into biochemical mechanisms of mental stress-induced left ventricular dysfunction</dc:title><dc:creator>Boyle S.</dc:creator><prism:publicationName>Metabolomics</prism:publicationName><prism:issn>15733882</prism:issn><prism:eIssn>15733890</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>571-582</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11306-014-0718-y</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Mental stress induced left ventricular dysfunction (LVD) has been associated with a greater risk of adverse events in coronary heart disease (CHD) patients independent of conventional risk indicators. The underlying biochemical mechanisms of this cardiovascular condition are poorly understood. Our objective was to use metabolomics technology to identify biochemical changes that co-occur with mental stress-induced LVD in patients with clinically stable CHD. Participants were adult CHD patients who were recruited for mental stress-induced myocardial ischemia screening. For this study, we randomly selected 30 patients representing the extremes of the mental stress-induced left ventricular ejection fraction (LVEF) change distribution; 15 who showed LVD (i.e. LVEF reduction ≥5) and 15 who showed a normal left ventricular response (NLVR; i.e. a LVEF increase of ≥5) to three mental stressors. An electrochemistry based metabolomics platform was used to profile pre- and post-stress serum samples yielding data for 22 known compounds, primarily within the tyrosine, tryptophan, purine and methionine pathways. There were significant stress-induced changes in several compounds. A comparison between the NLVR and LVD groups showed significant effects for kynurenine (p = .036, N-acetylserotonin (p = .054), uric acid (p = .015), tyrosine (p = .019) and a trend for methionine (p = .065); the NLVR group showed a significantly greater stress-induced reduction in all of those compounds compared to the LVD group. Many of these biochemicals have been implicated in other stress-related phenomena and are plausible candidates for mechanisms underlying LVD in response to mental stress.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005200</affiliation-url><afid>60005200</afid><affilname>Duke University School of Medicine</affilname><name-variant>Duke University Medical Center</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005200</affiliation-url><afid>60005200</afid><affilname>Duke University School of Medicine</affilname><name-variant>Duke University Medical Center</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114424727</affiliation-url><afid>114424727</afid><affilname>Counterpoint Health Solutions Inc</affilname><name-variant>Counterpoint Health Solutions</name-variant><affiliation-city>Bedford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005772114</author-url><authid>7005772114</authid><authname>Boyle S.</authname><surname>Boyle</surname><given-name>Stephen H.</given-name><initials>S.H.</initials><afid>60005200</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004338778</author-url><authid>7004338778</authid><authname>Matson W.</authname><surname>Matson</surname><given-name>Wayne R.</given-name><initials>W.R.</initials><afid>114424727</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56540090400</author-url><authid>56540090400</authid><authname>Velazquez E.</authname><surname>Velazquez</surname><given-name>Eric J.</given-name><initials>E.J.</initials><afid>60005200</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56553353400</author-url><authid>56553353400</authid><authname>Samad Z.</authname><surname>Samad</surname><given-name>Zainab</given-name><initials>Z.</initials><afid>60005200</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7409601895</author-url><authid>7409601895</authid><authname>Williams R.</authname><surname>Williams</surname><given-name>Redford B.</given-name><initials>R.B.</initials><afid>60005200</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55491673500</author-url><authid>55491673500</authid><authname>Sharma S.</authname><surname>Sharma</surname><given-name>Swati</given-name><initials>S.</initials><afid>114424727</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:12446197000</author-url><authid>12446197000</authid><authname>Thomas B.</authname><surname>Thomas</surname><given-name>Beena</given-name><initials>B.</initials><afid>114424727</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56535679000</author-url><authid>56535679000</authid><authname>Wilson J.</authname><surname>Wilson</surname><given-name>Jennifer L.</given-name><initials>J.L.</initials><afid>60005200</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56502212600</author-url><authid>56502212600</authid><authname>O’Connor C.</authname><surname>O’Connor</surname><given-name>Christopher</given-name><initials>C.</initials><afid>60005200</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56384717300</author-url><authid>56384717300</authid><authname>Jiang W.</authname><surname>Jiang</surname><given-name>Wei</given-name><initials>W.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56384717300</author-url><authid>56384717300</authid><authname>Jiang W.</authname><surname>Jiang</surname><given-name>Wei</given-name><initials>W.</initials><afid>60005200</afid><afid>60005200</afid></author><authkeywords>Left ventricular dysfunction | Mental stress | Metabolomics</authkeywords><intid>35964307</intid><source-id>130171</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923107063"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923107063?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923107063&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923107063&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1095643315000331"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923107063</prism:url><dc:identifier>SCOPUS_ID:84923107063</dc:identifier><eid>2-s2.0-84923107063</eid><dc:title>Cardiorespiratory ontogeny and response to environmental hypoxia of larval spiny lobster, Sagmariasus verreauxi</dc:title><dc:creator>Fitzgibbon Q.</dc:creator><prism:publicationName>Comparative Biochemistry and Physiology -Part A : Molecular and Integrative Physiology</prism:publicationName><prism:issn>10956433</prism:issn><prism:eIssn>15314332</prism:eIssn><prism:volume>184</prism:volume><prism:pageRange>76-82</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbpa.2015.02.007</prism:doi><pii>S1095643315000331</pii><dc:description>© 2015 Elsevier Inc. Cardiorespiratory function is vital to an organism's ability to respond to environmental stress and analysis of cardiorespiratory capacity of species or life stages can elucidate vulnerability to climate change. Spiny lobsters have one of the most complex pelagic larval life cycles of any invertebrate and recently there has been an unexplained decline in post-larval recruitment for a number of species. We conducted the first analysis of the larval ontogeny of oxygen consumption, heart rate, maxilla 2 ventilation rate and oxyregulatory capacity of the spiny lobster, Sagmariasus verreauxi, to gain insight into their vulnerability to ocean change and to investigate life stage specific sensitivity to temperature-dependent oxygen limitation. In normoxia, heart and maxilla 2 ventilation rates increased in early larval development before declining, which we hypothesise is related to the transition from myogenic to neurogenic cardiac control. Maxilla 2 ventilation rate was sensitive to hypoxia at all larval stages, while heart rate was only sensitive to hypoxia in the late phyllosoma stages. Oxygen consumption conformed to environmental hypoxia at all larval stages. Spiny lobster larvae have limited respiratory control due to immature gas exchange physiology, compounded by their exceptionally large size. The lack of oxyregulatory ability suggests that all development stages are vulnerable to changes in sea temperature and oxygen availability. The synergetic stressors of increased temperature and reduced dissolved oxygen in the marine environment will diminish spiny lobster larval performance, increasing the challenge to achieve their extended larval life cycle, which may contribute to declines in post-larval recruitment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015356</affiliation-url><afid>60015356</afid><affilname>University of Tasmania</affilname><name-variant>University of Tasmania</name-variant><affiliation-city>Hobart</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12782761600</author-url><authid>12782761600</authid><authname>Fitzgibbon Q.</authname><surname>Fitzgibbon</surname><given-name>Quinn P.</given-name><initials>Q.P.</initials><afid>60015356</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56632611300</author-url><authid>56632611300</authid><authname>Ruff N.</authname><surname>Ruff</surname><given-name>Nicole</given-name><initials>N.</initials><afid>60015356</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701787535</author-url><authid>6701787535</authid><authname>Battaglene S.</authname><surname>Battaglene</surname><given-name>Stephen C.</given-name><initials>S.C.</initials><afid>60015356</afid></author><authkeywords>Climate change | Crustacean | Heart rate | Oxygen consumption | Oxygen limitation | Phyllosoma | Puerulus | Ventilation</authkeywords><intid>1534914910</intid><source-id>3500148021</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930089544"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930089544?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930089544&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930089544&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930089544</prism:url><dc:identifier>SCOPUS_ID:84930089544</dc:identifier><eid>2-s2.0-84930089544</eid><dc:title>4-D flow magnetic resonance imaging: blood flow quantification compared to 2-D phase-contrast magnetic resonance imaging and Doppler echocardiography</dc:title><dc:creator>Gabbour M.</dc:creator><prism:publicationName>Pediatric Radiology</prism:publicationName><prism:issn>03010449</prism:issn><prism:eIssn>14321998</prism:eIssn><prism:volume>45</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>804-813</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00247-014-3246-z</prism:doi><dc:description>© 2014, Springer-Verlag Berlin Heidelberg. Background: Doppler echocardiography (echo) is the reference standard for blood flow velocity analysis, and two-dimensional (2-D) phase-contrast magnetic resonance imaging (MRI) is considered the reference standard for quantitative blood flow assessment. However, both clinical standard-of-care techniques are limited by 2-D acquisitions and single-direction velocity encoding and may make them inadequate to assess the complex three-dimensional hemodynamics seen in congenital heart disease. Four-dimensional flow MRI (4-D flow) enables qualitative and quantitative analysis of complex blood flow in the heart and great arteries. Objectives: The objectives of this study are to compare 4-D flow with 2-D phase-contrast MRI for quantification of aortic and pulmonary flow and to evaluate the advantage of 4-D flow-based volumetric flow analysis compared to 2-D phase-contrast MRI and echo for peak velocity assessment in children and young adults. Materials and methods: Two-dimensional phase-contrast MRI of the aortic root, main pulmonary artery (MPA), and right and left pulmonary arteries (RPA, LPA) and 4-D flow with volumetric coverage of the aorta and pulmonary arteries were performed in 50 patients (mean age: 13.1 ± 6.4 years). Four-dimensional flow analyses included calculation of net flow and regurgitant fraction with 4-D flow analysis planes similarly positioned to 2-D planes. In addition, 4-D flow volumetric assessment of aortic root/ascending aorta and MPA peak velocities was performed and compared to 2-D phase-contrast MRI and echo. Results: Excellent correlation and agreement were found between 2-D phase-contrast MRI and 4-D flow for net flow (r = 0.97, P &lt; 0.001) and excellent correlation with good agreement was found for regurgitant fraction (r = 0.88, P &lt; 0.001) in all vessels. Two-dimensional phase-contrast MRI significantly underestimated aortic (P = 0.032) and MPA (P &lt; 0.001) peak velocities compared to echo, while volumetric 4-D flow analysis resulted in higher (aortic: P = 0.001) or similar (MPA: P = 0.98) peak velocities relative to echo. Conclusion: Excellent flow parameter agreement between 2-D phase-contrast MRI and 4-D flow and the improved volumetric 4-D flow velocity analysis relative to echo suggests that 4-D flow has the potential to become a clinical alternative to 2-D phase-contrast MRI.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113120162</affiliation-url><afid>113120162</afid><affilname>Ann and Robert H. Lurie Children's Hospital of Chicago</affilname><name-variant>Ann and Robert H. Lurie Children's Hospital of Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013227</affiliation-url><afid>60013227</afid><affilname>Northwestern University Feinberg School of Medicine</affilname><name-variant>Northwestern University</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007363</affiliation-url><afid>60007363</afid><affilname>Northwestern University</affilname><name-variant>Northwestern University</name-variant><affiliation-city>Evanston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017031</affiliation-url><afid>60017031</afid><affilname>Children's Memorial Hospital</affilname><name-variant>Children's Memorial Hospital</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013227</affiliation-url><afid>60013227</afid><affilname>Northwestern University Feinberg School of Medicine</affilname><name-variant>Northwestern University</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55365224800</author-url><authid>55365224800</authid><authname>Gabbour M.</authname><surname>Gabbour</surname><given-name>Maya</given-name><initials>M.</initials><afid>113120162</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35254283400</author-url><authid>35254283400</authid><authname>Schnell S.</authname><surname>Schnell</surname><given-name>Susanne</given-name><initials>S.</initials><afid>60013227</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:34570188500</author-url><authid>34570188500</authid><authname>Jarvis K.</authname><surname>Jarvis</surname><given-name>Kelly</given-name><initials>K.</initials><afid>60007363</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:26659239500</author-url><authid>26659239500</authid><authname>Robinson J.</authname><surname>Robinson</surname><given-name>Joshua D.</given-name><initials>J.D.</initials><afid>60017031</afid><afid>60013227</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:26659239500</author-url><authid>26659239500</authid><authname>Robinson J.</authname><surname>Robinson</surname><given-name>Joshua D.</given-name><initials>J.D.</initials><afid>60017031</afid><afid>60013227</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003897095</author-url><authid>7003897095</authid><authname>Markl M.</authname><surname>Markl</surname><given-name>Michael</given-name><initials>M.</initials><afid>60013227</afid><afid>60007363</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003897095</author-url><authid>7003897095</authid><authname>Markl M.</authname><surname>Markl</surname><given-name>Michael</given-name><initials>M.</initials><afid>60013227</afid><afid>60007363</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603910958</author-url><authid>6603910958</authid><authname>Rigsby C.</authname><surname>Rigsby</surname><given-name>Cynthia K.</given-name><initials>C.K.</initials><afid>113120162</afid><afid>60013227</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603910958</author-url><authid>6603910958</authid><authname>Rigsby C.</authname><surname>Rigsby</surname><given-name>Cynthia K.</given-name><initials>C.K.</initials><afid>113120162</afid><afid>60013227</afid></author><authkeywords>4-D flow | Cardiovascular magnetic resonance | Congenital heart disease | Magnetic resonance imaging | Pediatric | Phase-contrast</authkeywords><intid>1036058578</intid><source-id>15753</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927673244"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927673244?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927673244&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927673244&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014480015000878"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927673244</prism:url><dc:identifier>SCOPUS_ID:84927673244</dc:identifier><eid>2-s2.0-84927673244</eid><dc:title>Effect of carvedilol against myocardial injury due to ischemia-reperfusion of the brain in rats</dc:title><dc:creator>Harima M.</dc:creator><prism:publicationName>Experimental and Molecular Pathology</prism:publicationName><prism:issn>00144800</prism:issn><prism:eIssn>10960945</prism:eIssn><prism:volume>98</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>558-562</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yexmp.2015.04.001</prism:doi><pii>S0014480015000878</pii><dc:description>© 2015 Elsevier Inc. We have previously reported the mechanism behind the myocardial injury and the activation of autonomic nervous system during the ischemia-reperfusion (IR) of the rat brain. This study was planned to investigate the effect of carvedilol, a β-blocker, in improving the myocardial injury caused by IR of the rat brain. We have used a whole cerebral IR model in rats by clamping both the right and left common carotid arteries. Rats were divided into five groups; Sham surgery group (Group-Sham), carvedilol treatment before ischemia group (Group-Is. +. C), vehicle control group (Group-Is. +. V), carvedilol treatment before reperfusion group (Group-Re. +. C) and the vehicle control group (Group-Re. +. V). We have measured the blood pressure and heart rate via a catheter, myocardial tissue β1-adrenaline receptor (β1-AR) levels, phosphor-p38 mitogen-activated protein kinase (p-p38 MAPK) signaling factor, malondialdehyde (MDA), and apoptosis (TUNEL assay and expression of caspase-7 protein). The results indicated that the increased expressions of β1-AR, p-p38 MAPK, caspase-7, apoptotic cells and MDA level in the myocardial tissue due to brain ischemia-reperfusion were significantly reduced by carvedilol treatment. From these observations we can suggest that, with the advantage of its antioxidant and β blocking action, carvedilol had played the improvement of myocardial injury in ischemia-reperfusion of the brain.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009613</affiliation-url><afid>60009613</afid><affilname>Niigata University of Pharmacy and Applied Life Sciences</affilname><name-variant>Niigata College of Pharmacy</name-variant><affiliation-city>Niigata</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009613</affiliation-url><afid>60009613</afid><affilname>Niigata University of Pharmacy and Applied Life Sciences</affilname><name-variant>Niigata College of Pharmacy</name-variant><affiliation-city>Niigata</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100312850</affiliation-url><afid>100312850</afid><affilname>Yamanashi Prefectural Central Hospital</affilname><name-variant>Yamanashi Prefectural Central Hospital</name-variant><affiliation-city>Kofu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34971238300</author-url><authid>34971238300</authid><authname>Harima M.</authname><surname>Harima</surname><given-name>Meilei</given-name><initials>M.</initials><afid>60009613</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:38860956300</author-url><authid>38860956300</authid><authname>Arumugam S.</authname><surname>Arumugam</surname><given-name>Somasundaram</given-name><initials>S.</initials><afid>60009613</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56591201400</author-url><authid>56591201400</authid><authname>Wen J.</authname><surname>Wen</surname><given-name>Juan</given-name><initials>J.</initials><afid>60009613</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55211229300</author-url><authid>55211229300</authid><authname>Pitchaimani V.</authname><surname>Pitchaimani</surname><given-name>Vigneshwaran</given-name><initials>V.</initials><afid>60009613</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55863612800</author-url><authid>55863612800</authid><authname>Karuppagounder V.</authname><surname>Karuppagounder</surname><given-name>Vengadeshprabhu</given-name><initials>V.</initials><afid>60009613</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56586124200</author-url><authid>56586124200</authid><authname>Afrin M.</authname><surname>Afrin</surname><given-name>Mst Rejina</given-name><initials>M.R.</initials><afid>60009613</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55211488800</author-url><authid>55211488800</authid><authname>Sreedhar R.</authname><surname>Sreedhar</surname><given-name>Remya</given-name><initials>R.</initials><afid>60009613</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56245194500</author-url><authid>56245194500</authid><authname>Miyashita S.</authname><surname>Miyashita</surname><given-name>Shizuka</given-name><initials>S.</initials><afid>60009613</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55940205700</author-url><authid>55940205700</authid><authname>Nomoto M.</authname><surname>Nomoto</surname><given-name>Mayumi</given-name><initials>M.</initials><afid>60009613</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56591433000</author-url><authid>56591433000</authid><authname>Ueno K.</authname><surname>Ueno</surname><given-name>Kazuyuki</given-name><initials>K.</initials><afid>60009613</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56590961600</author-url><authid>56590961600</authid><authname>Nakamura M.</authname><surname>Nakamura</surname><given-name>Masahiko</given-name><initials>M.</initials><afid>100312850</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55492737200</author-url><authid>55492737200</authid><authname>Watanabe K.</authname><surname>Watanabe</surname><given-name>Kenichi</given-name><initials>K.</initials><afid>60009613</afid></author><authkeywords>Apoptosis | Brain | Cardiac injury | Carvedilol | Ischemia-reperfusion</authkeywords><intid>1535647202</intid><source-id>13247</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926652950"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926652950?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926652950&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926652950&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926652950</prism:url><dc:identifier>SCOPUS_ID:84926652950</dc:identifier><eid>2-s2.0-84926652950</eid><dc:title>NFIL3 suppresses hypoxia-induced apoptotic cell death by targeting the insulin-like growth factor 2 receptor</dc:title><dc:creator>Lin K.</dc:creator><prism:publicationName>Journal of Cellular Biochemistry</prism:publicationName><prism:issn>07302312</prism:issn><prism:eIssn>10974644</prism:eIssn><prism:volume>116</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1113-1120</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1002/jcb.25067</prism:doi><dc:description>© 2015 Wiley Periodicals, Inc. The insulin-like growth factor-II/mannose 6-phosphate receptor (IGF2R) over-expression correlates with heart disease progression. The IGF2R is not only an IGF2 clearance receptor, but it also triggers signal transduction, resulting in cardiac hypertrophy, apoptosis and fibrosis. The present study investigated the nuclear factor IL-3 (NFIL3), a transcription factor of the basic leucine zipper superfamily, and its potential pro-survival effects in cardiomyocytes. NFIL3 might play a key role in heart development and act as a survival factor in the heart, but the regulatory mechanisms are still unclear. IGF2 and IGF2R protein expression were highly increased in rat hearts subjected to hemorrhagic shock. IGF2R protein expression was also up-regulated in H9c2 cells exposed to hypoxia. Over-expression of NFIL3 in H9c2 cardiomyoblast cells inhibited the induction of hypoxia-induced apoptosis and down-regulated IGF2R expression levels. Gel shift assay, double-stranded DNA pull-down assay and chromatin immune-precipitation analyses indicated that NFIL3 binds directly to the IGF2R promoter region. Using a luciferase assay, we further observed NFIL3 repress IGF2R gene promoter activity. Our results demonstrate that NFIL3 is an important negative transcription factor, which through binding to the promoter of IGF2R, suppresses the apoptosis induced by IGF2R signaling in H9c2 cardiomyoblast cells under hypoxic conditions. J. Cell. Biochem. 116: 1113-1120, 2015.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031941</affiliation-url><afid>60031941</afid><affilname>China Medical University Hospital Taichung</affilname><name-variant>China Medical University Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104521</affiliation-url><afid>60104521</afid><affilname>University of Taipei</affilname><name-variant>University of Taipei</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031941</affiliation-url><afid>60031941</afid><affilname>China Medical University Hospital Taichung</affilname><name-variant>China Medical University Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109965053</affiliation-url><afid>109965053</afid><affilname>Armed Forces General Hospital</affilname><name-variant>Armed Forces General Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100856160</affiliation-url><afid>100856160</afid><affilname>Central Taiwan University of Sciences and Technology</affilname><name-variant>Central Taiwan University of Sciences and Technology</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013041</affiliation-url><afid>60013041</afid><affilname>Bharathiar University</affilname><name-variant>Bharathiar University</name-variant><affiliation-city>Coimbatore</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031941</affiliation-url><afid>60031941</afid><affilname>China Medical University Hospital Taichung</affilname><name-variant>China Medical University Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072429</affiliation-url><afid>60072429</afid><affilname>Asia University Taiwan</affilname><name-variant>Asia University</name-variant><affiliation-city>Wufong</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56158058900</author-url><authid>56158058900</authid><authname>Lin K.</authname><surname>Lin</surname><given-name>Kuan Ho</given-name><initials>K.H.</initials><afid>60006988</afid><afid>60006988</afid><afid>60031941</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56158058900</author-url><authid>56158058900</authid><authname>Lin K.</authname><surname>Lin</surname><given-name>Kuan Ho</given-name><initials>K.H.</initials><afid>60006988</afid><afid>60006988</afid><afid>60031941</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56158058900</author-url><authid>56158058900</authid><authname>Lin K.</authname><surname>Lin</surname><given-name>Kuan Ho</given-name><initials>K.H.</initials><afid>60006988</afid><afid>60006988</afid><afid>60031941</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26660722900</author-url><authid>26660722900</authid><authname>Kuo C.</authname><surname>Kuo</surname><given-name>Chia Hua</given-name><initials>C.H.</initials><afid>60104521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24071187000</author-url><authid>24071187000</authid><authname>Kuo W.</authname><surname>Kuo</surname><given-name>Wei Wen</given-name><initials>W.W.</initials><afid>60006988</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56502922200</author-url><authid>56502922200</authid><authname>Ho T.</authname><surname>Ho</surname><given-name>Tsung Jung</given-name><initials>T.J.</initials><afid>60006988</afid><afid>60006988</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56502922200</author-url><authid>56502922200</authid><authname>Ho T.</authname><surname>Ho</surname><given-name>Tsung Jung</given-name><initials>T.J.</initials><afid>60006988</afid><afid>60006988</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8883719400</author-url><authid>8883719400</authid><authname>Pai P.</authname><surname>Pai</surname><given-name>Peiying</given-name><initials>P.</initials><afid>60031941</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56229985000</author-url><authid>56229985000</authid><authname>Chen W.</authname><surname>Chen</surname><given-name>Wei Kung</given-name><initials>W.K.</initials><afid>60031941</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56105651600</author-url><authid>56105651600</authid><authname>Pan L.</authname><surname>Pan</surname><given-name>Lung Fa</given-name><initials>L.F.</initials><afid>109965053</afid><afid>100856160</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56105651600</author-url><authid>56105651600</authid><authname>Pan L.</authname><surname>Pan</surname><given-name>Lung Fa</given-name><initials>L.F.</initials><afid>109965053</afid><afid>100856160</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56585432600</author-url><authid>56585432600</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Chien Cheng</given-name><initials>C.C.</initials><afid>60006988</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:13004112200</author-url><authid>13004112200</authid><authname>Padma V.</authname><surname>Padma</surname><given-name>V. Vijaya</given-name><initials>V.V.</initials><afid>60013041</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7406883142</author-url><authid>7406883142</authid><authname>Huang C.</authname><surname>Huang</surname><given-name>Chih Yang</given-name><initials>C.Y.</initials><afid>60031941</afid><afid>60006988</afid><afid>60072429</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7406883142</author-url><authid>7406883142</authid><authname>Huang C.</authname><surname>Huang</surname><given-name>Chih Yang</given-name><initials>C.Y.</initials><afid>60031941</afid><afid>60006988</afid><afid>60072429</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7406883142</author-url><authid>7406883142</authid><authname>Huang C.</authname><surname>Huang</surname><given-name>Chih Yang</given-name><initials>C.Y.</initials><afid>60031941</afid><afid>60006988</afid><afid>60072429</afid></author><authkeywords>APOPTOSIS | EBPRE | HYPOXIA | IGF2R SIGNALING | NFIL3</authkeywords><intid>1035479510</intid><source-id>17598</source-id></entry></search-results>
